MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01D5389E.1DBD9690"

This document is a Single File Web Page, also known as a Web Archive file.  If you are seeing this message, your browser or editor doesn't support Web Archive files.  Please download a browser that supports Web Archive, such as Windows? Internet Explorer?.

------=_NextPart_01D5389E.1DBD9690
Content-Location: file:///C:/9AEA4A32/cp-germcell-16protocol-3102.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="us-ascii"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dus-ascii">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link rel=3DFile-List href=3D"cp-germcell-16protocol-3102_files/filelist.xm=
l">
<link rel=3DPreview href=3D"cp-germcell-16protocol-3102_files/preview.wmf">
<link rel=3DEdit-Time-Data href=3D"cp-germcell-16protocol-3102_files/editda=
ta.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>Germ Cell Tumor</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Joe Schramm</o:Author>
  <o:LastAuthor>Anthony Lo</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>6</o:TotalTime>
  <o:LastPrinted>2015-12-09T15:00:00Z</o:LastPrinted>
  <o:Created>2019-07-12T02:39:00Z</o:Created>
  <o:LastSaved>2019-07-12T02:39:00Z</o:LastSaved>
  <o:Pages>18</o:Pages>
  <o:Words>17977</o:Words>
  <o:Characters>102473</o:Characters>
  <o:Company>College of American Pathologists</o:Company>
  <o:Lines>853</o:Lines>
  <o:Paragraphs>240</o:Paragraphs>
  <o:CharactersWithSpaces>120210</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
</xml><![endif]-->
<link rel=3DthemeData href=3D"cp-germcell-16protocol-3102_files/themedata.t=
hmx">
<link rel=3DcolorSchemeMapping
href=3D"cp-germcell-16protocol-3102_files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:DoNotHyphenateCaps/>
  <w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEve=
ry>
  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
  <w:UseMarginsForDrawingGridOrigin/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>JA</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:StyleSortMethod>0</w:StyleSortMethod>
  <w:Compatibility>
   <w:UsePrinterMetrics/>
   <w:WW6BorderRules/>
   <w:FootnoteLayoutLikeWW8/>
   <w:ShapeLayoutLikeWW8/>
   <w:AlignTablesRowByRow/>
   <w:ForgetLastTabAlignment/>
   <w:LayoutRawTableWidth/>
   <w:LayoutTableRowsApart/>
   <w:UseWord97LineBreakingRules/>
   <w:SelectEntireFieldWithStartOrEnd/>
   <w:UseWord2002TableStyleRules/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:UnderlineTabInNumList/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <w:DocumentVariables>
   <w:EN.InstantFormat>&lt;ENInstantFormat&gt;&lt;Enabled&gt;0&lt;/Enabled&=
gt;&lt;ScanUnformatted&gt;1&lt;/ScanUnformatted&gt;&lt;ScanChanges&gt;1&lt;=
/ScanChanges&gt;&lt;/ENInstantFormat&gt;</w:EN.InstantFormat>
   <w:EN.Layout>&lt;ENLayout&gt;&lt;Style&gt;Archives
    Pathology&lt;/Style&gt;&lt;LeftDelim&gt;{&lt;/LeftDelim&gt;&lt;RightDel=
im&gt;}&lt;/RightDelim&gt;&lt;FontName&gt;Arial&lt;/FontName&gt;&lt;FontSiz=
e&gt;11&lt;/FontSize&gt;&lt;ReflistTitle&gt;&lt;/ReflistTitle&gt;&lt;Starti=
ngRefnum&gt;1&lt;/StartingRefnum&gt;&lt;FirstLineIndent&gt;0&lt;/FirstLineI=
ndent&gt;&lt;HangingIndent&gt;720&lt;/HangingIndent&gt;&lt;LineSpacing&gt;0=
&lt;/LineSpacing&gt;&lt;SpaceAfter&gt;0&lt;/SpaceAfter&gt;&lt;/ENLayout&gt;=
</w:EN.Layout>
   <w:EN.Libraries>&lt;ENLibraries&gt;&lt;Libraries&gt;&lt;item&gt;Extragon=
adal
    germ cell.enl&lt;/item&gt;&lt;/Libraries&gt;&lt;/ENLibraries&gt;</w:EN.=
Libraries>
  </w:DocumentVariables>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef m:val=3D"off"/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapRight/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"subSup"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"true"
  DefSemiHidden=3D"true" DefQFormat=3D"false" DefPriority=3D"99"
  LatentStyleCount=3D"267">
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"header"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"footer"/>
  <w:LsdException Locked=3D"false" Priority=3D"35" QFormat=3D"true" Name=3D=
"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"page number"/>
  <w:LsdException Locked=3D"false" Priority=3D"10" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" Name=3D"Default Paragraph=
 Font"/>
  <w:LsdException Locked=3D"false" Priority=3D"11" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"22" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" Priority=3D"20" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"Document Map"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"Plain Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"0" Name=3D"Balloon Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"59" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" SemiHidden=3D"false" UnhideWhenUsed=3D"f=
alse"
   QFormat=3D"true" Name=3D"No Spacing"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Medium =
Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" UnhideWhenUsed=3D"false"
   QFormat=3D"true" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Shading Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light List Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Grid Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 1 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 2 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 1 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Revision"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 2 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 1 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 2 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 3 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Dark List Accent 1"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false"
   Name=3D"Colorful Shading Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Colorful List Accent 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Colorful Grid Accent 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Light Shading Accent 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light List Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Grid Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 1 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 2 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 1 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 2 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 1 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 2 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 3 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Dark List Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Shading Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful List Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Grid Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Shading Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light List Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Grid Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 1 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 2 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 1 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 2 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 1 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 2 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 3 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Dark List Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Shading Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful List Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Grid Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Shading Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light List Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Grid Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 1 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 2 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 1 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 2 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 1 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 2 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 3 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Dark List Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Shading Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful List Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Grid Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Shading Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light List Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Grid Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 1 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 2 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 1 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 2 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 1 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 2 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 3 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Dark List Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Shading Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful List Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Grid Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Shading Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light List Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Light Grid Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 1 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Shading 2 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 1 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium List 2 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 1 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 2 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Medium Grid 3 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Dark List Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Shading Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful List Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Colorful Grid Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" QFormat=3D"true" Name=3D=
"TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:SimSun;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:SimSun;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:3 0 0 0 1 0;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1593833729 1073750107 16 0 415 0;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:3 680460288 22 0 262145 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
h1
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";
	mso-font-kerning:0pt;
	mso-fareast-language:EN-US;
	mso-bidi-font-weight:normal;}
h2
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	tab-stops:18.0pt;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	mso-bidi-font-weight:normal;}
h3
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Normal;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:10.0pt;
	font-family:"Helvetica","sans-serif";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-weight:normal;
	text-decoration:underline;
	text-underline:single;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-priority:99;
	mso-style-link:"Comment Text Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:X-NONE;
	mso-fareast-language:X-NONE;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 216.0pt right 432.0pt;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 216.0pt right 432.0pt;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
span.MsoCommentReference
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-ansi-font-size:8.0pt;
	mso-bidi-font-size:8.0pt;}
span.MsoPageNumber
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	mso-style-parent:"";
	mso-ansi-font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
pre
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-link:"HTML Preformatted Char";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:X-NONE;
	mso-fareast-language:X-NONE;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"Comment Text";
	mso-style-link:"Comment Subject Char";
	mso-style-next:"Comment Text";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:X-NONE;
	mso-fareast-language:X-NONE;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-unhide:no;
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Courier New";
	mso-fareast-language:EN-US;}
p.Head2, li.Head2, div.Head2
	{mso-style-name:"Head 2";
	mso-style-priority:99;
	mso-style-unhide:no;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	tab-stops:22.3pt;
	border:none;
	mso-border-bottom-alt:solid windowtext .5pt;
	padding:0cm;
	mso-padding-alt:0cm 0cm 1.0pt 0cm;
	font-size:13.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.Head3, li.Head3, div.Head3
	{mso-style-name:"Head 3";
	mso-style-unhide:no;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:right;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.Head, li.Head, div.Head
	{mso-style-name:Head;
	mso-style-unhide:no;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:9.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	tab-stops:18.0pt;
	font-size:16.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Comment Text";
	font-family:"Arial","sans-serif";
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	mso-ansi-language:X-NONE;
	mso-fareast-language:X-NONE;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Comment Subject";
	font-family:"Arial","sans-serif";
	mso-ascii-font-family:Arial;
	mso-hansi-font-family:Arial;
	font-weight:bold;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"HTML Preformatted";
	mso-ansi-font-size:11.0pt;
	font-family:"Courier New";
	mso-ascii-font-family:"Courier New";
	mso-hansi-font-family:"Courier New";
	mso-bidi-font-family:Helvetica;}
p.ColorfulShading-Accent11, li.ColorfulShading-Accent11, div.ColorfulShadin=
g-Accent11
	{mso-style-name:"Colorful Shading - Accent 11";
	mso-style-priority:71;
	mso-style-unhide:no;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-size:10.0pt;
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	mso-fareast-language:EN-US;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("cp-germcell-16protocol-3102_files/header.htm"=
) fs;
	mso-footnote-continuation-separator:url("cp-germcell-16protocol-3102_files=
/header.htm") fcs;
	mso-footnote-continuation-notice:url("cp-germcell-16protocol-3102_files/he=
ader.htm") fcn;
	mso-endnote-separator:url("cp-germcell-16protocol-3102_files/header.htm") =
es;
	mso-endnote-continuation-separator:url("cp-germcell-16protocol-3102_files/=
header.htm") ecs;
	mso-endnote-continuation-notice:url("cp-germcell-16protocol-3102_files/hea=
der.htm") ecn;}
@page WordSection1
	{size:612.0pt 792.0pt;
	margin:72.0pt 54.0pt 72.0pt 54.0pt;
	mso-header-margin:36.0pt;
	mso-footer-margin:46.8pt;
	mso-title-page:yes;
	mso-header:url("cp-germcell-16protocol-3102_files/header.htm") h1;
	mso-even-footer:url("cp-germcell-16protocol-3102_files/header.htm") ef1;
	mso-footer:url("cp-germcell-16protocol-3102_files/header.htm") f1;
	mso-first-header:url("cp-germcell-16protocol-3102_files/header.htm") fh1;
	mso-first-footer:url("cp-germcell-16protocol-3102_files/header.htm") ff1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:612.0pt 792.0pt;
	margin:72.0pt 54.0pt 72.0pt 54.0pt;
	mso-header-margin:36.0pt;
	mso-footer-margin:46.8pt;
	mso-header:url("cp-germcell-16protocol-3102_files/header.htm") h2;
	mso-even-footer:url("cp-germcell-16protocol-3102_files/header.htm") ef1;
	mso-footer:url("cp-germcell-16protocol-3102_files/header.htm") f2;
	mso-first-header:url("cp-germcell-16protocol-3102_files/header.htm") fh2;
	mso-first-footer:url("cp-germcell-16protocol-3102_files/header.htm") ff1;
	mso-paper-source:0;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:612.0pt 792.0pt;
	margin:72.0pt 54.0pt 72.0pt 54.0pt;
	mso-header-margin:36.0pt;
	mso-footer-margin:46.8pt;
	mso-header:url("cp-germcell-16protocol-3102_files/header.htm") h3;
	mso-even-footer:url("cp-germcell-16protocol-3102_files/header.htm") ef1;
	mso-footer:url("cp-germcell-16protocol-3102_files/header.htm") f3;
	mso-first-header:url("cp-germcell-16protocol-3102_files/header.htm") fh2;
	mso-first-footer:url("cp-germcell-16protocol-3102_files/header.htm") ff1;
	mso-paper-source:0;}
div.WordSection3
	{page:WordSection3;}
 /* List Definitions */
 @list l0
	{mso-list-id:-227;
	mso-list-template-ids:550816202;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:"";
	mso-level-tab-stop:0cm;
	mso-level-number-position:left;
	margin-left:0cm;
	text-indent:0cm;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	margin-left:54.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	margin-left:90.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	margin-left:126.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:\F0FA;
	mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	margin-left:162.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	margin-left:198.0pt;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	margin-left:234.0pt;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	margin-left:270.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0FA;
	mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	margin-left:306.0pt;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l1
	{mso-list-id:448014286;
	mso-list-type:simple;
	mso-list-template-ids:1970799008;}
@list l1:level1
	{mso-level-number-format:alpha-upper;
	mso-level-tab-stop:90.0pt;
	mso-level-number-position:left;
	margin-left:90.0pt;
	text-indent:-18.0pt;}
@list l2
	{mso-list-id:856116803;
	mso-list-type:hybrid;
	mso-list-template-ids:1408670284 -444199974 288944708 -1051435342 17157818=
96 -681032084 464942210 974564830 -1768227878 -1633393100;}
@list l2:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:-;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";}
@list l2:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l2:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l2:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l2:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l2:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";
	mso-bidi-font-family:"Times New Roman";}
@list l2:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3
	{mso-list-id:1037967166;
	mso-list-type:hybrid;
	mso-list-template-ids:-1540179718 67698689 67698691 67698693 67698689 6769=
8691 67698693 67698689 67698691 67698693;}
@list l3:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
@list l3:level2
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level5
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l3:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l3:level8
	{mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:"Courier New";}
@list l3:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0A7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Wingdings;}
@list l4
	{mso-list-id:1144546185;
	mso-list-type:hybrid;
	mso-list-template-ids:-1347527842 67698689 67698689 67698715 67698703 6769=
8713 67698715 67698703 67698713 67698715;}
@list l4:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level2
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l4:level3
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;
	mso-bidi-font-family:"Times New Roman";}
@list l4:level4
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-bidi-font-family:"Times New Roman";}
@list l4:level5
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-bidi-font-family:"Times New Roman";}
@list l4:level6
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;
	mso-bidi-font-family:"Times New Roman";}
@list l4:level7
	{mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-bidi-font-family:"Times New Roman";}
@list l4:level8
	{mso-level-number-format:alpha-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	mso-bidi-font-family:"Times New Roman";}
@list l4:level9
	{mso-level-number-format:roman-lower;
	mso-level-tab-stop:none;
	mso-level-number-position:right;
	text-indent:-9.0pt;
	mso-bidi-font-family:"Times New Roman";}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-language:EN-US;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"2049"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DEN-US style=3D'tab-interval:36.0pt'>

<div class=3DWordSection1>

<p class=3DHead>Protocol for the Examination of Specimens From Patients With
Extragonadal Germ Cell Tumors*</p>

<p class=3DHead2 style=3D'border:none;mso-padding-alt:0cm 0cm 0cm 0cm'><span
style=3D'font-size:10.0pt;mso-bidi-font-family:Arial'><o:p>&nbsp;</o:p></sp=
an></p>

<table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D697
 style=3D'width:522.9pt;border-collapse:collapse;mso-yfti-tbllook:160;mso-p=
adding-alt:
 0cm 5.4pt 0cm 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=3D295 valign=3Dtop style=3D'width:221.4pt;padding:0cm 5.4pt 0cm=
 5.4pt'>
  <p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
  tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
  style=3D'mso-fareast-font-family:SimSun;mso-bidi-font-family:Arial'>Versi=
on: </span></b><span
  style=3D'mso-fareast-font-family:SimSun;mso-bidi-font-family:Arial'>GermC=
ell
  3.1.0.2<b style=3D'mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
  <td width=3D402 colspan=3D2 valign=3Dtop style=3D'width:301.5pt;padding:0=
cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
  tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
  style=3D'mso-fareast-font-family:SimSun;mso-bidi-font-family:Arial'>Proto=
col
  Posting Date: </span></b><span style=3D'mso-fareast-font-family:SimSun;
  mso-bidi-font-family:Arial'>August 2016<b style=3D'mso-bidi-font-weight:n=
ormal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1;mso-yfti-lastrow:yes;mso-row-margin-right:45.=
0pt'>
  <td width=3D637 colspan=3D2 valign=3Dtop style=3D'width:477.9pt;padding:0=
cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Includes =
the Children&#8217;s
  Oncology Group staging system<o:p></o:p></span></p>
  <p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><o:p>&nbsp;=
</o:p></b></p>
  <p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'>This protoc=
ol is NOT
  required <span style=3D'color:black'>for accreditation purposes</span></b=
><b
  style=3D'mso-bidi-font-weight:normal'><span style=3D'mso-bidi-font-family=
:Arial'><o:p></o:p></span></b></p>
  <p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
  tab-stops:18.0pt'><span style=3D'mso-fareast-font-family:SimSun;mso-bidi-=
font-family:
  Arial'><o:p>&nbsp;</o:p></span></p>
  </td>
  <td style=3D'mso-cell-special:placeholder;border:none;padding:0cm 0cm 0cm=
 0cm'
  width=3D60><p class=3D'MsoNormal'>&nbsp;</td>
 </tr>
 <![if !supportMisalignedColumns]>
 <tr height=3D0>
  <td width=3D295 style=3D'border:none'></td>
  <td width=3D342 style=3D'border:none'></td>
  <td width=3D60 style=3D'border:none'></td>
 </tr>
 <![endif]>
</table>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>*</span></b><span style=3D'mso-bidi-fo=
nt-family:
Arial'>This protocol applies to pediatric and adult patients with germ cell
tumors located in the mediastinum, sacrococcygeal area, retroperitoneum, ne=
ck,
and intracranial sites.<b style=3D'mso-bidi-font-weight:normal'><o:p></o:p>=
</b></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial;mso-font-kerning:9.0pt'>The following s=
hould NOT
be reported using this protocol:<o:p></o:p></span></b></p>

<table class=3DMsoNormalTable border=3D1 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D630
 style=3D'width:472.5pt;margin-left:5.4pt;border-collapse:collapse;border:n=
one;
 mso-border-alt:solid windowtext .5pt;mso-yfti-tbllook:160;mso-padding-alt:
 0cm 5.4pt 0cm 5.4pt;mso-border-insideh:.5pt solid windowtext;mso-border-in=
sidev:
 .5pt solid windowtext'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes'>
  <td width=3D630 valign=3Dtop style=3D'width:472.5pt;border:solid windowte=
xt 1.0pt;
  mso-border-alt:solid windowtext .5pt;background:silver;padding:0cm 5.4pt =
0cm 5.4pt'>
  <p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
  style=3D'mso-fareast-font-family:SimSun;mso-bidi-font-family:Arial'>Tumor=
 Type<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1'>
  <td width=3D630 valign=3Dtop style=3D'width:472.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:none'>Testicular germ cell t=
umors
  (consider the Testis protocol)</p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2;mso-yfti-lastrow:yes'>
  <td width=3D630 valign=3Dtop style=3D'width:472.5pt;border:solid windowte=
xt 1.0pt;
  border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:s=
olid windowtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=3DMsoNormal style=3D'mso-pagination:none'>Ovarian germ cell tumo=
rs
  (consider the Ovary, Fallopian Tube, Peritoneum protocol)</p>
  </td>
 </tr>
</table>

<h2><i style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:11.0pt=
'><o:p>&nbsp;</o:p></span></i></h2>

<h2><span style=3D'mso-bidi-font-family:Arial'>Authors<o:p></o:p></span></h=
2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Erin Rudzin=
ski,
MD*; Megan Dishop, MD*; M. John Hicks, MD<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial;mso-font-ker=
ning:
9.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial;mso-font-ker=
ning:
9.0pt'>With guidance from the CAP Cancer and CAP Pathology Electronic Repor=
ting
Committees.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:3.0pt'><i style=3D'mso-bidi-font-s=
tyle:normal'><span
style=3D'font-size:9.0pt;mso-bidi-font-family:Arial;mso-font-kerning:9.0pt'=
>*
Denotes primary author. </span></i><i style=3D'mso-bidi-font-style:normal'>=
<span
style=3D'font-size:9.0pt;mso-bidi-font-family:Arial;mso-font-kerning:10.0pt=
'>A</span></i><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:9.0pt;mso-bid=
i-font-family:
Arial;mso-font-kerning:9.0pt'>ll other contributing authors are listed alph=
abetically.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'tab-stops:center 252.0pt'><span style=3D'mso-=
bidi-font-family:
Arial;mso-font-kerning:9.0pt'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:0cm'><b style=3D'mso-bidi-font-weig=
ht:normal'><span
style=3D'mso-bidi-font-size:12.0pt;mso-bidi-font-family:Arial;mso-font-kern=
ing:
9.0pt'>Accreditation Requirements<o:p></o:p></span></b></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-size:12.0pt;mso-bidi-font=
-family:
Arial'>The use of this protocol is recommended for clinical care purposes, =
but
is not required for accreditation purposes.<span style=3D'color:black'> </s=
pan><span
style=3D'mso-bidi-font-style:italic'><o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'tab-stops:center 252.0pt'><span style=3D'mso-=
bidi-font-size:
12.0pt;mso-bidi-font-family:Arial;mso-font-kerning:9.0pt'><o:p>&nbsp;</o:p>=
</span></p>

<table class=3DMsoNormalTable border=3D0 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D649
 style=3D'width:486.9pt;border-collapse:collapse;mso-yfti-tbllook:160;mso-p=
adding-alt:
 0cm 5.4pt 0cm 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes;
  height:9.0pt'>
  <td width=3D649 valign=3Dtop style=3D'width:486.9pt;padding:0cm 5.4pt 0cm=
 5.4pt;
  height:9.0pt'>
  <p class=3DMsoNormal style=3D'margin-right:22.5pt;page-break-after:avoid;
  mso-outline-level:2;tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:no=
rmal'><span
  style=3D'mso-bidi-font-size:12.0pt;mso-fareast-font-family:SimSun;mso-bid=
i-font-family:
  Arial'>CAP Laboratory Accreditation Program Protocol Required Use Date: N=
ot
  applicable</span></b><b style=3D'mso-bidi-font-weight:normal'><i
  style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:8.0pt;mso-f=
areast-font-family:
  SimSun;mso-bidi-font-family:Arial'><o:p></o:p></span></i></b></p>
  </td>
 </tr>
</table>

<p class=3DMsoNormal><u><span style=3D'mso-bidi-font-family:Verdana'><o:p><=
span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></u></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Summary of Changes<o:p></o:p></span></=
b></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>V3.2.0.2 - =
Regional
lymph node order modified to report number involved before number examined =
<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

</div>

<span style=3D'font-size:10.0pt;font-family:"Arial","sans-serif";mso-fareas=
t-font-family:
"Times New Roman";mso-bidi-font-family:"Times New Roman";mso-ansi-language:
EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA'><br clear=3Dall
style=3D'page-break-before:always;mso-break-type:section-break'>
</span>

<div class=3DWordSection2>

<div style=3D'mso-element:para-border-div;border:none;border-bottom:solid w=
indowtext 1.0pt;
mso-border-bottom-alt:solid windowtext .5pt;padding:0cm 0cm 1.0pt 0cm'>

<p class=3DHead2>Surgical Pathology Cancer Case Summary</p>

</div>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Protocol po=
sting
date: August 2016<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h1><span style=3D'mso-bidi-font-family:Arial'>EXTRAGONADAL GERM CELL TUMOR=
: Biopsy,
Resection<o:p></o:p></span></h1>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial;mso-font-kerning:11.0pt'>Note: This case
summary is recommended for reporting Extragonadal Germ Cell tumors, but is =
not
required for accreditation purposes.<o:p></o:p></span></b></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Select a single response unless otherw=
ise
indicated.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Procedure<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><u><span style=3D'mso-bidi-font-family:Arial'>Biopsy<o:p>=
</o:p></span></u></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><span style=3D'mso-bidi-font-family:Arial'>___ Core needle
biopsy<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><span style=3D'mso-bidi-font-family:Arial'>___ Incisional=
 biopsy<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><span style=3D'mso-bidi-font-family:Arial'>___ Excisional
biopsy<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;</o=
:p></span></p>

<p class=3DMsoNormal><u><span style=3D'mso-bidi-font-family:Arial'>Resectio=
n<o:p></o:p></span></u></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Marginal
resection<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Wide re=
section<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Other
(specify): _________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Not spe=
cified<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Patient Age (Note A)<o:p></o:p></span>=
</b></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___
Congenital/neonatal (birth - 6 mo)<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___
Childhood/prepubertal (7 mo - 11 y)<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Postpub=
ertal/adult
(&#8805;12 y)<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Tumor Site (Note B)</span></b><span
style=3D'mso-bidi-font-family:Arial'><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Intracr=
anial<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Head an=
d neck
region (including thyroid; excluding intracranial)<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Mediast=
inum
(pericardium, heart, thymus, and lung)<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___
Retroperitoneum/abdomen<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Sacroco=
ccygeal<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Other
(specify): ________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Not spe=
cified<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Tumor Size (Note C)<o:p></o:p></span><=
/b></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Greatest di=
mension:
___ cm<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ Additional
dimensions: ___ x ___ cm<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Cannot =
be
determined (explain): ___________________________ <o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Histologic Type (Note D) <o:p></o:p></=
span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><o:p>&nbsp;</o:p=
></b></p>

<h3><span style=3D'font-family:"Arial","sans-serif"'>Teratoma<o:p></o:p></s=
pan></h3>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial;color:black'>___ Mature teratoma<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial;color:black'>___ Immature teratoma<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:22.5pt;text-indent:-22.5pt;page-b=
reak-after:
avoid'><span style=3D'mso-bidi-font-family:Arial'>___ Mature or immature te=
ratoma
with additional malignant somatic component <br>
(specify type, eg, epithelial malignancy, sarcoma): _______________________=
___<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><u><span style=3D'mso-bidi-font-family:Arial'>Malignan=
t Germ
Cell<o:p></o:p></span></u></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Germino=
ma<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Yolk sa=
c tumor<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Embryon=
al
carcinoma<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Chorioc=
arcinoma<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:22.5pt;text-indent:-22.5pt'><span
style=3D'mso-bidi-font-family:Arial'>___ Mixed germ cell tumor (any combina=
tion
of the above, with or without teratoma) <br>
(specify components):&nbsp;___________________________<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:22.5pt;text-indent:-22.5pt'><span
style=3D'mso-bidi-font-family:Arial'>___ Cannot be determined (explain):
________________________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>+ Histologic Grade (applicable to imma=
ture
teratomas only) (Note E)<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-left:72.0pt;text-indent:-72.0pt'><span
style=3D'mso-bidi-font-family:Arial'>+ ___ Grade 1<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:72.0pt;text-indent:-72.0pt'><span
style=3D'mso-bidi-font-family:Arial'>+ ___ Grade 2<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:72.0pt;text-indent:-72.0pt'><span
style=3D'mso-bidi-font-family:Arial'>+ ___ Grade 3<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:72.0pt;text-indent:-36.0pt'><span
style=3D'mso-bidi-font-family:Arial'>+ Percent of teratoma composed of imma=
ture
elements (if applicable): ____%<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:72.0pt;text-indent:-72.0pt'><span
style=3D'mso-bidi-font-family:Arial'>+ ___ Cannot be determined (explain):
____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:72.0pt;text-indent:-72.0pt'><span
style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>+Treatment History<o:p></o:p></span></=
b></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+___ No kno=
wn preoperative
therapy<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+___ Preope=
rative
therapy given<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+___ Not sp=
ecified<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2'><b
style=3D'mso-bidi-font-weight:normal'><span style=3D'mso-bidi-font-family:A=
rial'>+
Treatment Effect (Note F)<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'>+ ___ No known preoperative therapy (not applicable)<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal>+ ___ Not identified</p>

<p class=3DMsoNormal>+ ___ Present</p>

<p class=3DMsoNormal><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>+
Percent tumor necrosis: ____%</p>

<p class=3DMsoNormal>+___ Percent tumor necrosis cannot be determined</p>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:3'><b
style=3D'mso-bidi-font-weight:normal'>Microscopic Tumor Extension (applicab=
le to
sacrococcygeal </b><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>resections</span> only)<o:p></o:p></b>=
</p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Tumor i=
nvolving
coccyx identified<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Coccyx
uninvolved<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Cannot =
be
determined (explain): _______________________________<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:72.0pt;text-indent:-72.0pt'><span
style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Margins (Note G) <o:p></o:p></span></b=
></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Cannot =
be
assessed<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Uninvol=
ved by
tumor<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>Distance
of tumor from closest margin: ____ cm<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>Specify
margin: ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Involve=
d by
tumor<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>Specify
margin: ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DFR
style=3D'mso-bidi-font-family:Arial;mso-ansi-language:FR'>+ Lymph-Vascular
Invasion </span></b><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>(Note G)</span></b><b style=3D'mso-bid=
i-font-weight:
normal'><span lang=3DFR style=3D'mso-bidi-font-family:Arial;mso-ansi-langua=
ge:FR'><o:p></o:p></span></b></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ ___ Not
identified<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ ___ Prese=
nt <o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ ___ Canno=
t be
determined<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>+ Perineural Invasion<o:p></o:p></span=
></b></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ ___ Not
identified<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ ___ Prese=
nt<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ ___ Canno=
t be
determined<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>Regional Lymph Nodes<o:p></o:p></span>=
</b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'>___ No nodes submitted or found<o:p></o:p></span></p>

<p class=3DMsoFooter style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid;tab-stops:36.0pt'><span style=3D'mso-bidi-font-famil=
y:
Arial;mso-font-kerning:10.0pt'><o:p>&nbsp;</o:p></span></p>

<h2><i style=3D'mso-bidi-font-style:normal'><u><span style=3D'mso-bidi-font=
-family:
Arial;font-weight:normal'>Lymph Node Examination (required only if lymph no=
des
are present in the specimen)<o:p></o:p></span></u></i></h2>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:54.0pt;text-indent:-54.0pt;page-b=
reak-after:
avoid'>Number of Lymph Nodes Involved</p>

<p class=3DMsoNormal style=3D'margin-left:54.0pt;text-indent:-54.0pt;page-b=
reak-after:
avoid'><span style=3D'mso-bidi-font-family:Arial'>Specify: ____<o:p></o:p><=
/span></p>

<p class=3DMsoFooter style=3D'text-indent:36.0pt;mso-pagination:widow-orpha=
n lines-together;
page-break-after:avoid'><span style=3D'mso-bidi-font-family:Arial'>Specify
site(s), if known: ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>+
Histologic type present (specify): ____________________________<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-left:54.0pt;text-indent:-54.0pt'><span
style=3D'mso-bidi-font-family:Arial'>___ Number cannot be determined (expla=
in): ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Number of L=
ymph
Nodes Examined<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Specify: __=
__<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>___ Number =
cannot
be determined (explain): ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>Distant Metastasis (required=
 only
if confirmed pathologically for this case)<o:p></o:p></span></h2>

<p class=3DMsoNormal style=3D'tab-stops:49.5pt'><span style=3D'mso-bidi-fon=
t-family:
Arial'>___ Present<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>Specify
site(s), if known: ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
Size of largest metastasis (specify): ____________________________<o:p></o:=
p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
Metastases to other organs (specify): ____________________________<o:p></o:=
p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
Histologic type present (specify): ____________________________<o:p></o:p><=
/span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><b style=3D'mso-bidi-=
font-weight:
normal'><span style=3D'mso-bidi-font-family:Arial'>+ Pathologic Staging (se=
lect
all that apply) (Note H) <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><b style=3D'mso-bidi-=
font-weight:
normal'><o:p>&nbsp;</o:p></b></p>

<h3><span style=3D'font-family:"Arial","sans-serif";text-decoration:none;
text-underline:none'>+ </span><span style=3D'font-family:"Arial","sans-seri=
f";
mso-bidi-font-family:"Times New Roman"'>Children&#8217;s Oncology Group Sta=
ging
for any Malignant Extragonadal Germ Cell Tumors<br>
</span><span style=3D'font-family:"Arial","sans-serif";text-decoration:none;
text-underline:none'><span style=3D'mso-spacerun:yes'>&nbsp;&nbsp; </span><=
/span><span
style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"Times New R=
oman";
text-decoration:none;text-underline:none'>(see also specific staging systems
for mediastinal germ cell tumors)<o:p></o:p></span></h3>

<p class=3DMsoNormal style=3D'margin-top:3.0pt;margin-right:0cm;margin-bott=
om:3.0pt;
margin-left:9.35pt'><i style=3D'mso-bidi-font-style:normal'><span
style=3D'font-size:9.0pt'>Note: COG Staging is based </span></i><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:9.0pt;mso-bid=
i-font-family:
Arial'>on pretreatment tumor characteristics. Clinical information required=
 to
definitively assign stage (eg, gross residual disease or presence of metast=
atic
disease) may not be available to the pathologist. If applicable, the
appropriate stage group may be assigned by the pathologist.</span></i><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:9.0pt'> <o:p>=
</o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-left:67.5pt;text-indent:-67.5pt;page-b=
reak-after:
avoid'><span style=3D'mso-bidi-font-family:Arial'>+ ___ Stage I:<span
style=3D'mso-tab-count:1'>&nbsp; </span>Complete resection at any site;
coccygectomy for sacrococcygeal site; negative tumor margins <o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'margin-left:67.5pt;text-indent:-67.5pt;page-b=
reak-after:
avoid'><span style=3D'mso-bidi-font-family:Arial'>+ ___ Stage II:<span
style=3D'mso-tab-count:1'> </span>Microscopic residual; lymph nodes negativ=
e<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:67.5pt;text-indent:-67.5pt;page-b=
reak-after:
avoid'><span style=3D'mso-bidi-font-family:Arial'>+ ___ Stage III:<span
style=3D'mso-tab-count:1'>&nbsp; </span>Lymph nodes involved by metastatic
disease. Gross residual or biopsy only, retroperitoneal nodes negative or
positive<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:67.5pt;text-indent:-67.5pt'><span
style=3D'mso-bidi-font-family:Arial'>+ ___ Stage IV: Distant metastases,
including liver<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ <u>Moran =
and
Suster Proposed Clinical Staging for Mediastinal Germ Cell Tumors</u><sup>#=
</sup><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:67.5pt;text-indent:-67.5pt'><span
style=3D'mso-bidi-font-family:Arial'>+ ___ Stage I:<span style=3D'mso-tab-c=
ount:
1'>&nbsp; </span>Well-circumscribed tumor with or without focal adhesions to
the pleura or pericardium but without microscopic evidence of invasion into
adjacent structures<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:67.5pt;text-indent:-67.5pt'><span
style=3D'mso-bidi-font-family:Arial'>+ ___ Stage II:<span style=3D'mso-tab-=
count:
1'> </span>Tumor confined to the mediastinum with macroscopic and/or
microscopic evidence of infiltration into adjacent structures (ie, pleura,
pericardium, and great vessels)<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:67.5pt;text-indent:-67.5pt'><span
style=3D'mso-bidi-font-family:Arial'>+ ___ Stage III:<span style=3D'mso-tab=
-count:
1'>&nbsp; </span>Tumor with metastases<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Stage IIIA: With metastases to intrathoracic organs (lymph nodes, lung,
etc)<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Stage IIIB: With extrathoracic metastases<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:6.0pt;margin-right:0cm;margin-bott=
om:0cm;
margin-left:22.3pt;margin-bottom:.0001pt;text-indent:-22.3pt'><sup><span
style=3D'font-size:9.0pt;mso-bidi-font-family:Arial'>#</span></sup><span
style=3D'font-size:9.0pt;mso-bidi-font-family:Arial'> <i style=3D'mso-bidi-=
font-style:
normal'>Applies to adult (postpubertal) extragonadal germ cell tumors.</i><=
o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid;mso-outline-level:2;
tab-stops:18.0pt'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'mso-bidi-font-family:Arial'>+ Additional Clinical or Laboratory Fi=
ndings
(select all that apply)<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span style=3D'mso-bidi-font-family:Arial'>+ ___ No=
ne
identified<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span style=3D'mso-bidi-font-family:Arial'>+ ___
Cytogenetics (Note I)<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Not performed<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Not available<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Normal karyotype<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:widow-orphan lines-together;
page-break-after:avoid'><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Abnormal karyotype<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:2'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp; </span>+
___ Isochromosome 12p abnormality [i(12p)]<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:2'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp; </span>+
___ Other [eg, del(5q), trisomy 8, 11q23 abnormality] (specify):
______________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ ___ Serol=
ogic
markers (Note J)<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Not available<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Serum &#945;-fetoprotein (AFP) (specify level): _______<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Serum human chorionic gonadotropin (HCG) (specify level): _______<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'>+ ___ Associated syndromes (Note K)<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>+
___ Not known<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>+
___ Klinefelter<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>+
___ Down<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Other (eg, intersex, Li Fraumeni) (specify): ________________________<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><span style=3D'mso-bi=
di-font-family:
Arial'>+ ___ Associated malignancy (not part of the extragonadal germ cell
tumor)<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Leukemia (specify): ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Myelodysplastic syndrome (specify): ____________________________<o:p></=
o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp; </span>+
___ Other (specify): ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>+ ___ Other
findings (specify): ____________________________<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'mso-outline-level:2;tab-stops:18.0pt'><b
style=3D'mso-bidi-font-weight:normal'><span style=3D'mso-bidi-font-family:A=
rial'>+ Comment(s)</span></b></p>

</div>

<span style=3D'font-size:10.0pt;font-family:"Arial","sans-serif";mso-fareas=
t-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=3Dall style=3D'page-break-before:always;
mso-break-type:section-break'>
</span>

<div class=3DWordSection3>

<div style=3D'mso-element:para-border-div;border:none;border-bottom:solid w=
indowtext 1.0pt;
mso-border-bottom-alt:solid windowtext .5pt;padding:0cm 0cm 1.0pt 0cm'>

<h1 style=3D'border:none;mso-border-bottom-alt:solid windowtext .5pt;paddin=
g:
0cm;mso-padding-alt:0cm 0cm 1.0pt 0cm'><span style=3D'font-size:13.0pt;
mso-bidi-font-family:Arial'>Explanatory Notes<o:p></o:p></span></h1>

</div>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>A. Patient Age<o:p></o:p></s=
pan></h2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The behavio=
r of
pediatric and adult extragonadal germ cell tumors (EGCTs) is quite distinct=
. As
outlined below, within the pediatric age range, prognosis is worse with
increasing age. Most studies of pediatric EGCTs include both neonates and o=
lder
children, making it difficult to discern the precise pathology and clinical
course of EGCTs in the older child.</span><!--[if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Bethel&lt;/Author&gt;&lt;Year&gt;1=
998&lt;/Year&gt;&lt;RecNum&gt;1&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&=
gt;1&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Bethel,
C. A.&lt;/author&gt;&lt;author&gt;Mutabagani,
K.&lt;/author&gt;&lt;author&gt;Hammond, S.&lt;/author&gt;&lt;author&gt;Besn=
er,
G. E.&lt;/author&gt;&lt;author&gt;Caniano, D.
A.&lt;/author&gt;&lt;author&gt;Cooney, D. R.&lt;/author&gt;&lt;/authors&gt;=
&lt;/contributors&gt;&lt;auth-address&gt;Department
of Surgery, The Children&amp;apos;s Hospital, The Ohio State University,
Columbus, USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Nonteratomato=
us
germ cell tumors in children&lt;/title&gt;&lt;secondary-title&gt;J Pediatr
Surg&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title=
&gt;J
Pediatr Surg&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;1122-6;
discussion
1126-7&lt;/pages&gt;&lt;volume&gt;33&lt;/volume&gt;&lt;number&gt;7&lt;/numb=
er&gt;&lt;keywords&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&=
gt;Chi-Square
Distribution&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword=
&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Chorionic Gonadotropin/blood&lt;/ke=
yword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/key=
word&gt;&lt;keyword&gt;Incidence&lt;/keyword&gt;&lt;keyword&gt;Infant&lt;/k=
eyword&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Ne=
oplasms,
Germ Cell and
Embryonal/blood/*pathology/therapy&lt;/keyword&gt;&lt;keyword&gt;Ohio/epide=
miology&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&lt;keyword&=
gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/metabolism&lt;/keywor=
d&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1998&lt;/year&gt;&lt;pub-dat=
es&gt;&lt;date&gt;Jul&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;acces=
sion-num&gt;9694107&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&l=
t;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;a=
mp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D9694107
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Cushing&lt;/Author&gt;&lt;Year&gt;2004&lt;/Year&gt=
;&lt;RecNum&gt;2&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;2&lt;/rec-nu=
mber&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Cushing,
B.&lt;/author&gt;&lt;author&gt;Giller, R.&lt;/author&gt;&lt;author&gt;Culle=
n,
J. W.&lt;/author&gt;&lt;author&gt;Marina, N.
M.&lt;/author&gt;&lt;author&gt;Lauer, S. J.&lt;/author&gt;&lt;author&gt;Ols=
on,
T. A.&lt;/author&gt;&lt;author&gt;Rogers, P.
C.&lt;/author&gt;&lt;author&gt;Colombani,
P.&lt;/author&gt;&lt;author&gt;Rescorla,
F.&lt;/author&gt;&lt;author&gt;Billmire, D.
F.&lt;/author&gt;&lt;author&gt;Vinocur, C.
D.&lt;/author&gt;&lt;author&gt;Hawkins, E.
P.&lt;/author&gt;&lt;author&gt;Davis, M. M.&lt;/author&gt;&lt;author&gt;Per=
lman,
E. J.&lt;/author&gt;&lt;author&gt;London, W.
B.&lt;/author&gt;&lt;author&gt;Castleberry, R.
P.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;W=
ayne
State University School of Medicine and Children&amp;apos;s Hospital of
Michigan, Detroit, MI, USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;=
Randomized
comparison of combination chemotherapy with etoposide, bleomycin, and either
high-dose or standard-dose cisplatin in children and adolescents with high-=
risk
malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncolog=
y Group
9049 and Children&amp;apos;s Cancer Group
8882&lt;/title&gt;&lt;secondary-title&gt;J Clin
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;J
Clin Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;2691-700&lt;/p=
ages&gt;&lt;volume&gt;22&lt;/volume&gt;&lt;number&gt;13&lt;/number&gt;&lt;k=
eywords&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Antineop=
lastic
Agents/*administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Antineoplastic Combined Chemotherapy
Protocols/adverse&lt;/keyword&gt;&lt;keyword&gt;effects/*therapeutic
use&lt;/keyword&gt;&lt;keyword&gt;Bleomycin&lt;/keyword&gt;&lt;keyword&gt;C=
hild&lt;/keyword&gt;&lt;keyword&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Cisplatin/*administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Disease-Free
Survival&lt;/keyword&gt;&lt;keyword&gt;Dose-Response Relationship,
Drug&lt;/keyword&gt;&lt;keyword&gt;Etoposide&lt;/keyword&gt;&lt;keyword&gt;=
Female&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;M=
ale&lt;/keyword&gt;&lt;keyword&gt;Neoplasms,
Germ Cell and Embryonal/*drug
therapy/pathology&lt;/keyword&gt;&lt;keyword&gt;Ovarian Neoplasms/*drug
therapy/pathology&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&l=
t;keyword&gt;Risk
Factors&lt;/keyword&gt;&lt;keyword&gt;Testicular Neoplasms/*drug
therapy/pathology&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;=
2004&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;Jul
1&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;15226336=
&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www=
.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;=
amp;dopt=3DCitation&amp;amp;list_uids=3D15226336
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;De
Giorgi&lt;/Author&gt;&lt;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;3&lt;/RecNu=
m&gt;&lt;record&gt;&lt;rec-number&gt;3&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;De
Giorgi, U.&lt;/author&gt;&lt;author&gt;Demirer,
T.&lt;/author&gt;&lt;author&gt;Wandt, H.&lt;/author&gt;&lt;author&gt;Tavern=
a,
C.&lt;/author&gt;&lt;author&gt;Siegert,
W.&lt;/author&gt;&lt;author&gt;Bornhauser,
M.&lt;/author&gt;&lt;author&gt;Kozak, T.&lt;/author&gt;&lt;author&gt;Papian=
i,
G.&lt;/author&gt;&lt;author&gt;Ballardini, M.&lt;/author&gt;&lt;author&gt;R=
osti,
G.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;I=
stituto
Oncologico Romagnolo-Santa Maria delle Croci Hospital, Ravenna, Italy.
ugo_degiorgi@yahoo.com&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Secon=
d-line
high-dose chemotherapy in patients with mediastinal and retroperitoneal pri=
mary
non-seminomatous germ cell tumors: the EBMT
experience&lt;/title&gt;&lt;secondary-title&gt;Ann
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;Ann
Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;146-51&lt;/pages&gt=
;&lt;volume&gt;16&lt;/volume&gt;&lt;number&gt;1&lt;/number&gt;&lt;keywords&=
gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Adult&lt;/keywor=
d&gt;&lt;keyword&gt;Antineoplastic
Combined Chemotherapy Protocols/*therapeutic
use&lt;/keyword&gt;&lt;keyword&gt;Cisplatin/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Databases,
Factual&lt;/keyword&gt;&lt;keyword&gt;Disease-Free
Survival&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt=
;Humans&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Me=
diastinal
Neoplasms/*drug therapy/pathology&lt;/keyword&gt;&lt;keyword&gt;Middle
Aged&lt;/keyword&gt;&lt;keyword&gt;Neoplasms, Germ Cell and Embryonal/*drug
therapy/pathology&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&l=
t;keyword&gt;Retroperitoneal
Neoplasms/*drug therapy/pathology&lt;/keyword&gt;&lt;keyword&gt;Retrospecti=
ve
Studies&lt;/keyword&gt;&lt;keyword&gt;Salvage
Therapy&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2005&lt;/y=
ear&gt;&lt;pub-dates&gt;&lt;date&gt;Jan&lt;/date&gt;&lt;/pub-dates&gt;&lt;/=
dates&gt;&lt;accession-num&gt;15598952&lt;/accession-num&gt;&lt;urls&gt;&lt=
;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?c=
md=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=
=3D15598952
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;De
Giorgi&lt;/Author&gt;&lt;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;4&lt;/RecNu=
m&gt;&lt;record&gt;&lt;rec-number&gt;4&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;De
Giorgi, U.&lt;/author&gt;&lt;author&gt;Rosti,
G.&lt;/author&gt;&lt;author&gt;Slavin, S.&lt;/author&gt;&lt;author&gt;Yaniv,
I.&lt;/author&gt;&lt;author&gt;Harousseau, J.
L.&lt;/author&gt;&lt;author&gt;Ladenstein,
R.&lt;/author&gt;&lt;author&gt;Demirer, T.&lt;/author&gt;&lt;author&gt;Dini,
G.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;I=
stituto
Oncologico Romagnolo-Department of Oncology/Haematology, Santa Maria delle
Croci Hospital, Ravenna, Italy.
ugo_degiorgi@yahoo.com&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Salva=
ge
high-dose chemotherapy for children with extragonadal germ-cell
tumours&lt;/title&gt;&lt;secondary-title&gt;Br J
Cancer&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Br
J Cancer&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;412-7&lt;/pages&=
gt;&lt;volume&gt;93&lt;/volume&gt;&lt;number&gt;4&lt;/number&gt;&lt;keyword=
s&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Antineoplastic
Combined Chemotherapy Protocols/*administration &amp;amp;&lt;/keyword&gt;&l=
t;keyword&gt;dosage/adverse
effects&lt;/keyword&gt;&lt;keyword&gt;Brain Neoplasms/drug
therapy&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;C=
hild,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Combined Modality
Therapy&lt;/keyword&gt;&lt;keyword&gt;Databases,
Factual&lt;/keyword&gt;&lt;keyword&gt;Disease-Free Survival&lt;/keyword&gt;=
&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;Hematopoietic
Stem Cell
Transplantation&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;key=
word&gt;Infant&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keywor=
d&gt;Mediastinal
Neoplasms/drug therapy&lt;/keyword&gt;&lt;keyword&gt;Neoplasms, Germ Cell a=
nd
Embryonal/*drug therapy&lt;/keyword&gt;&lt;keyword&gt;Remission Induction&l=
t;/keyword&gt;&lt;keyword&gt;Retroperitoneal
Neoplasms/drug therapy&lt;/keyword&gt;&lt;keyword&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Salvage
Therapy&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2005&lt;/y=
ear&gt;&lt;pub-dates&gt;&lt;date&gt;Aug
22&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;1610624=
8&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://ww=
w.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp=
;amp;dopt=3DCitation&amp;amp;list_uids=3D16106248
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Lo
Curto&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt;&lt;RecNum&gt;5&lt;/RecNum=
&gt;&lt;record&gt;&lt;rec-number&gt;5&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Lo
Curto, M.&lt;/author&gt;&lt;author&gt;Lumia, F.&lt;/author&gt;&lt;author&gt=
;Alaggio,
R.&lt;/author&gt;&lt;author&gt;Cecchetto,
G.&lt;/author&gt;&lt;author&gt;Almasio, P.&lt;/author&gt;&lt;author&gt;Indo=
lfi,
P.&lt;/author&gt;&lt;author&gt;Siracusa,
F.&lt;/author&gt;&lt;author&gt;Bagnulo, S.&lt;/author&gt;&lt;author&gt;De
Bernardi, B.&lt;/author&gt;&lt;author&gt;De Laurentis,
T.&lt;/author&gt;&lt;author&gt;Di Cataldo, A.&lt;/author&gt;&lt;author&gt;T=
amaro,
P.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;D=
ipartimento
Materno Infantile, University of Palermo, Italy.
oncped@katamail.com&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Malignant
germ cell tumors in childhood: results of the first Italian cooperative stu=
dy
&amp;quot;TCG 91&amp;quot;&lt;/title&gt;&lt;secondary-title&gt;Med Pediatr
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;Med
Pediatr
Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;417-25&lt;/pages&gt=
;&lt;volume&gt;41&lt;/volume&gt;&lt;number&gt;5&lt;/number&gt;&lt;keywords&=
gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Age
Distribution&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword=
&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Cohort
Studies&lt;/keyword&gt;&lt;keyword&gt;Combined Modality
Therapy&lt;/keyword&gt;&lt;keyword&gt;Confidence
Intervals&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&g=
t;Germinoma/epidemiology/*pathology/*therapy&lt;/keyword&gt;&lt;keyword&gt;=
Humans&lt;/keyword&gt;&lt;keyword&gt;Incidence&lt;/keyword&gt;&lt;keyword&g=
t;Italy/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;=
keyword&gt;Multivariate
Analysis&lt;/keyword&gt;&lt;keyword&gt;Neoplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Ovarian Neoplasms/epidemiology/*patho=
logy/*therapy&lt;/keyword&gt;&lt;keyword&gt;Probability&lt;/keyword&gt;&lt;=
keyword&gt;Prognosis&lt;/keyword&gt;&lt;keyword&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Risk
Assessment&lt;/keyword&gt;&lt;keyword&gt;Sex
Distribution&lt;/keyword&gt;&lt;keyword&gt;Survival
Analysis&lt;/keyword&gt;&lt;keyword&gt;Testicular Neoplasms/epidemiology/*p=
athology/*therapy&lt;/keyword&gt;&lt;keyword&gt;Treatment
Outcome&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2003&lt;/y=
ear&gt;&lt;pub-dates&gt;&lt;date&gt;Nov&lt;/date&gt;&lt;/pub-dates&gt;&lt;/=
dates&gt;&lt;accession-num&gt;14515380&lt;/accession-num&gt;&lt;urls&gt;&lt=
;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?c=
md=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=
=3D14515380
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>1-5</sup></span><!--[if supportFi=
elds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> A recent study</span><!--[if supportF=
ields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Marina&lt;/Author&gt;&lt;Year&gt;2=
006&lt;/Year&gt;&lt;RecNum&gt;6&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&=
gt;6&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Marina,
N.&lt;/author&gt;&lt;author&gt;London, W.
B.&lt;/author&gt;&lt;author&gt;Frazier, A.
L.&lt;/author&gt;&lt;author&gt;Lauer, S.&lt;/author&gt;&lt;author&gt;Rescor=
la,
F.&lt;/author&gt;&lt;author&gt;Cushing,
B.&lt;/author&gt;&lt;author&gt;Malogolowkin, M.
H.&lt;/author&gt;&lt;author&gt;Castleberry, R.
P.&lt;/author&gt;&lt;author&gt;Womer, R. B.&lt;/author&gt;&lt;author&gt;Ols=
on,
T.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;S=
tanford
University Medical Center, Stanford, CA 94304-1812, USA.
neyssa.marina@stanford.edu&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;P=
rognostic
factors in children with extragonadal malignant germ cell tumors: a pediatr=
ic
intergroup study&lt;/title&gt;&lt;secondary-title&gt;J Clin
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;J
Clin Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;2544-8&lt;/pag=
es&gt;&lt;volume&gt;24&lt;/volume&gt;&lt;number&gt;16&lt;/number&gt;&lt;key=
words&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Age
Factors&lt;/keyword&gt;&lt;keyword&gt;Analysis of
Variance&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;=
Disease-Free
Survival&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt=
;Germinoma/blood/*diagnosis/pathology/therapy&lt;/keyword&gt;&lt;keyword&gt=
;Humans&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Ne=
oplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Predictive Value of
Tests&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&lt;keyword&gt=
;Proportional
Hazards Models&lt;/keyword&gt;&lt;keyword&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Risk
Factors&lt;/keyword&gt;&lt;keyword&gt;Survival
Analysis&lt;/keyword&gt;&lt;keyword&gt;Tumor Markers,
Biological/blood&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/metabolis=
m&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2006&lt;/year&gt=
;&lt;pub-dates&gt;&lt;date&gt;Jun
1&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;16735707=
&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www=
.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;=
amp;dopt=3DCitation&amp;amp;list_uids=3D16735707
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>6</sup></span><!--[if supportFiel=
ds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> has suggested that age 12 years or ol=
der is
a significantly adverse prognostic factor, especially for thoracic tumors, =
and
therefore may represent the transition point to adult type tumors. <o:p></o=
:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The notes t=
hat
follow are divided into congenital/neonatal EGCTs (birth to 6 months) and
childhood/prepubertal GCTs (7 months to approximately 12 years) because of =
the
well-documented differences in their pathology and prognosis.
Postpubertal/adult EGCTs are defined as occurring in patients 12 years and
older.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>These notes
describe important differences in the pathologic diagnosis and prognosis of
EGCTs in different age groups: congenital/neonatal, children (prepubertal),=
 and
adult (postpubertal). They are summarized in the Table. Within each age gro=
up,
the significance of anatomic site and morphologic subtyping is emphasized.
Other issues discussed include postchemotherapy evaluation, unique associat=
ed
malignancies, and associated syndromes. Finally, discussion of differential
diagnoses is presented based on anatomic location and patient age.<o:p></o:=
p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<div align=3Dcenter>

<table class=3DMsoNormalTable border=3D1 cellspacing=3D0 cellpadding=3D0 wi=
dth=3D571
 style=3D'width:428.35pt;margin-left:-23.85pt;border-collapse:collapse;
 border:none;mso-border-alt:solid windowtext .5pt;mso-padding-alt:0cm 5.4pt=
 0cm 5.4pt'>
 <tr style=3D'mso-yfti-irow:0;mso-yfti-firstrow:yes;height:11.2pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border:solid windowt=
ext 1.0pt;
  mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt;height:1=
1.2pt'>
  <p class=3DMsoNormal style=3D'margin-top:3.0pt;margin-right:0cm;margin-bo=
ttom:
  3.0pt;margin-left:0cm'><b style=3D'mso-bidi-font-weight:normal'><span
  style=3D'mso-bidi-font-family:Arial'>Key Features of Extragonadal Germ Ce=
ll
  Tumors (GCTs)</span></b><span style=3D'mso-bidi-font-family:Arial'><o:p><=
/o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:1;height:14.75pt'>
  <td width=3D571 style=3D'width:428.35pt;border-top:none;border-left:solid=
 windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;mso-border-top-alt:
  solid windowtext .5pt;mso-border-top-alt:solid windowtext .5pt;mso-border=
-left-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:14.75pt'>
  <p class=3DMsoNormal style=3D'margin-top:3.0pt'><span style=3D'mso-bidi-f=
ont-family:
  Arial'>Congenital/neonatal (birth - 6 mo)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:2;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Sacrococcygeal site most common<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:3;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>All sites appear to behave similarly<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:4;height:10.3pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.3pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Most are teratoma with or without yolk sac tumor<o:p></o:p></span>=
</p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:5;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Immaturity and histologic type of GCT may not be critical<o:p></o:=
p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:6;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Conservative approach with follow-up after surgical excision may be
  indicated<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:7;height:11.3pt'>
  <td width=3D571 style=3D'width:428.35pt;border-top:none;border-left:solid=
 windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;mso-border-left-al=
t:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:11.3pt'>
  <p class=3DMsoNormal style=3D'margin-top:3.0pt'><span style=3D'mso-bidi-f=
ont-family:
  Arial'>Childhood (7 mo - puberty)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:8;height:9.45pt'>
  <td width=3D571 style=3D'width:428.35pt;border-top:none;border-left:solid=
 windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;mso-border-left-al=
t:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:9.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Rare<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:9;height:11.45pt'>
  <td width=3D571 style=3D'width:428.35pt;border-top:none;border-left:solid=
 windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;mso-border-left-al=
t:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:11.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>More frequently yolk sac tumor<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:10;height:10.3pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.3pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>More frequent aggressive behavior and worse prognosis than neonata=
l<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:11;height:9.45pt'>
  <td width=3D571 style=3D'width:428.35pt;border-top:none;border-left:solid=
 windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;mso-border-left-al=
t:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:9.45pt'>
  <p class=3DMsoNormal style=3D'margin-top:3.0pt'><span style=3D'mso-bidi-f=
ont-family:
  Arial'>Adult (postpubertal)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:12;height:11.45pt'>
  <td width=3D571 style=3D'width:428.35pt;border-top:none;border-left:solid=
 windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;mso-border-left-al=
t:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:11.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>All may be associated with the development of non-germ cell neopla=
sms<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:13;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Generally poor prognosis at any site if present<o:p></o:p></span><=
/p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:14;height:10.3pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.3pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Mediastinal (including thymus)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:15;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Mature teratoma is benign<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:16;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Immature teratoma and other nonteratomatous GCTs are potentially
  aggressive<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:17;height:9.45pt'>
  <td width=3D571 style=3D'width:428.35pt;border-top:none;border-left:solid=
 windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;mso-border-left-al=
t:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:9.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Unique association with hematopoietic neoplasms<o:p></o:p></span><=
/p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:18;height:11.3pt'>
  <td width=3D571 style=3D'width:428.35pt;border-top:none;border-left:solid=
 windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;mso-border-left-al=
t:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:11.3pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Sacrococcygeal<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:19;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Most are mature teratoma, with benign behavior<o:p></o:p></span></=
p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:20;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Immaturity not shown to be an adverse feature<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:21;height:10.3pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.3pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Rarely associated with nonteratomatous GCTs, which behave aggressi=
vely<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:22;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Cervical (including thyroid)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:23;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Mature teratoma is benign<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:24;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-left:34.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Immature teratoma and other nonteratomatous GCTs are potentially
  aggressive<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:25;height:10.3pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border-top:none;bord=
er-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1=
.0pt;
  mso-border-left-alt:solid windowtext .5pt;mso-border-right-alt:solid wind=
owtext .5pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:10.3pt'>
  <p class=3DMsoNormal style=3D'margin-left:16.45pt'><span style=3D'mso-bid=
i-font-family:
  Arial'>Retroperitoneal<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style=3D'mso-yfti-irow:26;mso-yfti-lastrow:yes;height:10.45pt'>
  <td width=3D571 valign=3Dtop style=3D'width:428.35pt;border:solid windowt=
ext 1.0pt;
  border-top:none;mso-border-left-alt:solid windowtext .5pt;mso-border-bott=
om-alt:
  solid windowtext .5pt;mso-border-right-alt:solid windowtext .5pt;padding:
  0cm 5.4pt 0cm 5.4pt;height:10.45pt'>
  <p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bott=
om:6.0pt;
  margin-left:34.55pt'><span style=3D'mso-bidi-font-family:Arial'>Most are
  derived from occult gonadal primary<o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>B. Site<o:p></o:p></span></h=
2>

<p class=3DMsoNormal><u><span style=3D'mso-bidi-font-family:Arial'>Congenit=
al/Neonatal<o:p></o:p></span></u></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Other than =
direct
effects on local vital organs, the behavior of congenital and neonatal
extragonadal GCTs seems to be independent of anatomic location.</span><!--[=
if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Heerema-McKenney&lt;/Author&gt;&lt=
;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;7&lt;/RecNum&gt;&lt;record&gt;&lt;r=
ec-number&gt;7&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Heerema-McKenney,
A.&lt;/author&gt;&lt;author&gt;Harrison, M. R.&lt;/author&gt;&lt;author&gt;=
Bratton,
B.&lt;/author&gt;&lt;author&gt;Farrell,
J.&lt;/author&gt;&lt;author&gt;Zaloudek, C.&lt;/author&gt;&lt;/authors&gt;&=
lt;/contributors&gt;&lt;auth-address&gt;Departments
of Pathology, Division of Pediatric Surgery, and Fetal Treatment Center,
University of California, San Francisco, CA 94143,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Congenital teratoma: a
clinicopathologic study of 22 fetal and neonatal
tumors&lt;/title&gt;&lt;secondary-title&gt;Am J Surg
Pathol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Am
J Surg
Pathol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;29-38&lt;/pages&gt=
;&lt;volume&gt;29&lt;/volume&gt;&lt;number&gt;1&lt;/number&gt;&lt;keywords&=
gt;&lt;keyword&gt;Adult&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt=
;&lt;keyword&gt;Fetal
Diseases/blood/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Fetus&lt;/k=
eyword&gt;&lt;keyword&gt;Gestational
Age&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;Infa=
nt,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Pregnancy&lt;/keyword&gt;&lt;keyword&=
gt;Pregnancy
Complications,
Neoplastic/blood/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Sacrococc=
ygeal
Region/pathology&lt;/keyword&gt;&lt;keyword&gt;Spinal
Neoplasms/*congenital/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Tera=
toma/*congenital/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Treatment
Outcome&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/analysis&lt;/keywo=
rd&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2005&lt;/year&gt;&lt;pub-da=
tes&gt;&lt;date&gt;Jan&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;acce=
ssion-num&gt;15613854&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;=
&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp=
;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D15613854
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Huddart&lt;/Author&gt;&lt;Year&gt;2003&lt;/Year&gt=
;&lt;RecNum&gt;8&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;8&lt;/rec-nu=
mber&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Huddart,
S. N.&lt;/author&gt;&lt;author&gt;Mann, J.
R.&lt;/author&gt;&lt;author&gt;Robinson, K.&lt;/author&gt;&lt;author&gt;Raa=
fat,
F.&lt;/author&gt;&lt;author&gt;Imeson, J.&lt;/author&gt;&lt;author&gt;Gorna=
ll,
P.&lt;/author&gt;&lt;author&gt;Sokal, M.&lt;/author&gt;&lt;author&gt;Gray,
E.&lt;/author&gt;&lt;author&gt;McKeever, P.&lt;/author&gt;&lt;author&gt;Oak=
hill,
A.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;U=
niversity
Hospital of Wales, Heath Park, Cardiff CF4 4XW, UK.
huddartsn@msn.com&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Sacrococcy=
geal
teratomas: the UK Children&amp;apos;s Cancer Study Group&amp;apos;s experie=
nce.
I. Neonatal&lt;/title&gt;&lt;secondary-title&gt;Pediatr Surg
Int&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title&=
gt;Pediatr
Surg
Int&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;47-51&lt;/pages&gt;&l=
t;volume&gt;19&lt;/volume&gt;&lt;number&gt;1-2&lt;/number&gt;&lt;keywords&g=
t;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;Great
Britain/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&l=
t;keyword&gt;Incidence&lt;/keyword&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Ne=
oplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&lt;keyword&=
gt;Sacrococcygeal
Region/*pathology&lt;/keyword&gt;&lt;keyword&gt;Soft Tissue
Neoplasms/*diagnosis/epidemiology/pathology/*therapy&lt;/keyword&gt;&lt;key=
word&gt;Teratoma/*diagnosis/epidemiology/pathology/*therapy&lt;/keyword&gt;=
&lt;keyword&gt;Treatment
Outcome&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2003&lt;/y=
ear&gt;&lt;pub-dates&gt;&lt;date&gt;Apr&lt;/date&gt;&lt;/pub-dates&gt;&lt;/=
dates&gt;&lt;accession-num&gt;12721723&lt;/accession-num&gt;&lt;urls&gt;&lt=
;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?c=
md=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=
=3D12721723
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Marina&lt;/Author&gt;&lt;Year&gt;1992&lt;/Year&gt;=
&lt;RecNum&gt;9&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;9&lt;/rec-num=
ber&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Marina,
N.&lt;/author&gt;&lt;author&gt;Fontanesi, J.&lt;/author&gt;&lt;author&gt;Ku=
n,
L.&lt;/author&gt;&lt;author&gt;Rao, B.&lt;/author&gt;&lt;author&gt;Jenkins,=
 J.
J.&lt;/author&gt;&lt;author&gt;Thompson, E.
I.&lt;/author&gt;&lt;author&gt;Etcubanas,
E.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;D=
epartment
of Hematology/Oncology, St. Jude Children&amp;apos;s Research Hospital,
Memphis, Tennessee 38101-0318.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&=
gt;Treatment
of childhood germ cell tumors. Review of the St. Jude experience from 1979 =
to
1988&lt;/title&gt;&lt;secondary-title&gt;Cancer&lt;/secondary-title&gt;&lt;=
/titles&gt;&lt;periodical&gt;&lt;full-title&gt;Cancer&lt;/full-title&gt;&lt=
;/periodical&gt;&lt;pages&gt;2568-75&lt;/pages&gt;&lt;volume&gt;70&lt;/volu=
me&gt;&lt;number&gt;10&lt;/number&gt;&lt;keywords&gt;&lt;keyword&gt;Adolesc=
ent&lt;/keyword&gt;&lt;keyword&gt;Antineoplastic
Combined Chemotherapy Protocols/*therapeutic
use&lt;/keyword&gt;&lt;keyword&gt;Bleomycin/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;Ch=
ild,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Cisplatin/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Combined Modality
Therapy&lt;/keyword&gt;&lt;keyword&gt;Cyclophosphamide/administration &amp;=
amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Dactinomycin/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;H=
umans&lt;/keyword&gt;&lt;keyword&gt;Infant&lt;/keyword&gt;&lt;keyword&gt;Ma=
le&lt;/keyword&gt;&lt;keyword&gt;Neoplasms,
Germ Cell and
Embryonal/*drug&lt;/keyword&gt;&lt;keyword&gt;therapy/pathology/radiotherap=
y/surgery&lt;/keyword&gt;&lt;keyword&gt;Survival
Analysis&lt;/keyword&gt;&lt;keyword&gt;Vinblastine/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Vincristine/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1992&lt;/ye=
ar&gt;&lt;pub-dates&gt;&lt;date&gt;Nov
15&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;1384951=
&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www=
.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;=
amp;dopt=3DCitation&amp;amp;list_uids=3D1384951
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Marina&lt;/Author&gt;&lt;Year&gt;2006&lt;/Year&gt;=
&lt;RecNum&gt;6&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;6&lt;/rec-num=
ber&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Marina,
N.&lt;/author&gt;&lt;author&gt;London, W.
B.&lt;/author&gt;&lt;author&gt;Frazier, A.
L.&lt;/author&gt;&lt;author&gt;Lauer, S.&lt;/author&gt;&lt;author&gt;Rescor=
la, F.&lt;/author&gt;&lt;author&gt;Cushing,
B.&lt;/author&gt;&lt;author&gt;Malogolowkin, M. H.&lt;/author&gt;&lt;author=
&gt;Castleberry,
R. P.&lt;/author&gt;&lt;author&gt;Womer, R.
B.&lt;/author&gt;&lt;author&gt;Olson,
T.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;S=
tanford
University Medical Center, Stanford, CA 94304-1812, USA. neyssa.marina@stan=
ford.edu&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Prognostic
factors in children with extragonadal malignant germ cell tumors: a pediatr=
ic
intergroup study&lt;/title&gt;&lt;secondary-title&gt;J Clin
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;J
Clin Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;2544-8&lt;/pag=
es&gt;&lt;volume&gt;24&lt;/volume&gt;&lt;number&gt;16&lt;/number&gt;&lt;key=
words&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Age
Factors&lt;/keyword&gt;&lt;keyword&gt;Analysis of
Variance&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;=
Disease-Free
Survival&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt=
;Germinoma/blood/*diagnosis/pathology/therapy&lt;/keyword&gt;&lt;keyword&gt=
;Humans&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Ne=
oplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Predictive Value of
Tests&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&lt;keyword&gt=
;Proportional
Hazards Models&lt;/keyword&gt;&lt;keyword&gt;Retrospective Studies&lt;/keyw=
ord&gt;&lt;keyword&gt;Risk
Factors&lt;/keyword&gt;&lt;keyword&gt;Survival
Analysis&lt;/keyword&gt;&lt;keyword&gt;Tumor Markers,
Biological/blood&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/metabolis=
m&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2006&lt;/year&gt=
;&lt;pub-dates&gt;&lt;date&gt;Jun
1&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;16735707=
&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www=
.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;=
amp;dopt=3DCitation&amp;amp;list_uids=3D16735707
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>6-9</sup></span><!--[if supportFi=
elds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> Sacrococcygeal teratomas are the most
common GCT of the neonate, occurring more frequently in girls.</span><!--[i=
f supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Harms&lt;/Author&gt;&lt;Year&gt;19=
89&lt;/Year&gt;&lt;RecNum&gt;10&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&=
gt;10&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Harms,
D.&lt;/author&gt;&lt;author&gt;Schmidt,
D.&lt;/author&gt;&lt;author&gt;Leuschner,
I.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;A=
bteilung
Paidopathologie, Universitat, Kiel, Federal Republic of
Germany.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Abdominal,
retroperitoneal and sacrococcygeal tumours of the newborn and the very young
infant. Report from the Kiel Paediatric Tumour
Registry&lt;/title&gt;&lt;secondary-title&gt;Eur J
Pediatr&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-ti=
tle&gt;Eur
J Pediatr&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;720-8&lt;/pages=
&gt;&lt;volume&gt;148&lt;/volume&gt;&lt;number&gt;8&lt;/number&gt;&lt;keywo=
rds&gt;&lt;keyword&gt;Abdominal
Neoplasms/epidemiology/*pathology&lt;/keyword&gt;&lt;keyword&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Germany,
West&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;Inf=
ant&lt;/keyword&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Kidney
Neoplasms/epidemiology/pathology&lt;/keyword&gt;&lt;keyword&gt;Liver
Neoplasms/epidemiology/pathology&lt;/keyword&gt;&lt;keyword&gt;Neuroblastom=
a/epidemiology/pathology&lt;/keyword&gt;&lt;keyword&gt;Registries&lt;/keywo=
rd&gt;&lt;keyword&gt;Retroperitoneal
Neoplasms/epidemiology/*pathology&lt;/keyword&gt;&lt;keyword&gt;Sacrococcyg=
eal
Region&lt;/keyword&gt;&lt;keyword&gt;Teratoma/epidemiology/pathology&lt;/ke=
yword&gt;&lt;keyword&gt;Wilms
Tumor/epidemiology/pathology&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&=
lt;year&gt;1989&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;Aug&lt;/date&gt;&l=
t;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;2551691&lt;/accession-nu=
m&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov=
/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitati=
on&amp;amp;list_uids=3D2551691
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>10</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> After intracranial teratomas, other m=
ore
common sites of neonatal teratoma include the mediastinum (pericardium, hea=
rt,
thymus, and lung), head and neck region (including thyroid), and the<span
style=3D'mso-spacerun:yes'>&nbsp; </span>retroperitoneum.</span><!--[if sup=
portFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Dehner&lt;/Author&gt;&lt;Year&gt;1=
983&lt;/Year&gt;&lt;RecNum&gt;12&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number=
&gt;12&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Dehner,
L. P.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;=
title&gt;Gonadal
and extragonadal germ cell neoplasia of childhood&lt;/title&gt;&lt;secondar=
y-title&gt;Hum
Pathol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Hum
Pathol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;493-511&lt;/pages&=
gt;&lt;volume&gt;14&lt;/volume&gt;&lt;number&gt;6&lt;/number&gt;&lt;keyword=
s&gt;&lt;keyword&gt;Abdominal
Neoplasms/pathology&lt;/keyword&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt=
;&lt;keyword&gt;Animals&lt;/keyword&gt;&lt;keyword&gt;Cell
Transformation,
Neoplastic/pathology&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt=
;keyword&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Choriocarcinoma/pathology&lt;/keywo=
rd&gt;&lt;keyword&gt;Dysgerminoma/classification/epidemiology/*pathology&lt=
;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;Head
and Neck
Neoplasms/pathology&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt=
;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Me=
sonephroma/pathology&lt;/keyword&gt;&lt;keyword&gt;Mice&lt;/keyword&gt;&lt;=
keyword&gt;Ovarian
Neoplasms/classification/epidemiology/*pathology&lt;/keyword&gt;&lt;keyword=
&gt;Pregnancy&lt;/keyword&gt;&lt;keyword&gt;Sacrococcygeal
Region&lt;/keyword&gt;&lt;keyword&gt;Teratoma/classification/epidemiology/*=
pathology&lt;/keyword&gt;&lt;keyword&gt;Testicular
Neoplasms/classification/epidemiology/*pathology&lt;/keyword&gt;&lt;keyword=
&gt;Thoracic
Neoplasms/pathology&lt;/keyword&gt;&lt;keyword&gt;United
States&lt;/keyword&gt;&lt;keyword&gt;Uterine
Neoplasms/pathology&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&g=
t;1983&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;Jun&lt;/date&gt;&lt;/pub-da=
tes&gt;&lt;/dates&gt;&lt;accession-num&gt;6343221&lt;/accession-num&gt;&lt;=
urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/q=
uery.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;am=
p;list_uids=3D6343221
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Heerema-McKenney&lt;/Author&gt;&lt;Year&gt;2005&lt=
;/Year&gt;&lt;RecNum&gt;7&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;7&l=
t;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Heerema-McKenney,
A.&lt;/author&gt;&lt;author&gt;Harrison, M. R.&lt;/author&gt;&lt;author&gt;=
Bratton,
B.&lt;/author&gt;&lt;author&gt;Farrell,
J.&lt;/author&gt;&lt;author&gt;Zaloudek, C.&lt;/author&gt;&lt;/authors&gt;&=
lt;/contributors&gt;&lt;auth-address&gt;Departments
of Pathology, Division of Pediatric Surgery, and Fetal Treatment Center,
University of California, San Francisco, CA 94143,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Congenital teratoma: a
clinicopathologic study of 22 fetal and neonatal
tumors&lt;/title&gt;&lt;secondary-title&gt;Am J Surg
Pathol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Am
J Surg Pathol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;29-38&lt;/p=
ages&gt;&lt;volume&gt;29&lt;/volume&gt;&lt;number&gt;1&lt;/number&gt;&lt;ke=
ywords&gt;&lt;keyword&gt;Adult&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/key=
word&gt;&lt;keyword&gt;Fetal
Diseases/blood/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Fetus&lt;/k=
eyword&gt;&lt;keyword&gt;Gestational
Age&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;Infa=
nt,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Pregnancy&lt;/keyword&gt;&lt;keyword&=
gt;Pregnancy
Complications,
Neoplastic/blood/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Sacrococc=
ygeal
Region/pathology&lt;/keyword&gt;&lt;keyword&gt;Spinal
Neoplasms/*congenital/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Tera=
toma/*congenital/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Treatment
Outcome&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/analysis&lt;/keywo=
rd&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2005&lt;/year&gt;&lt;pub-da=
tes&gt;&lt;date&gt;Jan&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;acce=
ssion-num&gt;15613854&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;=
&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp=
;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D15613854
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Marina&lt;/Author&gt;&lt;Year&gt;1992&lt;/Year&gt;=
&lt;RecNum&gt;9&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;9&lt;/rec-num=
ber&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Marina,
N.&lt;/author&gt;&lt;author&gt;Fontanesi, J.&lt;/author&gt;&lt;author&gt;Ku=
n,
L.&lt;/author&gt;&lt;author&gt;Rao, B.&lt;/author&gt;&lt;author&gt;Jenkins,=
 J.
J.&lt;/author&gt;&lt;author&gt;Thompson, E. I.&lt;/author&gt;&lt;author&gt;=
Etcubanas,
E.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;D=
epartment
of Hematology/Oncology, St. Jude Children&amp;apos;s Research Hospital,
Memphis, Tennessee
38101-0318.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Treatment of
childhood germ cell tumors. Review of the St. Jude experience from 1979 to =
1988&lt;/title&gt;&lt;secondary-title&gt;Cancer&lt;/secondary-title&gt;&lt;=
/titles&gt;&lt;periodical&gt;&lt;full-title&gt;Cancer&lt;/full-title&gt;&lt=
;/periodical&gt;&lt;pages&gt;2568-75&lt;/pages&gt;&lt;volume&gt;70&lt;/volu=
me&gt;&lt;number&gt;10&lt;/number&gt;&lt;keywords&gt;&lt;keyword&gt;Adolesc=
ent&lt;/keyword&gt;&lt;keyword&gt;Antineoplastic
Combined Chemotherapy Protocols/*therapeutic
use&lt;/keyword&gt;&lt;keyword&gt;Bleomycin/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;Ch=
ild,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Cisplatin/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Combined Modality
Therapy&lt;/keyword&gt;&lt;keyword&gt;Cyclophosphamide/administration &amp;=
amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Dactinomycin/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;H=
umans&lt;/keyword&gt;&lt;keyword&gt;Infant&lt;/keyword&gt;&lt;keyword&gt;Ma=
le&lt;/keyword&gt;&lt;keyword&gt;Neoplasms,
Germ Cell and Embryonal/*drug&lt;/keyword&gt;&lt;keyword&gt;therapy/patholo=
gy/radiotherapy/surgery&lt;/keyword&gt;&lt;keyword&gt;Survival
Analysis&lt;/keyword&gt;&lt;keyword&gt;Vinblastine/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;keyword&gt;Vincristine/administration &amp;amp;
dosage&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1992&lt;/ye=
ar&gt;&lt;pub-dates&gt;&lt;date&gt;Nov
15&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;1384951=
&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www=
.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;=
amp;dopt=3DCitation&amp;amp;list_uids=3D1384951
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Marina&lt;/Author&gt;&lt;Year&gt;2006&lt;/Year&gt;=
&lt;RecNum&gt;6&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;6&lt;/rec-num=
ber&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Marina,
N.&lt;/author&gt;&lt;author&gt;London, W.
B.&lt;/author&gt;&lt;author&gt;Frazier, A. L.&lt;/author&gt;&lt;author&gt;L=
auer,
S.&lt;/author&gt;&lt;author&gt;Rescorla,
F.&lt;/author&gt;&lt;author&gt;Cushing,
B.&lt;/author&gt;&lt;author&gt;Malogolowkin, M.
H.&lt;/author&gt;&lt;author&gt;Castleberry, R.
P.&lt;/author&gt;&lt;author&gt;Womer, R. B.&lt;/author&gt;&lt;author&gt;Ols=
on,
T.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;S=
tanford
University Medical Center, Stanford, CA 94304-1812, USA.
neyssa.marina@stanford.edu&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;P=
rognostic
factors in children with extragonadal malignant germ cell tumors: a pediatr=
ic
intergroup study&lt;/title&gt;&lt;secondary-title&gt;J Clin Oncol&lt;/secon=
dary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title&gt;J
Clin
Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;2544-8&lt;/pages&gt=
;&lt;volume&gt;24&lt;/volume&gt;&lt;number&gt;16&lt;/number&gt;&lt;keywords=
&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Age
Factors&lt;/keyword&gt;&lt;keyword&gt;Analysis of Variance&lt;/keyword&gt;&=
lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;Disease-Free
Survival&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt=
;Germinoma/blood/*diagnosis/pathology/therapy&lt;/keyword&gt;&lt;keyword&gt=
;Humans&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Ne=
oplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Predictive Value of
Tests&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&lt;keyword&gt=
;Proportional
Hazards Models&lt;/keyword&gt;&lt;keyword&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Risk
Factors&lt;/keyword&gt;&lt;keyword&gt;Survival Analysis&lt;/keyword&gt;&lt;=
keyword&gt;Tumor
Markers, Biological/blood&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/=
metabolism&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2006&lt=
;/year&gt;&lt;pub-dates&gt;&lt;date&gt;Jun
1&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;16735707=
&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www=
.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;=
amp;dopt=3DCitation&amp;amp;list_uids=3D16735707
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Rescorla&lt;/Author&gt;&lt;Year&gt;1999&lt;/Year&g=
t;&lt;RecNum&gt;11&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;11&lt;/rec=
-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Rescorla,
F.
J.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;J=
.W.
Riley Hospital for Children, Indianapolis, Indiana 46202, USA.
frescorl@iupui.edu&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Pediatric
germ cell tumors&lt;/title&gt;&lt;secondary-title&gt;Semin Surg
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;Semin
Surg
Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;144-58&lt;/pages&gt=
;&lt;volume&gt;16&lt;/volume&gt;&lt;number&gt;2&lt;/number&gt;&lt;keywords&=
gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;Combined
Modality Therapy&lt;/keyword&gt;&lt;keyword&gt;Germinoma/classification/dia=
gnosis/*therapy&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;key=
word&gt;Neoplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Risk
Factors&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Tumor Markers, Biological&lt;/keyword&gt=
;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1999&lt;/year&gt;&lt;pub-dates&g=
t;&lt;date&gt;Mar&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession=
-num&gt;9988869&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;ur=
l&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;d=
b=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D9988869
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>6,7,9,11,12</sup></span><!--[if s=
upportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> Neonatal teratomas may occur anywhere=
 along
the body midline, following the course of the embryonic germ cell ridge. Th=
ese
tumors have a similar morphology at each site.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>In one publ=
ished
study<sup>13</sup> of 535 fetal and neonatal GCTs, they were enumerated as
follows: sacrococcygeal teratoma was the leading teratoma (214; 40%). Next =
were
intracranial (71; 13.3%) and cervical teratomas (70; 13.1%), followed by
palatal and nasopharyngeal (41; 8%), cardiac (40; 7.5%), gastric (14; 2.6%),
mediastinal (13; 2.6%), orbital (13; 2.4%), facial (8; 1.5%), and placental=
 (8;
1.5%) teratomas. There were 17 miscellaneous teratomas (3%) variously locat=
ed
in the tongue, tonsil, liver, retroperitoneum, eye, mesentery, ileum, testi=
s,
vulva, and anorectal area. In addition, 25 examples of fetus in fetu were
identified.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Prepubertal/Child<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Mediastinal=
 GCTs
occur more commonly in older adolescence and the postpubertal child. Mixed
malignant GCTs comprised of teratoma, yolk sac tumor, embryonal carcinoma, =
and
rarely choriocarcinoma are more frequent with increasing age. Germinoma is
generally not seen in children less than 10 years of age.</span><!--[if sup=
portFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Schneider&lt;/Author&gt;&lt;Year&g=
t;2004&lt;/Year&gt;&lt;RecNum&gt;19&lt;/RecNum&gt;&lt;record&gt;&lt;rec-num=
ber&gt;19&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Schneider,
D. T.&lt;/author&gt;&lt;author&gt;Calaminus, G.&lt;/author&gt;&lt;author&gt=
;Koch,
S.&lt;/author&gt;&lt;author&gt;Teske, C.&lt;/author&gt;&lt;author&gt;Schmid=
t,
P.&lt;/author&gt;&lt;author&gt;Haas, R. J.&lt;/author&gt;&lt;author&gt;Harm=
s,
D.&lt;/author&gt;&lt;author&gt;Gobel,
U.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;C=
linic
of Pediatric Hematology and Oncology, Heinrich-Heine-University, Medical
Center, Duesseldorf, Germany. makei@med.uni-duesseldorf.de&lt;/auth-address=
&gt;&lt;titles&gt;&lt;title&gt;Epidemiologic
analysis of 1,442 children and adolescents registered in the German germ ce=
ll
tumor protocols&lt;/title&gt;&lt;secondary-title&gt;Pediatr Blood
Cancer&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Pediatr
Blood Cancer&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;169-75&lt;/p=
ages&gt;&lt;volume&gt;42&lt;/volume&gt;&lt;number&gt;2&lt;/number&gt;&lt;ke=
ywords&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Age
Distribution&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword=
&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Cohort
Studies&lt;/keyword&gt;&lt;keyword&gt;Endodermal Sinus
Tumor/diagnosis/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keywo=
rd&gt;&lt;keyword&gt;Germany/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Ger=
minoma/diagnosis/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/key=
word&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Me=
diastinal
Neoplasms/diagnosis/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Ovarian
Neoplasms/diagnosis/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Prospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Registries/*statistics &amp;amp;
numerical data&lt;/keyword&gt;&lt;keyword&gt;Sex
Distribution&lt;/keyword&gt;&lt;keyword&gt;Teratoma/diagnosis/epidemiology&=
lt;/keyword&gt;&lt;keyword&gt;Testicular
Neoplasms/diagnosis/epidemiology&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&=
gt;&lt;year&gt;2004&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;Feb&lt;/date&g=
t;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;14752882&lt;/accessi=
on-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.ni=
h.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DC=
itation&amp;amp;list_uids=3D14752882
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>14</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> As in congenital teratoma, the progno=
sis of
mediastinal GCTs in children is significantly affected by tumor stage and
completeness of surgical excision (see Notes F and G).</span><!--[if suppor=
tFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Schneider&lt;/Author&gt;&lt;Year&g=
t;2000&lt;/Year&gt;&lt;RecNum&gt;20&lt;/RecNum&gt;&lt;record&gt;&lt;rec-num=
ber&gt;20&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Schneider,
D. T.&lt;/author&gt;&lt;author&gt;Calaminus,
G.&lt;/author&gt;&lt;author&gt;Reinhard,
H.&lt;/author&gt;&lt;author&gt;Gutjahr, P.&lt;/author&gt;&lt;author&gt;Krem=
ens,
B.&lt;/author&gt;&lt;author&gt;Harms, D.&lt;/author&gt;&lt;author&gt;Gobel,
U.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;D=
epartment
of Pediatric Hematology and Oncology, Heinrich-Heine-University, D]usseldor=
f,
Germany.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Primary mediastinal
germ cell tumors in children and adolescents: results of the German coopera=
tive
protocols MAKEI 83/86, 89, and 96&lt;/title&gt;&lt;secondary-title&gt;J Clin
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;J
Clin
Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;832-9&lt;/pages&gt;=
&lt;volume&gt;18&lt;/volume&gt;&lt;number&gt;4&lt;/number&gt;&lt;keywords&g=
t;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Antineoplastic
Agents/therapeutic use&lt;/keyword&gt;&lt;keyword&gt;Chemotherapy,
Adjuvant&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;=
Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Chorionic Gonadotropin, beta Subuni=
t,
Human/analysis&lt;/keyword&gt;&lt;keyword&gt;Cisplatin/therapeutic
use&lt;/keyword&gt;&lt;keyword&gt;Cohort
Studies&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;=
Follow-Up
Studies&lt;/keyword&gt;&lt;keyword&gt;Germinoma/secondary/*surgery&lt;/keyw=
ord&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;Infant&lt;/keywo=
rd&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Me=
diastinal
Neoplasms/*surgery&lt;/keyword&gt;&lt;keyword&gt;Neoplasm Recurrence,
Local/pathology&lt;/keyword&gt;&lt;keyword&gt;Neoplasm,
Residual&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&lt;keyword=
&gt;Prospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Radiotherapy,
Adjuvant&lt;/keyword&gt;&lt;keyword&gt;Remission Induction&lt;/keyword&gt;&=
lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Teratoma/secondary/*surgery&lt;/keyword&=
gt;&lt;keyword&gt;Treatment
Outcome&lt;/keyword&gt;&lt;keyword&gt;Tumor Markers,
Biological/analysis&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/analys=
is&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2000&lt;/year&g=
t;&lt;pub-dates&gt;&lt;date&gt;Feb&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates=
&gt;&lt;accession-num&gt;10673525&lt;/accession-num&gt;&lt;urls&gt;&lt;rela=
ted-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3D=
Retrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D10=
673525
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>15</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> Rarely, sarcomatous elements are repo=
rted
in pediatric mediastinal GCTs.</span><!--[if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Cushing&lt;/Author&gt;&lt;Year&gt;=
1983&lt;/Year&gt;&lt;RecNum&gt;21&lt;/RecNum&gt;&lt;record&gt;&lt;rec-numbe=
r&gt;21&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Cushing,
B.&lt;/author&gt;&lt;author&gt;Bhanot, P. K.&lt;/author&gt;&lt;author&gt;Wa=
tts,
F. B., Jr.&lt;/author&gt;&lt;author&gt;Hertzler, J.
H.&lt;/author&gt;&lt;author&gt;Brough, A.
J.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;tit=
le&gt;Rhabdomyosarcoma
and benign teratoma&lt;/title&gt;&lt;secondary-title&gt;Pediatr
Pathol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Pediatr
Pathol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;345-8&lt;/pages&gt=
;&lt;volume&gt;1&lt;/volume&gt;&lt;number&gt;3&lt;/number&gt;&lt;keywords&g=
t;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keywor=
d&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;Mediastinal
Neoplasms/*pathology/radiography&lt;/keyword&gt;&lt;keyword&gt;Neoplasms,
Multiple
Primary/*pathology&lt;/keyword&gt;&lt;keyword&gt;Rhabdomyosarcoma/*patholog=
y/radiography&lt;/keyword&gt;&lt;keyword&gt;Teratoma/*pathology/radiography=
&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1983&lt;/year&gt;=
&lt;pub-dates&gt;&lt;date&gt;Jul-Sep&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dat=
es&gt;&lt;accession-num&gt;6687285&lt;/accession-num&gt;&lt;urls&gt;&lt;rel=
ated-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=
=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=
=3D6687285
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>16</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Sacrococcyg=
eal
tumors in the older infant and child are predominantly presacral and pelvic,
with no externalized mass noted at birth. Malignancy rates are reportedly v=
ery
high in these children, most commonly due to yolk sac tumor.</span><!--[if =
supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Rescorla&lt;/Author&gt;&lt;Year&gt=
;1999&lt;/Year&gt;&lt;RecNum&gt;11&lt;/RecNum&gt;&lt;record&gt;&lt;rec-numb=
er&gt;11&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Rescorla,
F.
J.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;J=
.W.
Riley Hospital for Children, Indianapolis, Indiana 46202, USA.
frescorl@iupui.edu&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Pediatric
germ cell tumors&lt;/title&gt;&lt;secondary-title&gt;Semin Surg
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;Semin
Surg
Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;144-58&lt;/pages&gt=
;&lt;volume&gt;16&lt;/volume&gt;&lt;number&gt;2&lt;/number&gt;&lt;keywords&=
gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;Combined
Modality
Therapy&lt;/keyword&gt;&lt;keyword&gt;Germinoma/classification/diagnosis/*t=
herapy&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;N=
eoplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Risk
Factors&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Tumor Markers, Biological&lt;/keyword&gt=
;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1999&lt;/year&gt;&lt;pub-dates&g=
t;&lt;date&gt;Mar&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession=
-num&gt;9988869&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;ur=
l&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;d=
b=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D9988869
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Rescorla&lt;/Author&gt;&lt;Year&gt;1998&lt;/Year&g=
t;&lt;RecNum&gt;22&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;22&lt;/rec=
-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Rescorla,
F. J.&lt;/author&gt;&lt;author&gt;Sawin, R.
S.&lt;/author&gt;&lt;author&gt;Coran, A. G.&lt;/author&gt;&lt;author&gt;Dil=
lon,
P. W.&lt;/author&gt;&lt;author&gt;Azizkhan, R.
G.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;J=
.W.
Riley Hospital, Indianapolis, IN 46202,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Long-term outcome for
infants and children with sacrococcygeal teratoma: a report from the Childr=
ens
Cancer Group&lt;/title&gt;&lt;secondary-title&gt;J Pediatr
Surg&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title=
&gt;J
Pediatr
Surg&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;171-6&lt;/pages&gt;&=
lt;volume&gt;33&lt;/volume&gt;&lt;number&gt;2&lt;/number&gt;&lt;keywords&gt=
;&lt;keyword&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;*Coccyx&lt;/keyword&gt;&lt;keyword&=
gt;Combined
Modality Therapy&lt;/keyword&gt;&lt;keyword&gt;Endodermal Sinus
Tumor/*epidemiology/therapy&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keywor=
d&gt;&lt;keyword&gt;Follow-Up
Studies&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;=
Infant&lt;/keyword&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Ne=
oplasm
Recurrence, Local/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;*Sacrum&lt;/keyword&gt;&lt;keyword&gt=
;Spinal
Neoplasms/*epidemiology/therapy&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Teratoma/*epidemiology/therapy&lt;/keywo=
rd&gt;&lt;keyword&gt;Time
Factors&lt;/keyword&gt;&lt;keyword&gt;Treatment
Outcome&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1998&lt;/y=
ear&gt;&lt;pub-dates&gt;&lt;date&gt;Feb&lt;/date&gt;&lt;/pub-dates&gt;&lt;/=
dates&gt;&lt;accession-num&gt;9498381&lt;/accession-num&gt;&lt;urls&gt;&lt;=
related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cm=
d=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=
=3D9498381
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>12,17</sup></span><!--[if support=
Fields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> It is thought that many of these tumo=
rs
represent congenital sacrococcygeal GCTs (SGCTs) with an overgrowth of yolk=
 sac
tumor, analogous to the malignant recurrences of yolk sac tumors in children
with incompletely excised congenital SGCT.</span><!--[if supportFields]><sp=
an
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Gobel&lt;/Author&gt;&lt;Year&gt;20=
00&lt;/Year&gt;&lt;RecNum&gt;23&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&=
gt;23&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Gobel,
U.&lt;/author&gt;&lt;author&gt;Schneider, D.
T.&lt;/author&gt;&lt;author&gt;Calaminus, G.&lt;/author&gt;&lt;author&gt;Ha=
as,
R. J.&lt;/author&gt;&lt;author&gt;Schmidt,
P.&lt;/author&gt;&lt;author&gt;Harms,
D.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;D=
epartment
of Pediatric Hematology and Oncology, Children&amp;apos;s Hospital,
Heinrich-Heine-University, Medical Center, Dusseldorf, Germany.
makei@med.uni-duesseldorf.de&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt=
;Germ-cell
tumors in childhood and adolescence. GPOH MAKEI and the MAHO study
groups&lt;/title&gt;&lt;secondary-title&gt;Ann
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;Ann
Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;263-71&lt;/pages&gt=
;&lt;volume&gt;11&lt;/volume&gt;&lt;number&gt;3&lt;/number&gt;&lt;keywords&=
gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Biological
Markers&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;C=
ombined
Modality
Therapy&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;=
Neoplasm
Recurrence, Local&lt;/keyword&gt;&lt;keyword&gt;Neoplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Neoplasms, Germ Cell
and&lt;/keyword&gt;&lt;keyword&gt;Embryonal/diagnosis/epidemiology/genetics=
/*therapy&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&lt;keywor=
d&gt;Risk
Factors&lt;/keyword&gt;&lt;keyword&gt;Tumor Markers, Biological/secretion&l=
t;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2000&lt;/year&gt;&l=
t;pub-dates&gt;&lt;date&gt;Mar&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;=
&lt;accession-num&gt;10811491&lt;/accession-num&gt;&lt;urls&gt;&lt;related-=
urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetr=
ieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D108114=
91
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Rescorla&lt;/Author&gt;&lt;Year&gt;1999&lt;/Year&g=
t;&lt;RecNum&gt;11&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;11&lt;/rec=
-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Rescorla,
F.
J.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;J=
.W.
Riley Hospital for Children, Indianapolis, Indiana 46202, USA.
frescorl@iupui.edu&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Pediatric
germ cell tumors&lt;/title&gt;&lt;secondary-title&gt;Semin Surg
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;Semin
Surg Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;144-58&lt;/pag=
es&gt;&lt;volume&gt;16&lt;/volume&gt;&lt;number&gt;2&lt;/number&gt;&lt;keyw=
ords&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;Combined
Modality Therapy&lt;/keyword&gt;&lt;keyword&gt;Germinoma/classification/dia=
gnosis/*therapy&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;key=
word&gt;Neoplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Risk
Factors&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Tumor Markers,
Biological&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1999&lt=
;/year&gt;&lt;pub-dates&gt;&lt;date&gt;Mar&lt;/date&gt;&lt;/pub-dates&gt;&l=
t;/dates&gt;&lt;accession-num&gt;9988869&lt;/accession-num&gt;&lt;urls&gt;&=
lt;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi=
?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_ui=
ds=3D9988869
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>12,18</sup></span><!--[if support=
Fields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Although pe=
lvic
and/or retroperitoneal extension of a sacrococcygeal tumor is not unusual, =
an
exclusively retroperitoneal or abdominal location is uncommon, comprising l=
ess
than 5% of all EGCTs.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The majorit=
y of
intracranial germ cell tumors arise in structures around the third ventricl=
e,
most commonly in the pineal gland or suprasellar region. Other sites include
intraventricular, basal ganglionic, thalamic, cerebral hemispheric, bulbar,
intramedullary, and intrasellar. Most occur in the second decade of life, w=
ith
approximately one-quarter of all central nervous system germ cell tumors
arising in the prepubertal years.<sup>19</sup> The most common subtype is
germinoma, followed by teratoma.<sup>20</sup></span><!--[if supportFields]>=
<span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Bjornsson&lt;/Author&gt;&lt;Year&g=
t;1985&lt;/Year&gt;&lt;RecNum&gt;125&lt;/RecNum&gt;&lt;record&gt;&lt;rec-nu=
mber&gt;125&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Bjornsson,
J.&lt;/author&gt;&lt;author&gt;Scheithauer, B.
W.&lt;/author&gt;&lt;author&gt;Okazaki, H.&lt;/author&gt;&lt;author&gt;Leec=
h,
R. W.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;=
title&gt;Intracranial
germ cell tumors: pathobiological and immunohistochemical aspects of 70
cases&lt;/title&gt;&lt;secondary-title&gt;J Neuropathol Exp
Neurol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;J
Neuropathol Exp Neurol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;32=
-46&lt;/pages&gt;&lt;volume&gt;44&lt;/volume&gt;&lt;number&gt;1&lt;/number&=
gt;&lt;keywords&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;=
Adult&lt;/keyword&gt;&lt;keyword&gt;Brain
Neoplasms/analysis/*pathology&lt;/keyword&gt;&lt;keyword&gt;Choriocarcinoma=
/analysis/pathology&lt;/keyword&gt;&lt;keyword&gt;Chorionic
Gonadotropin/analysis&lt;/keyword&gt;&lt;keyword&gt;Dermoid Cyst/analysis/p=
athology&lt;/keyword&gt;&lt;keyword&gt;Dysgerminoma/analysis/*pathology&lt;=
/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;Histocytoch=
emistry&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;=
Immunochemistry&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keywo=
rd&gt;Mesonephroma/analysis/pathology&lt;/keyword&gt;&lt;keyword&gt;Pregnan=
cy&lt;/keyword&gt;&lt;keyword&gt;Teratoma/analysis/pathology&lt;/keyword&gt=
;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1985&lt;/year&gt;&lt;pub-dates&g=
t;&lt;date&gt;Jan&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession=
-num&gt;4038412&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;ur=
l&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;d=
b=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D4038412
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;</span><![endif]--><!--[if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Postpubertal/Adult<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The mediast=
inum is
the most common anatomic site for extragonadal GCTs in adults. These tumors=
 are
overwhelmingly restricted to males, but well-documented cases in women do
exist.<sup>21-22</sup> The histologic classification of GCTs at this site is
identical to that used in the gonads: seminomatous (pure), nonseminomatous
(yolk sac tumor, embryonal carcinoma, choriocarcinoma, and mixed GCTs), and
teratomas. One important difference is that, unlike the situation in the ad=
ult
testis or in congenital/pediatric GCT, the distinction between mature and
immature teratoma is important in the adult mediastinum.<o:p></o:p></span><=
/p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Sacrococcyg=
eal GCTs
in this age group are generally considered to have been present since birth=
. In
some cases, there is a history of a partially resected neonatal lesion to
support this interpretation. The location is similar to that seen in pediat=
ric
cases except that most are intrapelvic because tumors with an external
component would be expected to have been discovered in childhood.
Adenocarcinoma may arise in the SGCT of adults.<sup>23</sup><o:p></o:p></sp=
an></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><span
style=3D'mso-spacerun:yes'>&nbsp;</span><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The distrib=
ution of
cervical GCTs (CGCTs) in adults is similar to that seen in children, with
frequent involvement of the thyroid. Some cases have presented in continuity
with a mediastinal GCT.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Most purely
retroperitoneal GCTs in adults represent metastases from an undiscovered or
occult primary in the testicle or, rarely, in the ovary. In general, a
testicular primary must be excluded clinically.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Intracrania=
l germ
cell tumors are more common in the postpubertal child and younger adult, wi=
th
the anatomic location as described above.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>C. Tumor Size<o:p></o:p></sp=
an></h2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The number =
of
sections submitted varies with the size and character of the specimen and t=
he
nature of the underlying neoplastic process. At least 1 section per centime=
ter
of the tumor&#8217;s greatest diameter is recommended if the tumor is a germ
cell neoplasm because diverse elements may only be found in this way and mi=
ght
affect the tumor classification.<sup>24</sup><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Congenital/Neonatal<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Large SGCTs=
 may be
associated with fetal hydrops because of increased demands on the heart to
supply the tumor vasculature and may be associated with fatal intratumoral =
hemorrhage
with delivery. Survival with <i style=3D'mso-bidi-font-style:normal'>cervic=
al
teratoma </i>depends on the size of the tumor and extent of tissue involvem=
ent,
with respiratory compromise being the main cause of subsequent morbidity and
mortality.</span><!--[if supportFields]><span style=3D'mso-bidi-font-family=
:Arial'><span
style=3D'mso-element:field-begin'></span> ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Dehner&lt;/Author&gt;&lt;Year&gt;1=
983&lt;/Year&gt;&lt;RecNum&gt;12&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number=
&gt;12&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Dehner,
L. P.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;titles&gt;&lt;=
title&gt;Gonadal
and extragonadal germ cell neoplasia of
childhood&lt;/title&gt;&lt;secondary-title&gt;Hum
Pathol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Hum
Pathol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;493-511&lt;/pages&=
gt;&lt;volume&gt;14&lt;/volume&gt;&lt;number&gt;6&lt;/number&gt;&lt;keyword=
s&gt;&lt;keyword&gt;Abdominal
Neoplasms/pathology&lt;/keyword&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt=
;&lt;keyword&gt;Animals&lt;/keyword&gt;&lt;keyword&gt;Cell
Transformation,
Neoplastic/pathology&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt=
;keyword&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Choriocarcinoma/pathology&lt;/keywo=
rd&gt;&lt;keyword&gt;Dysgerminoma/classification/epidemiology/*pathology&lt=
;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt;Head
and Neck
Neoplasms/pathology&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt=
;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Me=
sonephroma/pathology&lt;/keyword&gt;&lt;keyword&gt;Mice&lt;/keyword&gt;&lt;=
keyword&gt;Ovarian
Neoplasms/classification/epidemiology/*pathology&lt;/keyword&gt;&lt;keyword=
&gt;Pregnancy&lt;/keyword&gt;&lt;keyword&gt;Sacrococcygeal
Region&lt;/keyword&gt;&lt;keyword&gt;Teratoma/classification/epidemiology/*=
pathology&lt;/keyword&gt;&lt;keyword&gt;Testicular
Neoplasms/classification/epidemiology/*pathology&lt;/keyword&gt;&lt;keyword=
&gt;Thoracic
Neoplasms/pathology&lt;/keyword&gt;&lt;keyword&gt;United
States&lt;/keyword&gt;&lt;keyword&gt;Uterine
Neoplasms/pathology&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&g=
t;1983&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;Jun&lt;/date&gt;&lt;/pub-da=
tes&gt;&lt;/dates&gt;&lt;accession-num&gt;6343221&lt;/accession-num&gt;&lt;=
urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/q=
uery.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;am=
p;list_uids=3D6343221
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>11</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> Neonates with cervical teratomas gene=
rally
have a good outcome when the tumor is resectable. Fetuses have a much lower
survival rate than neonates (23% versus 85%). Ten percent of the fetuses are
stillborn.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Some <i
style=3D'mso-bidi-font-style:normal'>epignathi </i>and <i style=3D'mso-bidi=
-font-style:
normal'>nasopharyngeal </i></span><i style=3D'mso-bidi-font-style:normal'>t=
eratomas</i><span
style=3D'mso-bidi-font-family:Arial'> are so large and extensive that they =
are
incompatible with life and therefore inoperable, which explains the high
mortality rate.<sup>25</sup> The most common presenting findings in these c=
ases
are a mass, respiratory distress, polyhydramnios, and dysphagia.</span><!--=
[if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Isaacs&lt;/Author&gt;&lt;Year&gt;2=
004&lt;/Year&gt;&lt;RecNum&gt;13&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number=
&gt;13&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Isaacs,
H., Jr.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address=
&gt;Department
of Pathology, Children&amp;apos;s Hospital San Diego, San Diego, CA 92123,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Perinatal (fetal and
neonatal) germ cell tumors&lt;/title&gt;&lt;secondary-title&gt;J Pediatr
Surg&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title=
&gt;J
Pediatr
Surg&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;1003-13&lt;/pages&gt=
;&lt;volume&gt;39&lt;/volume&gt;&lt;number&gt;7&lt;/number&gt;&lt;keywords&=
gt;&lt;keyword&gt;Abnormalities,
Multiple/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Brain Neoplasms/epidem=
iology&lt;/keyword&gt;&lt;keyword&gt;Comorbidity&lt;/keyword&gt;&lt;keyword=
&gt;Digestive
System Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Endodermal Sinus
Tumor/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;=
keyword&gt;Fetal
Diseases/*classification/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Head a=
nd
Neck Neoplasms/classification/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;H=
umans&lt;/keyword&gt;&lt;keyword&gt;Infant&lt;/keyword&gt;&lt;keyword&gt;In=
fant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Los
Angeles/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;=
keyword&gt;Neoplasm
Recurrence, Local/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Neoplasms, Germ
Cell and Embryonal/*classification/*epidemiology&lt;/keyword&gt;&lt;keyword=
&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Sacrococcygeal
Region&lt;/keyword&gt;&lt;keyword&gt;Spinal
Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Teratoma/epidemiology&lt;/keyword&gt;&lt=
;keyword&gt;Ultrasonography,
Prenatal&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2004&lt;/=
year&gt;&lt;pub-dates&gt;&lt;date&gt;Jul&lt;/date&gt;&lt;/pub-dates&gt;&lt;=
/dates&gt;&lt;accession-num&gt;15213888&lt;/accession-num&gt;&lt;urls&gt;&l=
t;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?=
cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uid=
s=3D15213888
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>13</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Because of =
the size
of some intracranial teratomas, identifiable anatomic landmarks are lost,
making it practically impossible to determine the exact site of origin.</sp=
an><!--[if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Isaacs&lt;/Author&gt;&lt;Year&gt;2=
004&lt;/Year&gt;&lt;RecNum&gt;13&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number=
&gt;13&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Isaacs,
H., Jr.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address=
&gt;Department
of Pathology, Children&amp;apos;s Hospital San Diego, San Diego, CA 92123,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Perinatal (fetal and
neonatal) germ cell tumors&lt;/title&gt;&lt;secondary-title&gt;J Pediatr
Surg&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title=
&gt;J
Pediatr
Surg&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;1003-13&lt;/pages&gt=
;&lt;volume&gt;39&lt;/volume&gt;&lt;number&gt;7&lt;/number&gt;&lt;keywords&=
gt;&lt;keyword&gt;Abnormalities,
Multiple/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Brain Neoplasms/epidem=
iology&lt;/keyword&gt;&lt;keyword&gt;Comorbidity&lt;/keyword&gt;&lt;keyword=
&gt;Digestive
System Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Endodermal Sinus
Tumor/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;=
keyword&gt;Fetal
Diseases/*classification/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Head a=
nd
Neck Neoplasms/classification/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;H=
umans&lt;/keyword&gt;&lt;keyword&gt;Infant&lt;/keyword&gt;&lt;keyword&gt;In=
fant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Los
Angeles/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;=
keyword&gt;Neoplasm
Recurrence, Local/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Neoplasms, Germ
Cell and Embryonal/*classification/*epidemiology&lt;/keyword&gt;&lt;keyword=
&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Sacrococcygeal
Region&lt;/keyword&gt;&lt;keyword&gt;Spinal
Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Teratoma/epidemiology&lt;/keyword&gt;&lt=
;keyword&gt;Ultrasonography,
Prenatal&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2004&lt;/=
year&gt;&lt;pub-dates&gt;&lt;date&gt;Jul&lt;/date&gt;&lt;/pub-dates&gt;&lt;=
/dates&gt;&lt;accession-num&gt;15213888&lt;/accession-num&gt;&lt;urls&gt;&l=
t;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?=
cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uid=
s=3D15213888
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>13</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> The anatomic location of the teratoma
cannot be determined in about a third of the patients because the brain is
replaced by tumor. When a point of origin can be found, the cerebral hemisp=
here
is the most common primary site, followed by the third ventricle and the pi=
neal
region. Large tumors erode through the skull and extend into the orbit, oral
cavity, or the neck. Spontaneous rupture during delivery of a fetal head en=
larged
by tumor has been reported.<sup>26</sup><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>D. Histologic Type<o:p></o:p=
></span></h2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The World H=
ealth
Organization (WHO) classification of germ cell tumors is the basis for most
contemporary classifications and is the one generally used for EGCTs.<sup>2=
7</sup>
According to this classification, germ cell neoplasms are divided roughly i=
nto
7 histologic categories: dysgerminoma, yolk sac tumor, embryonal carcinoma,
polyembryoma, choriocarcinoma, teratoma, and gonadoblastoma.</span><!--[if =
supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Isaacs&lt;/Author&gt;&lt;Year&gt;2=
004&lt;/Year&gt;&lt;RecNum&gt;13&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number=
&gt;13&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Isaacs,
H., Jr.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address=
&gt;Department
of Pathology, Children&amp;apos;s Hospital San Diego, San Diego, CA 92123,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Perinatal (fetal and
neonatal) germ cell tumors&lt;/title&gt;&lt;secondary-title&gt;J Pediatr
Surg&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title=
&gt;J
Pediatr Surg&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;1003-13&lt;/=
pages&gt;&lt;volume&gt;39&lt;/volume&gt;&lt;number&gt;7&lt;/number&gt;&lt;k=
eywords&gt;&lt;keyword&gt;Abnormalities,
Multiple/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Brain
Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Comorbidity&lt;/keywor=
d&gt;&lt;keyword&gt;Digestive
System Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Endodermal Sinus
Tumor/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;=
keyword&gt;Fetal
Diseases/*classification/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Head a=
nd
Neck
Neoplasms/classification/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Humans=
&lt;/keyword&gt;&lt;keyword&gt;Infant&lt;/keyword&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Los
Angeles/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;=
keyword&gt;Neoplasm
Recurrence, Local/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Neoplasms, Germ
Cell and Embryonal/*classification/*epidemiology&lt;/keyword&gt;&lt;keyword=
&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Sacrococcygeal
Region&lt;/keyword&gt;&lt;keyword&gt;Spinal
Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Teratoma/epidemiology&lt;/keyword&gt;&lt=
;keyword&gt;Ultrasonography,
Prenatal&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2004&lt;/=
year&gt;&lt;pub-dates&gt;&lt;date&gt;Jul&lt;/date&gt;&lt;/pub-dates&gt;&lt;=
/dates&gt;&lt;accession-num&gt;15213888&lt;/accession-num&gt;&lt;urls&gt;&l=
t;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?=
cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uid=
s=3D15213888
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>27</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> Gonadoblastoma, a neoplasm typically =
found
in dysgenetic gonads, is included in the category of germ cell tumors (mixed
germ cell, sex cord-stromal tumors). According to this classification, fetu=
s in
fetu is regarded as a form of mature teratoma. The most common germ cell tu=
mors
occurring in the perinatal period in order of rank are teratoma, yolk sac
tumor, choriocarcinoma, and gonadoblastoma.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Extragonada=
l germ
cell neoplasms can be classified for histopathology using mediastinal nomen=
clature
(ie, teratomatous and nonteratomatous lesions).<sup>28</sup><o:p></o:p></sp=
an></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Congenital/Neonatal<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Most germ c=
ell
tumors of the fetus and neonate are histologically benign and are classifie=
d as
either mature or immature teratomas.</span><!--[if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE &lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Isaacs&lt;/Author&gt=
;&lt;Year&gt;2004&lt;/Year&gt;&lt;RecNum&gt;13&lt;/RecNum&gt;&lt;record&gt;=
&lt;rec-number&gt;13&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Isaacs,
H., Jr.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address=
&gt;Department
of Pathology, Children&amp;apos;s Hospital San Diego, San Diego, CA 92123,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Perinatal (fetal and
neonatal) germ cell tumors&lt;/title&gt;&lt;secondary-title&gt;J Pediatr
Surg&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title=
&gt;J
Pediatr Surg&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;1003-13&lt;/=
pages&gt;&lt;volume&gt;39&lt;/volume&gt;&lt;number&gt;7&lt;/number&gt;&lt;k=
eywords&gt;&lt;keyword&gt;Abnormalities,
Multiple/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Brain
Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Comorbidity&lt;/keywor=
d&gt;&lt;keyword&gt;Digestive
System Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Endodermal Sinus
Tumor/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;=
keyword&gt;Fetal
Diseases/*classification/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Head a=
nd
Neck Neoplasms/classification/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;H=
umans&lt;/keyword&gt;&lt;keyword&gt;Infant&lt;/keyword&gt;&lt;keyword&gt;In=
fant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Los
Angeles/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;=
keyword&gt;Neoplasm
Recurrence, Local/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Neoplasms, Germ
Cell and Embryonal/*classification/*epidemiology&lt;/keyword&gt;&lt;keyword=
&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Sacrococcygeal
Region&lt;/keyword&gt;&lt;keyword&gt;Spinal
Neoplasms/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Teratoma/epidemiology&lt;/keyword&gt;&lt=
;keyword&gt;Ultrasonography,
Prenatal&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2004&lt;/=
year&gt;&lt;pub-dates&gt;&lt;date&gt;Jul&lt;/date&gt;&lt;/pub-dates&gt;&lt;=
/dates&gt;&lt;accession-num&gt;15213888&lt;/accession-num&gt;&lt;urls&gt;&l=
t;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?=
cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uid=
s=3D15213888
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>13</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> <i style=3D'mso-bidi-font-style:norma=
l'>Yolk
sac tumor </i>(endodermal sinus tumor) is the leading malignant germ cell t=
umor
of the perinatal period and throughout childhood. In the fetus and neonate,=
 it
occurs most often with a teratoma and adversely affects the prognosis.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The sacroco=
ccygeal
area is the location associated with the highest incidence of malignancy, in
the form of yolk sac tumor. The overall frequency of neonatal <i
style=3D'mso-bidi-font-style:normal'>sacrococcygeal teratomas </i>with a yo=
lk sac
tumor is approximately 10%. The values cited in the literature range from 2=
.5%
to 25%.<sup>13,29</sup> The presence of immature neuroglial elements in a
neonatal teratoma has no bearing on prognosis, and generally these patients
have a favorable outcome. It is well known that an important relationship
exists between the age at diagnosis of a patient with a sacrococcygeal tera=
toma
and outcome. The incidence of malignancy in the neonate is approximately 10=
%,
approaching almost 100% by 3 years.<sup>13,29-31</sup><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Congenital
teratomas are commonly immature and often contain admixed yolk sac tumor and
rarely, embryonal carcinoma. In the neonate, the diagnosis of an immature t=
umor
is routinely based on the presence of immature neuroepithelium. Choriocarci=
noma
may be seen as a metastasis from the placenta in the infant but is not repo=
rted
as a component of primary extracranial EGCTs of childhood.<sup>32</sup>
Similarly, the presence of germinoma in a congenital teratoma would be very
unusual.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Prepubertal/Child<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The occurre=
nce of
admixed yolk sac tumor or recurrence as yolk sac tumor is more common with =
the
presentation of teratoma in patients older than 6 months. Similarly, in old=
er
infants (after 7 months), the incidence of teratoma falls, whereas the
incidence of pure yolk sac tumor increases. Most yolk sac tumors are diagno=
sed between
7 months and the third year of life. Pure embryonal carcinomas are rare bef=
ore
5 years old.</span><!--[if supportFields]><span style=3D'mso-bidi-font-fami=
ly:
Arial'><span style=3D'mso-element:field-begin'></span> ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Schneider&lt;/Author&gt;&lt;Year&g=
t;2004&lt;/Year&gt;&lt;RecNum&gt;19&lt;/RecNum&gt;&lt;record&gt;&lt;rec-num=
ber&gt;19&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Schneider,
D. T.&lt;/author&gt;&lt;author&gt;Calaminus,
G.&lt;/author&gt;&lt;author&gt;Koch, S.&lt;/author&gt;&lt;author&gt;Teske,
C.&lt;/author&gt;&lt;author&gt;Schmidt, P.&lt;/author&gt;&lt;author&gt;Haas=
, R.
J.&lt;/author&gt;&lt;author&gt;Harms, D.&lt;/author&gt;&lt;author&gt;Gobel,
U.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;C=
linic
of Pediatric Hematology and Oncology, Heinrich-Heine-University, Medical
Center, Duesseldorf, Germany.
makei@med.uni-duesseldorf.de&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt=
;Epidemiologic
analysis of 1,442 children and adolescents registered in the German germ ce=
ll
tumor protocols&lt;/title&gt;&lt;secondary-title&gt;Pediatr Blood
Cancer&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Pediatr
Blood Cancer&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;169-75&lt;/p=
ages&gt;&lt;volume&gt;42&lt;/volume&gt;&lt;number&gt;2&lt;/number&gt;&lt;ke=
ywords&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Age
Distribution&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword=
&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;Cohort
Studies&lt;/keyword&gt;&lt;keyword&gt;Endodermal Sinus
Tumor/diagnosis/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keywo=
rd&gt;&lt;keyword&gt;Germany/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Ger=
minoma/diagnosis/*epidemiology&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/key=
word&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Me=
diastinal
Neoplasms/diagnosis/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Ovarian
Neoplasms/diagnosis/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Prospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Registries/*statistics &amp;amp;
numerical data&lt;/keyword&gt;&lt;keyword&gt;Sex
Distribution&lt;/keyword&gt;&lt;keyword&gt;Teratoma/diagnosis/epidemiology&=
lt;/keyword&gt;&lt;keyword&gt;Testicular
Neoplasms/diagnosis/epidemiology&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&=
gt;&lt;year&gt;2004&lt;/year&gt;&lt;pub-dates&gt;&lt;date&gt;Feb&lt;/date&g=
t;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;14752882&lt;/accessi=
on-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.ni=
h.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DC=
itation&amp;amp;list_uids=3D14752882
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>14</sup></span><!--[if supportFie=
lds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> As noted, prognosis worsens with incr=
easing
age, and the prognosis (ie, recurrence rate) of completely resected EGCTs
worsens at approximately 7 months. The designation of a child as prepuberta=
l is
sometimes difficult, but at least 1 study</span><!--[if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span>
ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Marina&lt;/Author&gt;&lt;Year&gt;2=
006&lt;/Year&gt;&lt;RecNum&gt;6&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&=
gt;6&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Marina,
N.&lt;/author&gt;&lt;author&gt;London, W.
B.&lt;/author&gt;&lt;author&gt;Frazier, A.
L.&lt;/author&gt;&lt;author&gt;Lauer, S.&lt;/author&gt;&lt;author&gt;Rescor=
la,
F.&lt;/author&gt;&lt;author&gt;Cushing, B.&lt;/author&gt;&lt;author&gt;Malo=
golowkin,
M. H.&lt;/author&gt;&lt;author&gt;Castleberry, R. P.&lt;/author&gt;&lt;auth=
or&gt;Womer,
R. B.&lt;/author&gt;&lt;author&gt;Olson,
T.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;S=
tanford
University Medical Center, Stanford, CA 94304-1812, USA.
neyssa.marina@stanford.edu&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;P=
rognostic
factors in children with extragonadal malignant germ cell tumors: a pediatr=
ic
intergroup study&lt;/title&gt;&lt;secondary-title&gt;J Clin
Oncol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-titl=
e&gt;J
Clin Oncol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;2544-8&lt;/pag=
es&gt;&lt;volume&gt;24&lt;/volume&gt;&lt;number&gt;16&lt;/number&gt;&lt;key=
words&gt;&lt;keyword&gt;Adolescent&lt;/keyword&gt;&lt;keyword&gt;Age
Factors&lt;/keyword&gt;&lt;keyword&gt;Analysis of
Variance&lt;/keyword&gt;&lt;keyword&gt;Child&lt;/keyword&gt;&lt;keyword&gt;=
Disease-Free
Survival&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keyword&gt;&lt;keyword&gt=
;Germinoma/blood/*diagnosis/pathology/therapy&lt;/keyword&gt;&lt;keyword&gt=
;Humans&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Ne=
oplasm
Staging&lt;/keyword&gt;&lt;keyword&gt;Predictive Value of
Tests&lt;/keyword&gt;&lt;keyword&gt;Prognosis&lt;/keyword&gt;&lt;keyword&gt=
;Proportional
Hazards Models&lt;/keyword&gt;&lt;keyword&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;Risk Factors&lt;/keyword&gt;&lt;keywo=
rd&gt;Survival
Analysis&lt;/keyword&gt;&lt;keyword&gt;Tumor Markers,
Biological/blood&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/metabolis=
m&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2006&lt;/year&gt=
;&lt;pub-dates&gt;&lt;date&gt;Jun
1&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;accession-num&gt;16735707=
&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;&lt;url&gt;http://www=
.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp;amp;db=3DPubMed&amp;=
amp;dopt=3DCitation&amp;amp;list_uids=3D16735707
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>6</sup></span><!--[if supportFiel=
ds]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'> suggests 12 years or older is a signi=
ficant
age boundary. <o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Postpubertal/Adult<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Approximate=
ly 43%
of all mediastinal GCTs contain teratoma and include mature teratoma (63%),
immature teratoma (4%), and teratoma with other malignant components (ie,
sarcoma, other malignant germ cell element, or carcinoma; 33%).<sup>28</sup>
Because histologically mature mediastinal teratomas behave in a clinically
benign fashion regardless of patient age, and immature teratomas have the
potential for aggressive behavior, the distinction is critical to patient
management in adults. Mature teratomas are histologically similar to those
occurring in the ovary. Despite their similarity to ovarian GCTs, monodermal
teratomas such as struma ovarii have not been described in the mediastinum.=
<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>In adults, =
the most
common nonteratomatous component is germinoma/seminoma, but yolk sac tumor,
embryonal carcinoma, and choriocarcinoma may also occur. Mediastinal germin=
oma frequently
involves the thymus, with resultant cyst formation and thymic epithelial ce=
ll
hyperplasia.<sup>33</sup> This may make the recognition of the germinomatou=
s component
difficult. A high level of suspicion is necessary in the case of cystic les=
ions
of the thymus, especially if associated with a granulomatous response. The
morphology of nonteratomatous components is otherwise identical to those in=
 the
gonads and will not be repeated here because it has been reviewed in detail
elsewhere.<sup>34</sup> All nonteratomatous elements should be regarded as
malignant in adults.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>In most SGC=
Ts in
adults with adequate descriptions or illustrations, the histology of the ge=
rm
cell component is that of a mature teratoma, which is benign if it is pure.
Several cases are reported as &#8216;&#8216;malignant teratoma&#8217;&#8217;
without further description or illustration. Specific diagnoses and clear
descriptions or illustrations do reveal the existence of rare cases of
nonteratomatous GCTs including dysgerminoma, yolk sac tumor, and embryonal
carcinoma.<sup>35,36</sup> When follow-up is provided, these tumors exhibit=
 the
expected malignant behavior.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Cervical GC=
Ts are
quite rare in adults but have been described with a variety of histologic
patterns. Mature teratomas may occur at this site and, when pure, have a
uniformly benign behavior.<sup>36-40</sup> Nonteratomatous GCTs, including
embryonal carcinoma and yolk sac tumor, have been described.<sup>41,42</sup>
The few reports of non-germ cell neoplasms arising in CGCT include carcinom=
as<sup>43,44</sup>
and, possibly, chondrosarcoma.<sup>41</sup> Too few of such cases have been
described to make generalizations about their behavior, but they would be
expected to be aggressive, based on reports from other sites (see Note J).<=
o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>E.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Grade (Immature Teratomas)<o:p></o=
:p></span></h2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The histolo=
gic
grade of the tumor is based on 3 factors: degree of immaturity, presence of=
 a
neuroepithelial component, and the quantity of the latter.<sup>45</sup><o:p=
></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Grade 1 is =
given to
neoplasms with some immaturity but with neuroepithelium absent or limited t=
o a
rare low-power magnification (X40) field within the tumor, and not more tha=
n 1
such focus in any slide.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Grade 2 is =
given
when immaturity and neuroepithelium were present to a greater degree than g=
rade
1. Neuroepithelium is common but does not exceed 3 low-power microscopic fi=
elds
in any 1 slide.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Grade 3 is =
given
when immaturity and neuroepithelium were prominent, the latter occupying 4 =
or
more low-magnification microscopic fields within individual sections.<o:p><=
/o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Congenital/Neonatal<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The presenc=
e or
grade of immaturity, as defined by Norris et al<sup>45</sup> for ovarian
teratomas, is not predictive of malignant behavior in congenital EGCTs,
although immature teratomas are more likely to have admixed yolk sac tumor.=
 It
is well recognized that incomplete surgical resection of neonatal teratomas=
 is
associated with recurrences of a pure yolk sac tumor, as seen in cases of
sacrococcygeal teratoma for which coccygectomy was not performed.<sup>8,24,=
46,47</sup>
In some cases with recurrence, foci of the yolk sac tumor could not be
identified in the original resected teratoma.<sup>8,24</sup> It is unclear
whether that is due to incomplete sampling of the original lesion or whether
elements of a residual immature teratoma can give rise to a yolk sac tumor.=
<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Prepubertal/Child<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Increased p=
atient
age, sacrococcygeal location, and grade 2 to 3 immaturity are more frequent=
ly
associated with admixed yolk sac tumor.<sup>46</sup><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Postpubertal/Adult<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Mediastinal
immature teratomas, like their testicular counterparts, are most commonly
identified by cellular spindled stroma (ie, immature mesenchyme) surrounding
glandular epithelium. Immature neuroepithelial elements similar to those se=
en
in immature teratomas of the ovary may also be identified. Immature
neuroepithelium should be distinguished from mature ependyma, a relatively =
common
finding in mature teratomas. Other admixed immature elements frequently inc=
lude
cartilage and glandular epithelium, but the diagnosis of immaturity does not
typically depend on these elements. At present, there is no grading schema =
for
extragonadal immature teratomas; however, it is reasonable to report the
percentage of immature elements.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>In SGCTs, t=
he
existence of an immature teratoma in the absence of a nonteratomatous compo=
nent
seems to be quite infrequent, because it is only rarely described.<sup>48</=
sup>
The significance of immature tissues is not clear, but we are not aware of a
documented case of aggressive behavior.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Immature ce=
rvical
teratomas demonstrate malignant behavior,<sup>49-52</sup> similar to those
arising in the mediastinum, but unlike those of other extragonadal sites. In
some cases, the immature component is described as predominantly neural.<o:=
p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><b style=3D'mso-bidi-font-weight:normal'><span style=3D'mso-bidi-font-f=
amily:
Arial;text-decoration:none;text-underline:none'>F. </span></b><b
style=3D'mso-bidi-font-weight:normal'><span style=3D'font-family:"Arial","s=
ans-serif";
mso-bidi-font-family:"Times New Roman";text-decoration:none;text-underline:
none'>Postchemotherapy Evaluation<o:p></o:p></span></b></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Patients wi=
th
malignant EGCTs (especially adults) often receive cisplatin-based chemother=
apy
before surgical resection. This clinical practice places an extreme importa=
nce
on the initial biopsy interpretation and also creates challenges in the
evaluation of the resection specimen. The posttherapy tissue usually shows
necrosis, fibrosis, mixed inflammatory infiltrates, and xanthogranulomatous
inflammation. Because response to therapy is one of the main prognostic
variables, the percentage of viable nonteratomatous GCT should be reported,=
 a
finding present in up to 50% of resection specimens, even after normalizati=
on
of serum markers.<sup>53</sup> Less than 10% viable tumor cells is a good
prognostic factor as defined by the International Germ Cell Consensus
Classification Group (IGCCCG).<sup>54</sup> Residual viable tumor may be
relatively focal; therefore, areas of scarring, necrosis, or hemorrhage sho=
uld
be carefully examined.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>G. Margins/Vascular Invasion=
<o:p></o:p></span></h2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Because
completeness of excision is also an important prognostic factor, the excisi=
on
specimens should be inked and the margin status should be reported. Any
adherence of the mass to other structures should be carefully described. If
there is question about adherence, consultation with the surgeon is strongly
recommended.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Incomplete
resection of a neonatal mature teratoma has been reported to recur in adult=
hood
as adenocarcinoma.<sup>55,56</sup> The presence of a non-germ cell malignan=
cy
in a SGCT is a poor prognostic feature and requires complete surgical excis=
ion
and consideration of chemotherapy or radiation therapy.<o:p></o:p></span></=
p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Vascular in=
vasion
can involve blood vessels or lymphatics. In suspicious cases, blood vessels=
 can
be</span><b style=3D'mso-bidi-font-weight:normal'> </b><span style=3D'mso-b=
idi-font-family:
Arial'>highlighted with immunoperoxidase staining for factor VIII, CD31, an=
d CD34.<span
style=3D'mso-spacerun:yes'>&nbsp; </span>Lymphatic markers such as D2-40 (p=
odoplanin)
or LYVE1 may confirm lymphatic invasion. </span></p>

<h2 style=3D'page-break-after:auto'><o:p>&nbsp;</o:p></h2>

<h2><span style=3D'mso-bidi-font-family:Arial'>H. Staging<o:p></o:p></span>=
</h2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Clinical and
pathologic staging is very important in the prognosis of EGCTs. Unfortunate=
ly,
there is not an officially recognized American Joint Committee on Cancer
(AJCC)/International Union Against Cancer (UICC) TNM staging protocol for
EGCTs. The Children&#8217;s Oncology Group utilizes a 4-tiered staging syst=
em
for all EGCTs.<sup>12</sup> Surgeons also carefully define anatomic resecti=
ons
specifically of sacrococcygeal EGCTs. The WHO recommends using a modificati=
on
of the AJCC TNM staging of soft tissue tumors.<sup>57</sup> Moran and Suste=
r<sup>28</sup>
have also proposed a novel staging system specifically for mediastinal GCTs
based on an outcome study of 322 cases.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>In the Pedi=
atric
Oncology Group/Children&#8217;s Cancer Group Intergroup study,<sup>46</sup>
there were 22 children with completely resected, extragonadal, immature
teratomas, including 6 (27%) with admixed yolk sac tumor. None of the patie=
nts
received adjuvant chemotherapy. Three of the 22 children (14%) developed
recurrent yolk sac tumors, including 1 child with no admixed yolk sac tumor=
 at
diagnosis. Each of these children was treated for their recurrence with sur=
gery
and platinum-based chemotherapy (cisplatin, etoposide, and bleomycin). The
conclusion of the study was that complete surgical excision is effective
treatment for children with immature teratomas, with or without admixed yolk
sac tumor. The authors noted that patients with extragonadal tumors are a
higher risk group and require very careful follow-up. Although adjuvant che=
motherapy
could be considered in these patients, it is not recommended because of the
toxicity of unnecessary chemotherapy and the success of salvage therapy for
those children who do relapse.<sup>46</sup><o:p></o:p></span></p>

<pre style=3D'margin-top:12.0pt'><span lang=3DX-NONE style=3D'font-size:10.=
0pt;
font-family:"Arial","sans-serif";mso-bidi-font-family:"Times New Roman"'>A =
rare finding in extragonadal teratomas of very young children is the occurr=
ence of nodal gliomatosis in regional lymph nodes draining the teratoma.<su=
p>58</sup> The authors have had personal experience with such cases in whic=
h the finding had no effect on the patient&#8217;s clinical course and did =
not seem to warrant a designation of a &#8220;metastasis&#8221; upstaging t=
he patient. It is thought that the phenomenon is similar to peritoneal glio=
matosis in ovarian teratomas.<sup>58</sup> Studies suggest that gliomatosis=
 peritonei is a metaplastic phenomenon of pluripotent M&uuml;llerian stem c=
ells because it appears to be genetically unrelated to the teratoma.<sup>59=
</sup></span><sup><span
style=3D'font-size:10.0pt;font-family:"Arial","sans-serif";mso-ansi-languag=
e:
EN-US'>,60</span></sup><span lang=3DX-NONE style=3D'font-size:10.0pt;font-f=
amily:
"Arial","sans-serif";mso-bidi-font-family:"Times New Roman"'> It is unclear=
 whether the finding in lymph nodes is clonally related to the teratoma.<o:=
p></o:p></span></pre>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal style=3D'page-break-after:avoid'><u><span style=3D'mso=
-bidi-font-family:
Arial'>Mediastinal Germ Cell Tumors<o:p></o:p></span></u></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The overall
clinical outcome for primary mediastinal immature teratoma and nonteratomat=
ous
GCTs is reportedly worse than gonadal GCTs, but outcomes are improving with
preoperative cisplatin-based combination chemotherapy strategies.<sup>61-64=
</sup>
With neoadjuvant chemotherapy, good prognostic factors include completeness=
 of
resection, less than 10% viable tumor cells, and low-risk group as defined =
by
the IGCCCG&#8217;s Moran and Suster Proposed Clinical Staging System for
Mediastinal GCTs.<sup>54</sup> <o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>In the IGCC=
CG
groupings, there are prognostic differences among histologic subtypes of GC=
T.
Pure mediastinal seminoma has a better outcome than tumors with a
nonseminomatous component. The reported 5-year survival of 90% with
cisplatin-based combination chemotherapy rivals the outcome of testicular
seminomas.<sup>61,62,65</sup> Poor prognostic features of pure seminoma inc=
lude
liver or other nonpulmonary visceral metastases and metastases to 2 or more
sites.<sup>61</sup> Primary mediastinal choriocarcinoma is rare but reporte=
dly
has a much worse prognosis than other histologic subtypes owing to the
hematogenous dissemination at the time of diagnosis.<sup>66</sup> At least =
some
studies that include choriocarcinomas suggest an improved prognosis under
current chemotherapeutic regimens.<sup>67</sup> Embryonal carcinoma and yolk
sac tumor, whether pure or in association with any other components (semino=
ma
or teratoma), have a similar outcome and are generally regarded as poor
prognostic findings. As discussed above, mature teratoma is benign, but
immature teratoma has some potential for malignant behavior. In stage I pure
immature teratomas (ie, no infiltration of adjacent structures and no mixed
germ cell elements or secondary malignancy), the risk for aggressive behavi=
or
may be fairly low, but clinical outcome data are limited.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>I. Cytogenetics<o:p></o:p></=
span></h2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>It is well
documented that pediatric GCTs are distinct from adult GCTs cytogenetically.
Although the majority of adult malignant GCTs have the isochromosome 12p
abnormality, this aberration is very rare in children younger than 10 years=
.<sup>68</sup>
Although some yolk sac tumors have shown aberrations of the short arm of
chromosome 12 by interphase fluorescence in situ hybridization,<sup>69,70</=
sup>
no cytogenetic abnormality has been found to specifically correlate with
histology or primary tumor site in children. Aberrations of 1p, 1q, 6q,
chromosome and the sex chromosomes are also frequently encountered.<sup>68,=
71</sup>
In a Children&#8217;s Oncology Group study of 81 pediatric GCTs (gonadal and
extragonadal), the 12p isochromosome was only found in adolescent boys. It
remains to be investigated whether isochromosome 12p might be a better
prognostic factor than age in the peripubertal period.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>There is an=
 unusual
association between mediastinal GCTs, hematologic malignancies, and
cytogenetics.<sup>72-79</sup> Although it is unknown why they are associated
with only mediastinal tumors, genetic studies have demonstrated that both t=
he
GCT and hematopoietic components are clonally related.<sup>72,75</sup> The =
germ
cell component is typically yolk sac tumor, but immature teratomas and other
nonseminomatous GCTs are also described. The most commonly associated
hematopoietic malignancy is acute myeloid leukemia of megakaryocytic or
monocytic differentiation (ie, M7, M4, and M5), which comprises approximate=
ly
half of all cases.<sup>65,80,81</sup> Other reported malignancies include t=
he
spectrum of acute myeloid leukemia subtypes,<sup>78,79</sup> acute
undifferentiated leukemia,<sup>80</sup> myelodysplastic syndrome,<sup>82,83=
</sup>
myeloproliferative disorder,<sup>80,84,85</sup> &#8216;&#8216;malignant
histiocytosis,&#8217;&#8217;<sup>75</sup> mastocytosis,<sup>86</sup> and ac=
ute
lymphoblastic leukemia.<sup>76,80</sup> These hematopoietic tumors may invo=
lve
the mediastinal GCT or be completely extramediastinal.<sup>81</sup> The
hematopoietic component frequently shows an isochromosome 12 [i(12p)],<sup>=
72</sup>
the most common genetic alteration in GCTs, but may additionally harbor
translocations more typical of the specific morphologic phenotype [eg, del
(5q), trisomy 8]. This finding suggests that the non-i(12p) aberration
determines the tumor phenotype.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Germ cell
tumor-associated acute leukemias are an ominous finding because they are
typically refractory to current treatment modalities, with a reported survi=
val
of less than 2 years in all reported patients. The main differential diagno=
stic
consideration in this setting is a therapy-related myelodysplastic syndrome=
 or
acute leukemia following etoposide administration.<sup>73</sup> Therapy-rel=
ated
diseases can be distinguished by their occurrence later in the course (25 t=
o 60
months), the absence of i(12p), and the possible presence of an
etoposide-related translocation such as 11q23.<sup>87-89</sup><o:p></o:p></=
span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>J. Tissue and Serologic Mark=
ers<o:p></o:p></span></h2>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Tissue
Immunohistochemistry<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Extragonada=
l GCTs
typically show immunoreactivity patterns identical to their gonadal
counterparts.<sup>90</sup> In general, embryonal carcinoma, yolk sac tumor,
choriocarcinoma, and the epithelial elements of teratoma all show cytokerat=
in
AE1/AE3 reactivity. Although cytokeratin AE1/AE3 expression in testicular
seminomas has been proposed as a potential marker of early carcinomatous
progression,<sup>91</sup> this concept has not been addressed in extragonad=
al
sites. A dotlike paranuclear reactivity pattern to low-molecular-weight
cytokeratin (ie, CAM 5.2) is seen in up to 80% of mediastinal seminomas.<su=
p>90,92</sup><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Although
placental-like alkaline phosphatase has traditionally been the marker of ch=
oice
to objectively verify germ cell origin (mostly seminoma) in the setting of =
an
&#8216;&#8216;undifferentiated&#8217;&#8217; neoplasm,<sup>93-95</sup> its =
lack
of sensitivity, generally high background staining, and the development of
newer antibodies have rendered placental-like alkaline phosphatase less use=
ful
in current diagnostic practice. Strong membranous CD117 (c-kit)
immunoreactivity has been reported in 75% to 100% of seminomas,<sup>94</sup>
but it is not specific because it marks other non-germ cell carcinomas in t=
he
differential diagnosis, such as lung<sup>96</sup> and thymic carcinomas.<su=
p>96-98</sup>
In addition, embryonal carcinoma, yolk sac tumor, and choriocarcinoma may s=
how
some degree of weak CD117 reactivity. CD30 is also used in the workup of a
poorly differentiated malignant neoplasm because it is positive in more than
80% of embryonal carcinomas, but careful morphologic and clinical correlati=
on
is required because it also marks a spectrum of hematopoietic malignancies =
in
the differential diagnosis as well.<sup>99</sup><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Newer marke=
rs show
better specificity for germ cells tumors. Nearly 100% of seminomas and
embryonal carcinomas show nuclear reactivity for OCT4, and the specificity
within this morphologic differential seems better than other available mark=
ers.<sup>100-102</sup>
OCT4 is rapidly becoming the marker of choice for documenting germ cell ori=
gin
(ie, seminoma or embryonal carcinoma) in the workup of an undifferentiated
neoplasm. Yolk sac tumors and choriocarcinoma show cytoplasmic and membrano=
us
reactivity for the oncofetal protein glypican-3, with no significant reacti=
vity
in embryonal carcinoma or germinoma.<sup>103,104</sup> Most recently, SALL4=
 has
been shown to demonstrate strong nuclear staining in germinoma, embryonal
carcinoma, and yolk sac tumors. SALL4 appears more sensitive than either
glypican-3 or AFP for the diagnosis of yolk sac tumor.<sup>105,106</sup> The
mononuclear trophoblast cells of choriocarcinoma are also reactive for SALL=
4. <o:p></o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'><o:p><span
 style=3D'text-decoration:none'>&nbsp;</span></o:p></span></h3>

<h3><span style=3D'font-family:"Arial","sans-serif"'>&#945;-</span><span
style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"Times New R=
oman"'>Fetoprotein<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Serum AFP i=
s not a
reliable marker for yolk sac tumor because of its low sensitivity.<sup>107<=
/sup>
Serum evaluation of AFP and HCG is frequently more useful than immunohistoc=
hemistry.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>The presenc=
e of
minute, occult, yolk sac tumor elements in large sacrococcygeal teratomas c=
an
be overlooked. Hawkins et al<sup>24</sup> described 6 children with mature =
or
immature sacrococcygeal teratomas initially diagnosed in the newborn period,
who had the appropriate operation and subsequently had yolk sac tumor
recurrences 7 to 33 months later. Histologic detection of foci of yolk sac
tumor in sacrococcygeal teratomas is very important because serum AFP levels
are not always helpful as a marker, being normally high in the newborn peri=
od
as a result of fetal production.<sup>24</sup> Moreover, primitive gut and l=
iver
tissues in preterm teratomas also react with the AFP antibody, which makes
establishing the histologic diagnosis of this sometimes subtle malignancy d=
ifficult.
<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Most of the=
 tumor
recurrences after congenital teratoma are yolk sac tumor, and AFP is useful=
 in
following these patients. Neonatal levels are normally elevated, and the
initial AFP level does not seem to correlate with the presence or absence of
yolk sac tumor in neonatal teratomas. Postoperative monitoring can be usefu=
l,
because the AFP level should fall after tumor excision, as it normally woul=
d in
the neonate.</span><!--[if supportFields]><span style=3D'mso-bidi-font-fami=
ly:
Arial'><span style=3D'mso-element:field-begin'></span> ADDIN EN.CITE
&lt;EndNote&gt;&lt;Cite&gt;&lt;Author&gt;Heerema-McKenney&lt;/Author&gt;&lt=
;Year&gt;2005&lt;/Year&gt;&lt;RecNum&gt;7&lt;/RecNum&gt;&lt;record&gt;&lt;r=
ec-number&gt;7&lt;/rec-number&gt;&lt;ref-type
name=3D&quot;Journal
Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&gt;&lt;authors&gt;&lt;=
author&gt;Heerema-McKenney,
A.&lt;/author&gt;&lt;author&gt;Harrison, M. R.&lt;/author&gt;&lt;author&gt;=
Bratton,
B.&lt;/author&gt;&lt;author&gt;Farrell, J.&lt;/author&gt;&lt;author&gt;Zalo=
udek,
C.&lt;/author&gt;&lt;/authors&gt;&lt;/contributors&gt;&lt;auth-address&gt;D=
epartments
of Pathology, Division of Pediatric Surgery, and Fetal Treatment Center,
University of California, San Francisco, CA 94143,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Congenital teratoma: a
clinicopathologic study of 22 fetal and neonatal
tumors&lt;/title&gt;&lt;secondary-title&gt;Am J Surg
Pathol&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-tit=
le&gt;Am
J Surg Pathol&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;29-38&lt;/p=
ages&gt;&lt;volume&gt;29&lt;/volume&gt;&lt;number&gt;1&lt;/number&gt;&lt;ke=
ywords&gt;&lt;keyword&gt;Adult&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/key=
word&gt;&lt;keyword&gt;Fetal
Diseases/blood/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Fetus&lt;/k=
eyword&gt;&lt;keyword&gt;Gestational
Age&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;Infa=
nt,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Pregnancy&lt;/keyword&gt;&lt;keyword&=
gt;Pregnancy
Complications,
Neoplastic/blood/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Sacrococc=
ygeal
Region/pathology&lt;/keyword&gt;&lt;keyword&gt;Spinal
Neoplasms/*congenital/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Tera=
toma/*congenital/*pathology/surgery&lt;/keyword&gt;&lt;keyword&gt;Treatment
Outcome&lt;/keyword&gt;&lt;keyword&gt;alpha-Fetoproteins/analysis&lt;/keywo=
rd&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;2005&lt;/year&gt;&lt;pub-da=
tes&gt;&lt;date&gt;Jan&lt;/date&gt;&lt;/pub-dates&gt;&lt;/dates&gt;&lt;acce=
ssion-num&gt;15613854&lt;/accession-num&gt;&lt;urls&gt;&lt;related-urls&gt;=
&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3DRetrieve&amp=
;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=3D15613854
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;Cite&gt;&lt;Author&gt;Rescorla&lt;/Author&gt;&lt;Year&gt;1998&lt;/Year&g=
t;&lt;RecNum&gt;22&lt;/RecNum&gt;&lt;record&gt;&lt;rec-number&gt;22&lt;/rec=
-number&gt;&lt;ref-type
name=3D&quot;Journal Article&quot;&gt;17&lt;/ref-type&gt;&lt;contributors&g=
t;&lt;authors&gt;&lt;author&gt;Rescorla,
F. J.&lt;/author&gt;&lt;author&gt;Sawin, R.
S.&lt;/author&gt;&lt;author&gt;Coran, A. G.&lt;/author&gt;&lt;author&gt;Dil=
lon,
P. W.&lt;/author&gt;&lt;author&gt;Azizkhan, R. G.&lt;/author&gt;&lt;/author=
s&gt;&lt;/contributors&gt;&lt;auth-address&gt;J.W.
Riley Hospital, Indianapolis, IN 46202,
USA.&lt;/auth-address&gt;&lt;titles&gt;&lt;title&gt;Long-term outcome for
infants and children with sacrococcygeal teratoma: a report from the Childr=
ens
Cancer Group&lt;/title&gt;&lt;secondary-title&gt;J Pediatr
Surg&lt;/secondary-title&gt;&lt;/titles&gt;&lt;periodical&gt;&lt;full-title=
&gt;J
Pediatr Surg&lt;/full-title&gt;&lt;/periodical&gt;&lt;pages&gt;171-6&lt;/pa=
ges&gt;&lt;volume&gt;33&lt;/volume&gt;&lt;number&gt;2&lt;/number&gt;&lt;key=
words&gt;&lt;keyword&gt;Child,
Preschool&lt;/keyword&gt;&lt;keyword&gt;*Coccyx&lt;/keyword&gt;&lt;keyword&=
gt;Combined
Modality Therapy&lt;/keyword&gt;&lt;keyword&gt;Endodermal Sinus
Tumor/*epidemiology/therapy&lt;/keyword&gt;&lt;keyword&gt;Female&lt;/keywor=
d&gt;&lt;keyword&gt;Follow-Up
Studies&lt;/keyword&gt;&lt;keyword&gt;Humans&lt;/keyword&gt;&lt;keyword&gt;=
Infant&lt;/keyword&gt;&lt;keyword&gt;Infant,
Newborn&lt;/keyword&gt;&lt;keyword&gt;Male&lt;/keyword&gt;&lt;keyword&gt;Ne=
oplasm
Recurrence, Local/epidemiology&lt;/keyword&gt;&lt;keyword&gt;Retrospective
Studies&lt;/keyword&gt;&lt;keyword&gt;*Sacrum&lt;/keyword&gt;&lt;keyword&gt=
;Spinal
Neoplasms/*epidemiology/therapy&lt;/keyword&gt;&lt;keyword&gt;Survival
Rate&lt;/keyword&gt;&lt;keyword&gt;Teratoma/*epidemiology/therapy&lt;/keywo=
rd&gt;&lt;keyword&gt;Time
Factors&lt;/keyword&gt;&lt;keyword&gt;Treatment
Outcome&lt;/keyword&gt;&lt;/keywords&gt;&lt;dates&gt;&lt;year&gt;1998&lt;/y=
ear&gt;&lt;pub-dates&gt;&lt;date&gt;Feb&lt;/date&gt;&lt;/pub-dates&gt;&lt;/=
dates&gt;&lt;accession-num&gt;9498381&lt;/accession-num&gt;&lt;urls&gt;&lt;=
related-urls&gt;&lt;url&gt;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cm=
d=3DRetrieve&amp;amp;db=3DPubMed&amp;amp;dopt=3DCitation&amp;amp;list_uids=
=3D9498381
&lt;/url&gt;&lt;/related-urls&gt;&lt;/urls&gt;&lt;/record&gt;&lt;/Cite&gt;&=
lt;/EndNote&gt;<span
style=3D'mso-element:field-separator'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><sup>7,17</sup></span><!--[if supportF=
ields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-end'>=
</span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h3><span style=3D'font-family:"Arial","sans-serif";mso-bidi-font-family:"T=
imes New Roman"'>Human
Chorionic Gonadotropin<o:p></o:p></span></h3>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Serum &szli=
g;-HCG
immunohistochemistry can be used to identify choriocarcinoma. Isolated
syncytial trophoblasts can stain positively in seminomas. Evaluation of ser=
um
&szlig;-HCG is also helpful in establishing the presence of occult
choriocarcinoma.<o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>K. Associated Syndromes and
Malignancies<o:p></o:p></span></h2>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'>Some consti=
tutional
syndromes are thought to have an increased incidence of EGCTs, including
Klinefelter<sup>68,108-113</sup> and Down syndrome.<sup> 68,114,115</sup><s=
pan
style=3D'mso-spacerun:yes'>&nbsp; </span>The association of hematopoietic
malignancies with mediastinal EGCTs was described in note H (Cytogenetics).
Sarcomatous differentiation, which is most frequent in the mediastinum, may
occur in association with teratomas or, less commonly, with other malignant
GCTs.<sup>82,116-120</sup> As in the gonads, secondary squamous cell carcin=
oma,
adenosquamous carcinoma, and colonic-type adenocarcinoma may rarely complic=
ate
extragonadal teratomas.<sup>120</sup> The presence of sarcomatous or
carcinomatous elements portend a very poor prognosis. <o:p></o:p></span></p>

<p class=3DMsoNormal><span style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;=
</o:p></span></p>

<h2><span style=3D'mso-bidi-font-family:Arial'>References<o:p></o:p></span>=
</h2>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><!--[=
if supportFields]><span
style=3D'mso-bidi-font-family:Arial'><span style=3D'mso-element:field-begin=
'></span><span
style=3D'mso-spacerun:yes'>&nbsp;</span>ADDIN EN.REFLIST <span style=3D'mso=
-element:
field-separator'></span></span><![endif]--><span style=3D'mso-bidi-font-fam=
ily:
Arial'>1.<span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s=
pan>Bethel
CA, Mutabagani K, Hammond S, Besner GE, Caniano DA, Cooney DR. Nonteratomat=
ous
germ cell tumors in children. <i style=3D'mso-bidi-font-style:normal'>J Ped=
iatr
Surg</i>. 1998;33(7):1122-1126; discussion 1126-1127.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>2.<span style=3D'mso-tab-count:1'>&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp; </span>Cushing
B, Giller R, Cullen JW, et al. Randomized comparison of combination
chemotherapy with etoposide, bleomycin, and either high-dose or standard-do=
se
cisplatin in children and adolescents with high-risk malignant germ cell
tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and
Children's Cancer Group 8882. </span><i style=3D'mso-bidi-font-style:normal=
'><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>J Clin =
Oncol</span></i><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>.
2004;22(13):2691-2700.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>3.<span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>De Giorgi U,
Demirer T, Wandt H, et al. </span><span style=3D'mso-bidi-font-family:Arial=
'>Second-line
high-dose chemotherapy in patients with mediastinal and retroperitoneal pri=
mary
non-seminomatous germ cell tumors: the EBMT experience. <i style=3D'mso-bid=
i-font-style:
normal'>Ann Oncol</i>. 2005;16(1):146-151.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>4.<span style=3D'mso-tab-count:1'>&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp; </span>De
Giorgi U, Rosti G, Slavin S, et al. Salvage high-dose chemotherapy for chil=
dren
with extragonadal germ-cell tumours. <i style=3D'mso-bidi-font-style:normal=
'>Br J
Cancer</i>. 2005;93(4):412-417.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>5.<span style=3D'mso-tab-count:1'>&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp; </span>Lo
Curto M, Lumia F, Alaggio R, et al. Malignant germ cell tumors in childhood:
results of the first Italian cooperative study &quot;TCG 91&quot;. <i
style=3D'mso-bidi-font-style:normal'>Med Pediatr Oncol</i>. 2003;41(5):417-=
425.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>6.<span style=3D'mso-tab-count:1'>&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp; </span>Marina
N, London WB, Frazier AL, et al. Prognostic factors in children with
extragonadal malignant germ cell tumors: a pediatric intergroup study. <i
style=3D'mso-bidi-font-style:normal'>J Clin Oncol</i>. 2006;24(16):2544-254=
8.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>7.<span style=3D'mso-tab-count:1'>&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp; </span>Heerema-McKenney
A, Harrison MR, Bratton B, Farrell J, Zaloudek C. Congenital teratoma: a
clinicopathologic study of 22 fetal and neonatal tumors. <i style=3D'mso-bi=
di-font-style:
normal'>Am J Surg Pathol</i>. 2005;29(1):29-38.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>8.<span style=3D'mso-tab-count:1'>&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp; </span>Huddart
SN, Mann JR, Robinson K, et al. Sacrococcygeal teratomas: the UK Children's
Cancer Study Group's experience. I. Neonatal. <i style=3D'mso-bidi-font-sty=
le:
normal'>Pediatr Surg Int</i>. 2003;19(1-2):47-51.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>9.<span style=3D'mso-tab-count:1'>&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp; </span>Marina
N, Fontanesi J, Kun L, et al. Treatment of childhood germ cell tumors: revi=
ew
of the St. Jude experience from 1979 to 1988. <i style=3D'mso-bidi-font-sty=
le:
normal'>Cancer</i>. 1992;70(10):2568-2575.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>10.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Harms
D, Schmidt D, Leuschner I. Abdominal, retroperitoneal and sacrococcygeal
tumours of the newborn and the very young infant: report from the Kiel
Paediatric Tumour Registry. <i style=3D'mso-bidi-font-style:normal'>Eur J P=
ediatr</i>.
1989;148(8):720-728.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>11.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Dehner
LP. Gonadal and extragonadal germ cell neoplasia of childhood. <i
style=3D'mso-bidi-font-style:normal'>Hum Pathol</i>. 1983;14(6):493-511.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>12.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Rescorla
FJ. Pediatric germ cell tumors. <i style=3D'mso-bidi-font-style:normal'>Sem=
in
Surg Oncol</i>. 1999;16(2):144-158.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>13.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Isaacs
H Jr. Perinatal (fetal and neonatal) germ cell tumors. </span><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-font=
-family:
Arial;mso-ansi-language:DE'>J Pediatr Surg</span></i><span lang=3DDE
style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>. 2004;39(7):1003=
-1013.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>14.<span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp; </span>Schneider DT, Cal=
aminus
G, Koch S, et al. </span><span style=3D'mso-bidi-font-family:Arial'>Epidemi=
ologic
analysis of 1,442 children and adolescents registered in the German germ ce=
ll
tumor protocols. <i style=3D'mso-bidi-font-style:normal'>Pediatr Blood Canc=
er</i>.
2004;42(2):169-175.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>15.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Schneider
DT, Calaminus G, Reinhard H, et al. Primary mediastinal germ cell tumors in
children and adolescents: results of the German cooperative protocols MAKEI
83/86, 89, and 96. <i style=3D'mso-bidi-font-style:normal'>J Clin Oncol</i>.
2000;18(4):832-839.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>16.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Cushing
B, Bhanot PK, Watts FB Jr, Hertzler JH, Brough AJ. Rhabdomyosarcoma and ben=
ign
teratoma. <i style=3D'mso-bidi-font-style:normal'>Pediatr Pathol</i>.
1983;1(3):345-348.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>17.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Rescorla
FJ, Sawin RS, Coran AG, Dillon PW, Azizkhan RG. Long-term outcome for infan=
ts
and children with sacrococcygeal teratoma: a report from the Childrens Canc=
er
Group. <i style=3D'mso-bidi-font-style:normal'>J Pediatr Surg</i>. 1998;33(=
2):171-176.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>18.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Gobel
U, Schneider DT, Calaminus G, Haas RJ, Schmidt P, Harms D. Germ-cell tumors=
 in
childhood and adolescence. GPOH MAKEI and the MAHO study groups. <i
style=3D'mso-bidi-font-style:normal'>Ann Oncol</i>. 2000;11(3):263-271.<o:p=
></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>19.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Rosenblum
MD, Matsutani M, Va Meir EG. CNS germ cell tumors. In: Kleihues P, Cavenee =
WK,
eds. <i style=3D'mso-bidi-font-style:normal'>World Health Organization
Classification of Tumours. Pathology and Genetics of Tumors of the Nervous
System.</i> Lyon, France: IARC Press; 2000:208.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>20.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Bjornsson
J, Scheithauer BW, Okazaki H, Leech RW. Intracranial germ cell tumors:
pathobiological and immunohistochemical aspects of 70 cases. <i
style=3D'mso-bidi-font-style:normal'>J Neuropathol Exp Neurol</i>.
1985;44(1):32-46.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>21.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Coskun
U, Gunel N, Yildirim Y, Memis L, Boyacioglu ZM. Primary mediastinal yolk sac
tumor in a 66-year-old woman. <i style=3D'mso-bidi-font-style:normal'>Med P=
rinc
Pract</i>. 2002;11(4):218-220.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>22.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Shimizu
J, Yazaki U, Kinoshita T, Tatsuzawa Y, Kawaura Y, Nonomura A. Primary
mediastinal germ cell tumor in a middle-aged woman: case report and literat=
ure
review. <i style=3D'mso-bidi-font-style:normal'>Tumori</i>. 2001;87(4):269-=
271.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>23.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Ng
EW, Porcu P, Loehrer PJ Sr. Sacrococcygeal teratoma in adults: case reports=
 and
a review of the literature. <i style=3D'mso-bidi-font-style:normal'>Cancer<=
/i>.
1999;86(7):1198-1202.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>24.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Hawkins
E, Issacs H, Cushing B, Rogers P. Occult malignancy in neonatal sacrococcyg=
eal
teratomas: a report from a Combined Pediatric Oncology Group and Children's
Cancer Group study. <i style=3D'mso-bidi-font-style:normal'>Am J Pediatr He=
matol
Oncol</i>. 1993;15(4):406-409.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>25.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Isaacs
H Jr. Tumors. In: Gilbert-Barness E, ed. <i style=3D'mso-bidi-font-style:no=
rmal'>Potter's
Pathology of the Fetus and Infant</i>. Vol 2. St. Louis, MO: Mosby;
1997:1242-1339.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>26.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Isaacs
H Jr. I. Perinatal brain tumors: a review of 250 cases. <i style=3D'mso-bid=
i-font-style:
normal'>Pediatr Neurol</i>. 2002;27(4):249-261.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>27.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Nogales
F, Talerman A, Kubik-Huch RA, Tavassoli FA, Devouassoux-Shisheboran M. Germ
cell tumors. In: Tavassoli FA, Devilee P, eds. <i style=3D'mso-bidi-font-st=
yle:
normal'>Pathology and Genetics of Tumours of the Breast and Female Genital
Organs.</i> Lyon, France: IARC Press; 2003. <i style=3D'mso-bidi-font-style=
:normal'>World
Health Organization Classification of Tumours.</i><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>28.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Moran
CA, Suster S. Primary germ cell tumors of the mediastinum, I: analysis of 3=
22
cases with special emphasis on teratomatous lesions and a proposal for
histopathologic classification and clinical staging. <i style=3D'mso-bidi-f=
ont-style:
normal'>Cancer</i>. 1997;80(4):681-690.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>29.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Isaacs
H Jr. <i style=3D'mso-bidi-font-style:normal'>Germ Cell Tumors: Tumors of t=
he
Fetus and Newborn.</i> Vol 35. Philadelphia, PA: Saunders; 1997.<o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>30.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Noseworthy
J, Lack EE, Kozakewich HP, Vawter GF, Welch KJ. Sacrococcygeal germ cell tu=
mors
in childhood: an updated experience with 118 patients. <i style=3D'mso-bidi=
-font-style:
normal'>J Pediatr Surg</i>. 1981;16(3):358-364.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>31.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Dehner
LP. Neoplasms of the fetus and neonate. </span><span lang=3DDE style=3D'mso=
-bidi-font-family:
Arial;mso-ansi-language:DE'>In: Naeye RL, Kissane JM, NKaufman N, eds. </sp=
an><i
style=3D'mso-bidi-font-style:normal'><span style=3D'mso-bidi-font-family:Ar=
ial'>Perinatal
Diseases, International Academy of Pathology</span></i><span style=3D'mso-b=
idi-font-family:
Arial'>. Vol. 22. Baltimore, MD: Williams and Wilkins; 1981:286-345.<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>32.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Sebire
NJ, Lindsay I, Fisher RA, Seckl MJ. Intraplacental choriocarcinoma: experie=
nce
from a tertiary referral center and relationship with infantile choriocarci=
noma.
<i style=3D'mso-bidi-font-style:normal'>Fetal Pediatr Pathol</i>.
2005;24(1):21-29.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>33.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Moran
CA, Suster S. Mediastinal seminomas with prominent cystic changes: a
clinicopathologic study of 10 cases. <i style=3D'mso-bidi-font-style:normal=
'>Am J
Surg Pathol</i>. 1995;19(9):1047-53.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>34.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Ulbright
TM, Amin MB, Young RH. <i style=3D'mso-bidi-font-style:normal'>Tumors of th=
e Testis,
Adnexa, Spermatic Cord, and Scrotum.</i> Washington, DC: Armed Forces Insti=
tute
of Pathology; 1999.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>35.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Ahmed
HA, Pollock DJ. Malignant sacrococcygeal teratoma in the adult. <i
style=3D'mso-bidi-font-style:normal'>Histopathology</i>. 1985;9(3):359-363.=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>36.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Conklin
J, Abell MR. Germ cell neoplasms of sacrococcygeal region. <i style=3D'mso-=
bidi-font-style:
normal'>Cancer</i>. 1967;20(12):2105-2117.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>37.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Kuhel
WI. Adherence of benign cervical teratomas to surrounding soft tissue. <i
style=3D'mso-bidi-font-style:normal'>Arch Otolaryngol Head Neck Surg</i>.
1999;125(2):236-237.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>38.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Kuhel
WI, Yagoda M, Peterson P. Benign cervical teratoma in the adult: report of a
rare case with dense fibrosis involving adjacent vital structures. <i
style=3D'mso-bidi-font-style:normal'>Otolaryngol Head Neck Surg</i>.
1996;115(1):152-155.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>39.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Mochizuki
Y, Noguchi S, Yokoyama S, et al. Cervical teratoma in a fetus and an adult:=
 two
case reports and review of literature. <i style=3D'mso-bidi-font-style:norm=
al'>Acta
Pathol Jpn</i>. 1986;36(6):935-943.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>40.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Sawafuji
M, Kakizaki T, Yamamoto T, Kikuchi K, Kobayashi K, Ito K. A case of cervical
teratoma in adult [in Japanese]. <i style=3D'mso-bidi-font-style:normal'>Ni=
ppon
Kyobu Geka Gakkai Zasshi</i>. 1993;41(11):2220-2223.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>41.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Als
C, Laeng H, Cerny T, Kinser JA, Rosler H, Hausler R. Primary cervical malig=
nant
teratoma with a rib metastasis in an adult: five-year survival after surgery
and chemotherapy. A case report with a review of the literature. <i
style=3D'mso-bidi-font-style:normal'>Ann Oncol</i>. 1998;9(9):1015-1022.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>42.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Tobey
DN, Mangham C. Malignant cervical teratomas. <i style=3D'mso-bidi-font-styl=
e:
normal'>Otolaryngol Head Neck Surg</i>. 1980;88(3):215-217.<o:p></o:p></spa=
n></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>43.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Colton
JJ, Batsakis JG, Work WP. Teratomas of the neck in adults. <i style=3D'mso-=
bidi-font-style:
normal'>Arch Otolaryngol</i>. 1978;104(5):271-272.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>44.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Murao
T, Nakanishi M, Toda K, Konishi H. Malignant teratoma of the thyroid gland =
in
an adolescent female. <i style=3D'mso-bidi-font-style:normal'>Acta Pathol J=
pn</i>.
1979;29(1):109-117.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>45.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Norris
HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a
clinical and pathologic study of 58 cases. <i style=3D'mso-bidi-font-style:=
normal'>Cancer</i>.
1976;37(5):2359-2372.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>46.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Marina
NM, Cushing B, Giller R, et al. Complete surgical excision is effective
treatment for children with immature teratomas with or without malignant
elements: a Pediatric Oncology Group/Children's Cancer Group Intergroup Stu=
dy. <i
style=3D'mso-bidi-font-style:normal'>J Clin Oncol</i>. 1999;17(7):2137-2143=
.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>47.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Tapper
D, Lack EE. Teratomas in infancy and childhood: a 54-year experience at the
Children's Hospital Medical Center. <i style=3D'mso-bidi-font-style:normal'=
>Ann
Surg</i>. 1983;198(3):398-410.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>48.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Lopes
A, Pearson SE, Roberts JT, Monaghan JM. Immature presacral teratoma in an a=
dult
female. <i style=3D'mso-bidi-font-style:normal'>Gynecol Oncol</i>.
1990;38(1):135-137.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>49.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Bowker
CM, Whittaker RS. Malignant teratoma of the thyroid: case report and litera=
ture
review of thyroid teratoma in adults. <i style=3D'mso-bidi-font-style:norma=
l'>Histopathology</i>.
1992;21(1):81-83.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>50.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Buckley
NJ, Burch WM, Leight GS. Malignant teratoma in the thyroid gland of an adul=
t: a
case report and a review of the literature. <i style=3D'mso-bidi-font-style=
:normal'>Surgery</i>.
1986;100(5):932-937.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>51.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Hajdu
SI, Hajdu EO. Malignant teratoma of the neck. <i style=3D'mso-bidi-font-sty=
le:
normal'>Arch Pathol</i>. 1967;83(6):567-570.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>52.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Jayaram
G, Cheah PL, Yip CH. Malignant teratoma of the thyroid with predominantly
neuroepithelial differentiation: fine needle aspiration cytologic, histolog=
ic
and immunocytochemical features of a case. <i style=3D'mso-bidi-font-style:=
normal'>Acta
Cytol</i>. 2000;44(3):375-379.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>53.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Ulbright
TM, Roth LM. A pathologic analysis of lesions following modern chemotherapy=
 for
metastatic germ-cell tumors. <i style=3D'mso-bidi-font-style:normal'>Pathol=
 Annu</i>.
1990;25 Pt 1:313-340.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>54.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>International
Germ Cell Cancer Collaborative Group. International Germ Cell Consensus
Classification: a prognostic factor-based staging system for metastatic germ
cell cancers. <i style=3D'mso-bidi-font-style:normal'>J Clin Oncol</i>.
1997;15(2):594-603.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>55.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Lack
EE, Glaun RS, Hefter LG, Seneca RP, Steigman C, Athari F. Late occurrence of
malignancy following resection of a histologically mature sacrococcygeal
teratoma: report of a case and literature review. <i style=3D'mso-bidi-font=
-style:
normal'>Arch Pathol Lab Med</i>. 1993;117(7):724-728.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>56.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Lahdenne
P, Heikinheimo M, Perkkio M, Rapola J, Miettinen M. Cell differentiation in
sacrococcygeal teratomas: an immunohistochemical and follow-up study. <i
style=3D'mso-bidi-font-style:normal'>Pathol Res Pract</i>. 1990;186(3):336-=
343.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>57.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Wick
MR, Perlman EJ, Orazi A, et al. Germ cell tumors of the mediastinum. In: Tr=
avis
WD, Brambilla E, Muller-Hermelink HK, et al, eds. <i style=3D'mso-bidi-font=
-style:
normal'>World Health Organization Classification of Tumours. Pathology and =
Genetics
of Tumours of the Lung, Pleura, Thymus, and Heart.</i> Lyon, France: IARC
press; 2004:198-201.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>58.<span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp; </span>Perrone T, Steine=
r M,
Dehner LP. </span><span style=3D'mso-bidi-font-family:Arial'>Nodal gliomato=
sis
and alpha-fetoprotein production: two unusual facets of grade I ovarian
teratoma. <i style=3D'mso-bidi-font-style:normal'>Arch Pathol Lab Med</i>.
1986;110(10):975-977.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>59.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Robboy
SJ, Scully RE. Ovarian teratoma with glial implants on the peritoneum: an
analysis of 12 cases. <i style=3D'mso-bidi-font-style:normal'>Hum Pathol</i=
>.
1970;1(4):643-653.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>60.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Ferguson
AW, Katabuchi H, Ronnett BM, Cho KR. Glial implants in gliomatosis peritonei
arise from normal tissue, not from the associated teratoma. <i
style=3D'mso-bidi-font-style:normal'>Am J Pathol</i>. 2001;159(1):51-55.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>61.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Bokemeyer
C, Droz JP, Horwich A, et al. Extragonadal seminoma: an international
multicenter analysis of prognostic factors and long term treatment outcome.=
 <i
style=3D'mso-bidi-font-style:normal'>Cancer</i>. 2001;91(7):1394-1401.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>62.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Bokemeyer
C, Hartmann JT, Fossa SD, et al. Extragonadal germ cell tumors: relation to
testicular neoplasia and management options. <i style=3D'mso-bidi-font-styl=
e:
normal'>APMIS</i>. 2003;111(1):49-59; discussion 59-63.<o:p></o:p></span></=
p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>63.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Fizazi
K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary
chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic
factors and role of postsurgery chemotherapy--results from an international
study group. <i style=3D'mso-bidi-font-style:normal'>J Clin Oncol</i>.
2001;19(10):2647-2657.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>64.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Hartmann
JT, Nichols CR, Droz JP, et al. Prognostic variables for response and outco=
me
in patients with extragonadal germ-cell tumors. <i style=3D'mso-bidi-font-s=
tyle:
normal'>Ann Oncol</i>. 2002;13(7):1017-1028.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>65.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Bokemeyer
C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediast=
inum
and retroperitoneum: results from an international analysis. <i
style=3D'mso-bidi-font-style:normal'>J Clin Oncol</i>. 2002;20(7):1864-1873=
.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>66.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Moran
CA, Suster S. Primary mediastinal choriocarcinomas: a clinicopathologic and
immunohistochemical study of eight cases. <i style=3D'mso-bidi-font-style:n=
ormal'>Am
J Surg Pathol</i>. 1997;21(9):1007-1012.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>67.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Takeda
S, Miyoshi S, Ohta M, Minami M, Masaoka A, Matsuda H. Primary germ cell tum=
ors
in the mediastinum: a 50-year experience at a single Japanese institution. =
<i
style=3D'mso-bidi-font-style:normal'>Cancer</i>. 2003;97(2):367-376.<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>68.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Bussey
KJ, Lawce HJ, Olson SB, et al. Chromosome abnormalities of eighty-one pedia=
tric
germ cell tumors: sex-, age-, site-, and histopathology-related differences=
: a
Children's Cancer Group study. <i style=3D'mso-bidi-font-style:normal'>Genes
Chromosomes Cancer</i>. 1999;25(2):134-146.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>69.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Jenderny
J, Koster E, Borchers O, et al. Interphase cytogenetics on paraffin section=
s of
paediatric extragonadal yolk sac tumours. </span><i style=3D'mso-bidi-font-=
style:
normal'><span lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-langua=
ge:DE'>Virchows
Arch</span></i><span lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi=
-language:
DE'>. 1996;428(1):53-57.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>70.<span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp; </span>Stock C, Ambros I=
M,
Lion T, et al. </span><span style=3D'mso-bidi-font-family:Arial'>Detection =
of
numerical and structural chromosome abnormalities in pediatric germ cell tu=
mors
by means of interphase cytogenetics. <i style=3D'mso-bidi-font-style:normal=
'>Genes
Chromosomes Cancer</i>. 1994;11(1):40-50.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>71.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Perlman
EJ, Cushing B, Hawkins E, Griffin CA. Cytogenetic analysis of childhood
endodermal sinus tumors: a Pediatric Oncology Group study. <i style=3D'mso-=
bidi-font-style:
normal'>Pediatr Pathol</i>. 1994;14(4):695-708.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>72.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Downie
PA, Vogelzang NJ, Moldwin RL, et al. Establishment of a leukemia cell line =
with
i(12p) from a patient with a mediastinal germ cell tumor and acute
lymphoblastic leukemia. <i style=3D'mso-bidi-font-style:normal'>Cancer Res<=
/i>.
1994;54(18):4999-5004.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>73.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Hartmann
JT, Nichols CR, Droz JP, et al. Hematologic disorders associated with prima=
ry
mediastinal nonseminomatous germ cell tumors. <i style=3D'mso-bidi-font-sty=
le:
normal'>J Natl Cancer Inst</i>. 2000;92(1):54-61.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>74.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Keung
YK, Liang R, Chiu EK. Acute leukemia associated with mediastinal germ cell
tumor: de novo versus therapy-related leukemia. <i style=3D'mso-bidi-font-s=
tyle:
normal'>West J Med</i>. 1993;158(4):409-412.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>75.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Ladanyi
M, Samaniego F, Reuter VE, et al. Cytogenetic and immunohistochemical evide=
nce
for the germ cell origin of a subset of acute leukemias associated with med=
iastinal
germ cell tumors. <i style=3D'mso-bidi-font-style:normal'>J Natl Cancer Ins=
t</i>.
1990;82(3):221-227.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>76.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Larsen
M, Evans WK, Shepherd FA, Phillips MJ, Bailey D, Messner H. Acute lymphobla=
stic
leukemia: possible origin from a mediastinal germ cell tumor. <i
style=3D'mso-bidi-font-style:normal'>Cancer</i>. 1984;53(3):441-444.<o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>77.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Lee
KC. Hematopoietic precursor cells within the yolk sac tumor component are t=
he
source of secondary hematopoietic malignancies in patients with mediastinal
germ cell tumors. <i style=3D'mso-bidi-font-style:normal'>Cancer</i>.
1994;73(5):1535-1536.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>78.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Vasey
PA, Dunlop DJ, Kaye SB. Primary mediastinal germ cell tumour and acute
monocytic leukaemia occurring concurrently in a 15-year-old boy. <i
style=3D'mso-bidi-font-style:normal'>Ann Oncol</i>. 1994;5(7):649-652.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>79.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Vlasveld
LT, Splinter TA, Hagemeijer A, Van Lom K, Lowenberg B. Acute myeloid leukae=
mia
with +i(12p) shortly after treatment of mediastinal germ cell tumour. <i
style=3D'mso-bidi-font-style:normal'>Br J Haematol</i>. 1994;88(1):196-198.=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>80.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Nichols
CR, Roth BJ, Heerema N, Griep J, Tricot G. Hematologic neoplasia associated
with primary mediastinal germ-cell tumors. <i style=3D'mso-bidi-font-style:=
normal'>N
Engl J Med</i>. 1990;322(20):1425-1429.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>81.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Orazi
A, Neiman RS, Ulbright TM, Heerema NA, John K, Nichols CR. Hematopoietic
precursor cells within the yolk sac tumor component are the source of secon=
dary
hematopoietic malignancies in patients with mediastinal germ cell tumors. <i
style=3D'mso-bidi-font-style:normal'>Cancer</i>. 1993;71(12):3873-3881.<o:p=
></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>82.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Motzer
RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation:
diverse malignant histologies arising in men with germ cell tumors. <i
style=3D'mso-bidi-font-style:normal'>J Urol</i>. 1998;159(1):133-138.<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>83.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Sole
F, Bosch F, Woessner S, et al. Refractory anemia with excess of blasts and =
isochromosome
12p in a patient with primary mediastinal germ-cell tumor. <i style=3D'mso-=
bidi-font-style:
normal'>Cancer Genet Cytogenet</i>. 1994;77(2):111-113.<o:p></o:p></span></=
p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>84.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Garnick
MB, Griffin JD. Idiopathic thrombocytopenia in association with extragonadal
germ cell cancer. <i style=3D'mso-bidi-font-style:normal'>Ann Intern Med</i=
>.
1983;98(6):926-927.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>85.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Helman
LJ, Ozols RF, Longo DL. Thrombocytopenia and extragonadal germ-cell neoplas=
m. <i
style=3D'mso-bidi-font-style:normal'>Ann Intern Med</i>. 1984;101(2):280.<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>86.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Chariot
P, Monnet I, Gaulard P, Abd-Alsamad I, Ruffie P, De Cremoux H. Systemic
mastocytosis following mediastinal germ cell tumor: an association confirme=
d. <i
style=3D'mso-bidi-font-style:normal'>Hum Pathol</i>. 1993;24(1):111-112.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>87.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Felix
CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. <i
style=3D'mso-bidi-font-style:normal'>Med Pediatr Oncol</i>. 2001;36(5):525-=
535.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>88.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Ohshima
A, Miura I, Chubachi A, et al. 11q23 aberration is an additional chromosomal
change in de novo acute leukemia after treatment with etoposide and
mitoxantrone. <i style=3D'mso-bidi-font-style:normal'>Am J Hematol</i>.
1996;53(4):264-266.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>89.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Stanulla
M, Wang J, Chervinsky DS, Aplan PD. Topoisomerase II inhibitors induce DNA
double-strand breaks at a specific site within the AML1 locus. <i
style=3D'mso-bidi-font-style:normal'>Leukemia</i>. 1997;11(4):490-496.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>90.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Suster
S, Moran CA, Dominguez-Malagon H, Quevedo-Blanco P. Germ cell tumors of the
mediastinum and testis: a comparative immunohistochemical study of 120 case=
s. <i
style=3D'mso-bidi-font-style:normal'>Hum Pathol</i>. 1998;29(7):737-742.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>91.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Tickoo
SK, Hutchinson B, Bacik J, et al. Testicular seminoma: a clinicopathologic =
and
immunohistochemical study of 105 cases with special reference to seminomas =
with
atypical features. <i style=3D'mso-bidi-font-style:normal'>Int J Surg Patho=
l</i>.
2002;10(1):23-32.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>92.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Moran
CA, Suster S, Przygodzki RM, Koss MN. Primary germ cell tumors of the
mediastinum, II: mediastinal seminomas--a clinicopathologic and
immunohistochemical study of 120 cases. <i style=3D'mso-bidi-font-style:nor=
mal'>Cancer</i>.
1997;80(4):691-698.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>93.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Cheville
JC, Rao S, Iczkowski KA, Lohse CM, Pankratz VS. Cytokeratin expression in
seminoma of the human testis. <i style=3D'mso-bidi-font-style:normal'>Am J =
Clin
Pathol</i>. 2000;113(4):583-588.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>94.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Leroy
X, Augusto D, Leteurtre E, Gosselin B. CD30 and CD117 (c-kit) used in
combination are useful for distinguishing embryonal carcinoma from seminoma=
. </span><i
style=3D'mso-bidi-font-style:normal'><span lang=3DDE style=3D'mso-bidi-font=
-family:
Arial;mso-ansi-language:DE'>J Histochem Cytochem</span></i><span lang=3DDE
style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>. 2002;50(2):283-=
285.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>95.<span
style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp; </span>Niehans GA, Maniv=
el JC,
Copland GT, Scheithauer BW, Wick MR. </span><span style=3D'mso-bidi-font-fa=
mily:
Arial'>Immunohistochemistry of germ cell and trophoblastic neoplasms. <i
style=3D'mso-bidi-font-style:normal'>Cancer</i>. 1988;62(6):1113-1123.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>96.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Butnor
KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL. The spectrum of Kit (CD11=
7)
immunoreactivity in lung and pleural tumors: a study of 96 cases using a
single-source antibody with a review of the literature. <i style=3D'mso-bid=
i-font-style:
normal'>Arch Pathol Lab Med</i>. 2004;128(5):538-543.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>97.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Nakagawa
K, Matsuno Y, Kunitoh H, Maeshima A, Asamura H, Tsuchiya R. Immunohistochem=
ical
KIT (CD117) expression in thymic epithelial tumors. <i style=3D'mso-bidi-fo=
nt-style:
normal'>Chest</i>. 2005;128(1):140-144.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>98.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Pan
CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic ca=
rcinomas
but is absent in thymomas. <i style=3D'mso-bidi-font-style:normal'>J Pathol=
</i>.
2004;202(3):375-381.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>99.<span style=3D'mso-tab-count:1'>&nb=
sp;&nbsp;&nbsp;&nbsp; </span>Ferreiro
JA. Ber-H2 expression in testicular germ cell tumors. <i style=3D'mso-bidi-=
font-style:
normal'>Hum Pathol</i>. 1994;25(5):522-524.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>100.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Emerson
RE, Ulbright TM. The use of immunohistochemistry in the differential diagno=
sis of
tumors of the testis and paratestis. <i style=3D'mso-bidi-font-style:normal=
'>Semin
Diagn Pathol</i>. 2005;22(1):33-50.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>101.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Hattab
EM, Tu PH, Wilson JD, Cheng L. OCT4 immunohistochemistry is superior to
placental alkaline phosphatase (PLAP) in the diagnosis of central nervous
system germinoma. <i style=3D'mso-bidi-font-style:normal'>Am J Surg Pathol<=
/i>.
2005;29(3):368-371.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.35pt;text-indent:-27.35pt'><sp=
an
style=3D'mso-bidi-font-family:Arial'>102.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Jones
TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular
tumors: a sensitive and specific marker for seminoma and embryonal carcinom=
a. <i
style=3D'mso-bidi-font-style:normal'>Am J Surg Pathol</i>. 2004;28(7):935-9=
40.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.35pt;text-indent:-27.35pt;tab-=
stops:
45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0=
pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial'>103.<span
style=3D'mso-tab-count:1'>&nbsp;&nbsp; </span>Zynger DL, Dimov ND, Luan C, =
Teh
BT, Yang XJ. Glypican 3: a novel marker in testicular germ cell tumors. </s=
pan><i
style=3D'mso-bidi-font-style:normal'>Am J Surg Pathol.</i><span style=3D'ms=
o-bidi-font-size:
11.0pt;mso-bidi-font-family:Arial'> 2006;30(12):1570-1575.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-left:27.35pt;text-indent:-27.35pt;tab-=
stops:
45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0=
pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial'>104.<span
style=3D'mso-tab-count:1'>&nbsp;&nbsp; </span>Zynger DL, Everton MJ, Dimov =
ND,
Chou PM, Yang XJ. Expression of glypican 3 in ovarian and extragonadal germ
cell tumors. </span><i style=3D'mso-bidi-font-style:normal'>Am J Clin Patho=
l. </i><span
style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial'>2008;130(2):=
224-230.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.35pt;text-indent:-27.35pt;tab-=
stops:
45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0=
pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial'>105.&nbsp;<s=
pan
style=3D'mso-tab-count:1'>&nbsp; </span>Cao D, Li J, Guo CC, Allan RW, Hump=
hrey
PA.&nbsp;SALL4 is a novel diagnostic marker for testicular germ cell tumors=
. <i
style=3D'mso-bidi-font-style:normal'>Am J Surg Pathol.</i> 2009;33(7):1065-=
1077.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.35pt;text-indent:-27.35pt;tab-=
stops:
45.8pt 91.6pt 137.4pt 183.2pt 229.0pt 274.8pt 320.6pt 366.4pt 412.2pt 458.0=
pt 503.8pt 549.6pt 595.4pt 641.2pt 687.0pt 732.8pt'><span
style=3D'mso-bidi-font-size:11.0pt;mso-bidi-font-family:Arial'>106. <span
style=3D'mso-tab-count:1'>&nbsp; </span>Cao D, Guo S, Allan RW, Molberg KH,=
 Peng
Y. SALL4 is a novel sensitive and specific marker of ovarian primitive germ
cell tumors and is particularly useful in distinguishing yolk sac tumor from
clear cell carcinoma. <i style=3D'mso-bidi-font-style:normal'>Am J Surg Pat=
hol. </i>2009;33(6):894-904.</span><span
style=3D'mso-bidi-font-family:Arial'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>107.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Ramalingam
P, Malpica A, Silva EG, Gershenson DM, Liu JL, Deavers MT. The use of
cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from
endometrioid and clear cell carcinomas. <i style=3D'mso-bidi-font-style:nor=
mal'>Am
J Surg Pathol</i>. 2004;28(11):1499-1505.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>108.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Hasle
H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefe=
lter
syndrome. <i style=3D'mso-bidi-font-style:normal'>Br J Cancer</i>.
1995;71(2):416-420.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>109.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Aguirre
D, Nieto K, Lazos M, et al. Extragonadal germ cell tumors are often associa=
ted
with Klinefelter syndrome. <i style=3D'mso-bidi-font-style:normal'>Hum Path=
ol</i>.
2006;37(4):477-480.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>110.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Beresford
L, Fernandez CV, Cummings E, Sanderson S, Ming-Yu W, Giacomantonio M.
Mediastinal polyembryoma associated with Klinefelter syndrome. <i
style=3D'mso-bidi-font-style:normal'>J Pediatr Hematol Oncol</i>.
2003;25(4):321-323.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>111.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Nichols
CR, Heerema NA, Palmer C, Loehrer PJ Sr, Williams SD, Einhorn LH. Klinefelt=
er's
syndrome associated with mediastinal germ cell neoplasms. <i style=3D'mso-b=
idi-font-style:
normal'>J Clin Oncol</i>. 1987;5(8):1290-1294.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>112.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Turner
AR, MacDonald RN, Gilbert JA, Petursson S. Mediastinal germ cell cancers in
Klinefelter's syndrome. </span><i style=3D'mso-bidi-font-style:normal'><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>Ann Int=
ern Med</span></i><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>.
1981;94(2):279.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
lang=3DDE style=3D'mso-bidi-font-family:Arial;mso-ansi-language:DE'>113.<sp=
an
style=3D'mso-tab-count:1'>&nbsp;&nbsp; </span>Volkl TM, Langer T, Aigner T,=
 et
al. </span><span style=3D'mso-bidi-font-family:Arial'>Klinefelter syndrome =
and
mediastinal germ cell tumors. <i style=3D'mso-bidi-font-style:normal'>Am J =
Med
Genet A</i>. 2006;140(5):471-481.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>114.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Dexeus
FH, Logothetis CJ, Chong C, Sella A, Ogden S. Genetic abnormalities in men =
with
germ cell tumors. <i style=3D'mso-bidi-font-style:normal'>J Urol</i>. 1988;=
140(1):80-84.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>115.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Satge
D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M. A tumor profile in D=
own
syndrome. <i style=3D'mso-bidi-font-style:normal'>Am J Med Genet</i>.
1998;78(3):207-216.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>116.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Caballero
C, Gomez S, Matias-Guiu X, Prat J. Rhabdomyosarcomas developing in associat=
ion
with mediastinal germ cell tumours. <i style=3D'mso-bidi-font-style:normal'=
>Virchows
Arch A Pathol Anat Histopathol</i>. 1992;420(6):539-543.<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>117.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Gonzalez-Vela
JL, Savage PD, Manivel JC, Torkelson JL, Kennedy BJ. Poor prognosis of
mediastinal germ cell cancers containing sarcomatous components. <i
style=3D'mso-bidi-font-style:normal'>Cancer</i>. 1990;66(6):1114-1116.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>118.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Manivel
C, Wick MR, Abenoza P, Rosai J. The occurrence of sarcomatous components in
primary mediastinal germ cell tumors. <i style=3D'mso-bidi-font-style:norma=
l'>Am
J Surg Pathol</i>. 1986;10(10):711-717.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>119.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Ulbright
TM, Clark SA, Einhorn LH. Angiosarcoma associated with germ cell tumors. <i
style=3D'mso-bidi-font-style:normal'>Hum Pathol</i>. 1985;16(3):268-272.<o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-left:27.0pt;text-indent:-27.0pt'><span
style=3D'mso-bidi-font-family:Arial'>120.<span style=3D'mso-tab-count:1'>&n=
bsp;&nbsp; </span>Ulbright
TM, Loehrer PJ, Roth LM, Einhorn LH, Williams SD, Clark SA. The development=
 of
non-germ cell malignancies within germ cell tumors: a clinicopathologic stu=
dy
of 11 cases. <i style=3D'mso-bidi-font-style:normal'>Cancer</i>.
1984;54(9):1824-1833.<o:p></o:p></span></p>

<p class=3DMsoNormal><!--[if supportFields]><span style=3D'mso-bidi-font-fa=
mily:
Arial'><span style=3D'mso-element:field-end'></span></span><![endif]--><span
style=3D'mso-bidi-font-family:Arial'><o:p>&nbsp;</o:p></span></p>

</div>

</body>

</html>

------=_NextPart_01D5389E.1DBD9690
Content-Location: file:///C:/9AEA4A32/cp-germcell-16protocol-3102_files/preview.wmf
Content-Transfer-Encoding: base64
Content-Type: image/x-wmf

AQAJAAADMtgAAAAAIdgAAAAABQAAAAwCkAAAASHYAABBCyAAzACQAAABAAAAAJAAAAEAAAAAKAAA
AAABAACQAAAAAQAYAAAAAAAAsAEAAAAAAAAAAAAAAAAAAAAAAP///wAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////////wAA
AAAAAP///wAAAAAAAP//////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////wAAAAAA
AP///wAAAAAAAP//////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wAAAAAAAP//
/wAAAAAAAP//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////wAAAAAAAP///wAA
AAAAAP//////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////wAAAAAAAP///wAAAAAA
AP//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////
/////////////////////////////////////9v//2Y6kLb/tmYAZtv/ttu2ttv//2Y6kLb/tmYA
Ztv/tra2tgA6kNuQOtv//5BmkP//27b//2YAZtv/ttu2ttv//wA6kNu2ZpBmkLb/22YAZv//ttv/
/zo6kLbbkGYAZtv/tmY6kNv/tpBmkLb/22YAZtv/tpBmkNv/29vb25BmkLb/2/+2ttv//wA6kP+2
Ztv//wA6kP+2Zv///9v//wA6kP+2Ztv//7bb22Y6ZmY6Ztv/tmY6kNv/trbb22YAZtv/tpC2tmYA
Ztv/trbb25A6Ztv/22Y6kNv/tmY6kLb/tjo6ZmYAOtv/ttu2ttv//zo6kNu2Zrb//2YAZrb/tmYA
Orb/tpA6Zrb/22YAZtv/ttvb25BmkNv/2//b2///////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////
/////////////////////////////////9v//5BmkNvbtv///////2a2/9v//7aQ2///tpC229u2
tv//29v//9vb2//b27b//7aQttvbtra2tpC2tmYAZrb/traQtrbbtmYAZv//trb//7aQttvbttu2
tv///9v//zo6kNvbkLaQ27a2Zv///7b//2YAZtv/ttvb25C2tv+2ttv//2Y6kNv/tpCQtv/bttv/
/9u2ttv//2Y6kNv/tra2tpCQtv/btrb//7aQttvbtpC2traQtrbbtraQttvbtra2tmY6kNv/tra2
tmY6kP//ttv////b29v//9vb29vb2zo6kP/bkNv//9u2tv///7bb/////9v//zo6kNvbkLa2ttu2
ttv////b29v//5C2traQttvbtpCQttvbtra2tmY6kP//ttv////b27b//2YAZtv/tmY6kLb/tmYA
Zv//ttv//9vb27aQtrb/22YAZrb/traQtv/btv//////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////////wAA
AAAAAP///wAAAAAAAP//////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////wAAAAAA
AP///wAAAAAAAP//////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wAAAAAAAP//
/wAAAAAAAP//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////wAAAAAAAP///wAA
AAAAAP//////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////wAAAAAAAP///wAAAAAA
AP//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////////wAA
AAAAAP///wAAAAAAAP//////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////wAAAAAA
AP///wAAAAAAAP//////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wAAAAAAAP//
/wAAAAAAAP//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////wAAAAAAAP///wAA
AAAAAP//////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////wAAAAAAAP///wAAAAAA
AP//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////
/////////////////////////////////9v//zo6kP/bkNv//2Y6kNv/tv/b29v//5BmkNv/29vb
22Y6kNv/tv/b29v//5BmkP//27b//7ZmZtv//wA6kP+2Zrb//2YAZrb/tmYAZv//trb//2YAOv//
ttv//2Y6kNv/tmY6kNv/tv/b29v//9vb25BmkNv/2wA6kNuQOv///9v//2Y6kNv/tmY6kP//ttv/
/2Y6kP//trb//2YAZrb/tmYAZrb/tmYAZv//trb//2YAZtv/ttu2trb//2YAZrb/tmYAZtv/ttu2
tv///9v//wA6kNuQOrb//2YAZrb/tmYAZtv/ttvb27a2trbb22YAZrb/tmYAZv//tv///9v//7bb
22YAZv//ttv//9u2trb//2YAZtv/tmY6kLb/tmYAZtv/tra2tv/b2////9v//2Y6kNv/tmY6kNv/
tgA6kNuQOv///9v//2Y6kLb/tmYAZtv/ttu2tv///9v//9vb22Y6kNv/tjpmkGYAOtv/ttvb25Bm
kLb/22YAZrb/tmYAZv//tv///9v//2Y6kLb/tmYAZtv/tpC2tmYAZtv/tpC2tmYAZv//tv///9v/
/2Y6kNv/tmY6kNv/tgA6kNuQOtv//2Y6kP//trb//2YAZtv/ttu2trb//2YAZtv/tpBmkP//29v/
/2Y6kNv/tgA6kNuQOtv//9vb22Y6kLb/tmYAZv//trb//2YAZv//tv//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////
/////////////////////////////////////////////////////////////////////9v////b
29v//9u22///29v//7aQ27a2Ztv//7aQ27a2Zv///9v//2Y6kP//ttv//9vb27aQtv//2////7b/
/7aQttvbttu2tv///9v//9vb29vb25CQtv/bttv//2Y6kNv/tpCQtv/btrb//7aQtrbbtmYAZv//
ttv//2Y6kP//tv//////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////////wAA
AAAAAP///wAAAAAAAP//////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////
/////////////////////////////////////////////////////9v//9vb2//b29v//zo6kP/b
kNv//9u2tv///////9v//9u2tv///9v//2Y6kNv/tra22//btrb//7aQttvbtv/b29v//2Y6kNv/
tpC2traQtv/bttv//9vb27aQtv//2////9v//zo6kP/bkLb///+2trb///+2ttv////b27b//2YA
Zrb/traQtv/bttv//7a2tra2tmY6kP//ttv//7a2tpC2traQttvbtpCQtv/btv///9v//9u2tv//
/9v////b27b//7aQtrbbtraQtv/bttv//9vb22Y6kP//ttv//7aQ27a2Zv///////9v//9u2ttv/
///b27b//7aQttvbttu2trb//7aQtrbbtv+2trb//7aQtv/bttv//9u2ttv//5CQtv/btrb//2YA
Zv//ttv//7a229vbttu22///29v//7a2trbb22YAZv//trb//7aQtv/btv///9v//5C2ttu2tmY6
kLb/tmYAZv//tv///9v//5C2tv+2ttv//2Y6kNv/ttu2trb//2YAZv//tv///////9v//zpmtra2
ZraQtv/bttv//9u2ttv//2Y6kP//ttv//7a229vbtra22//bttv//7a2tpC2tv+2ttv//2Y6kP//
ttv//7a229vbttu2trb//2YAZv//tv//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////wAAAAAA
AP///wAAAAAAAP//////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wAAAAAAAP//
/wAAAAAAAP//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////
/////////////////////////////////////////////9v//2Y6kP//ttv//2Y6kLb/tmYAZv//
ttv//2Y6kNv/tpBmkP//27b//2YAZv//trb//2YAZtv/ttu2ttv////b29v//2Y6kNv/ttvb25Bm
kP//29v//2Y6kNv/ttu2trb//2YAZtv/trbb22YAZrb/tpA6Zrb/22YAZv//ttv////b29v//9vb
25BmkP//29v//5C2tmYAZv//trb//5A6Zrb/22YAZtv/tgA6kNuQOtv//wA6kNuQOv///7b//2YA
Ztv/tmY6kLb/tmYAZrb/tmYAZrb/tmYAZv//tv///9v//5C2tmYAZtv/ttu2trb//5A6Zv//29v/
/7bb22YAZv//ttv//7bb25A6Ztv/22Y6kNv/tv/b27b//5A6Ztv/22Y6kP//ttv//5C2tmYAZv//
ttv//2Y6kNv/tmY6kP//ttv//7a2tmY6kLb/tmYAZtv/tpBmkLb/22YAZtv/tpBmkP//29v////b
29v//2Y6kNv/tmY6kP//ttv////b29v//9vb25BmkP//29v//2Y6kP//trb//2YAZtv/tv/b29v/
/5C2tmYAZv//trb//2YAZtv/tmY6kNv/ttvb25C2tmYAZrb/tmYAZv//tv///9v//5C2tmYAZtv/
ttu2ttv//2Y6kP//trb//5A6Zrb/25A6Ztv/25C2tmYAZrb/tmYAZv//trb///+2ttv//2Y6kNv/
ttvb27bb22YAZtv/tmY6kP//tv///9v//2Y6kNv/tmY6kNv/tra2tmY6kLb/tmYAZv//ttv//5Bm
kLb/22YAZtv/tpBmkNv/2//b2///////////////////////////////////////////////////
/////////////////////////////////////////////////////////////wAAAAAAAP///wAA
AAAAAP//////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////wAAAAAAAP///wAAAAAA
AP//////////////////////////////////////////////////////////////////////////
/9v//zo6kP/bkLb///+2trb///+2tv///9v//7bb22YAZv//trb//7aQttvbtra2ttu2ttv//2Y6
kNv/tra2ttu2trb//7aQttvbtpCQtv/btv///9v//5CQtv/btrb//2YAZtv/tra22//bttv//9u2
29v/27a2tv/b27b//2YAZtv/traQ27a2Zv///7b//2YAZv//ttv//5CQttvbtra2tmY6kP//tv//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////
////////////////////////////////////////////////////////////////////////////
/////9v//wA6kP+2Ztv//2Y6kNv/tmY6kNv/tmY6kNv/tra2tmY6kNv/tpBmkP//29v//2Y6kNv/
traQkNv//9vb2wA6kNuQOtv//2Y6kNv/tpCQkGY6kP//ttv//2Y6kNv/tmY6kP//ttv//7a2tmY6
kNv/tmY6kNv/tpCQkP/b29v//zo6kNvbkNvb2//b29v//2Y6kNv/tra2tmY6kNv/tmY6kP//ttv/
/7aQkNv//5BmkNv/22Y6kNv/tmY6kNv/tra2tpCQkNvb22Y6kP//ttv//2Y6kNv/tra2ttvb22Y6
kNv/tmY6kP//ttv//2Y6kNv/tmY6kNv/tra2tmY6kNv/tmY6kP//ttv//5CQkJBmkP//29v//2Y6
kNv/tpCQkGY6kP//ttv//9vb29vb25BmkNv/27a2tmY6kNv/tmY6kP//ttv//2Y6kNv/ttvb22Y6
kP//ttv//2Y6kNv/tmY6kNv/tmY6kNv/tmY6kP//trb//7aQkJBmkNv/22Y6kNv/ttvb29vb22Y6
kNv/tv/b2///////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////
/////////////////////////////////////////////////////////////////9v//wA6kLZm
AP///////7b///+2ttv//2Y6kP//trb//2YAZtv/tmY6kNv/trbb22YAZv//ttv//2Y6kNv/tmY6
kLb/tpA6Zrb/22YAZv//tv///7b//7ZmZrb//2YAZtv/tgA6kNuQOv///////9v//9vb22Y6kLb/
tmYAZv//ttv//zo6kP/bkNv//zo6kP/bkNv//zo6kP/bkP///9v//zo6kP/bkNv//2Y6kNv/tmY6
kLb/tpA6Zrb/22YAZv//ttv//9u2ttv//2Y6kNv/tmY6kLb/tmYAZv//tv///9v//zo6kP/bkNv/
/zo6kNvbkDo6kP/bkP///9v//zo6kP/bkNv//2Y6kNv/tv/b29v//2Y6kLb/tmYAZtv/trbb22YA
Zrb/tmYAZtv/tpBmkP//2////9v//2Y6kP//ttv//7bb22YAZrb/tpA6Ztv/29vb25C2tmYAZv//
ttv//2Y6kNv/trbb25A6Zv//29v//wA6kP+2Zrb//2YAZtv/tmY6kLb/tmYAZtv/ttu2ttv//9vb
29vb22Y6kLb/tmYAZv//ttv//zo6kP/bkLb//2YAZtv/tgA6kNuQOv///9v//wA6kNuQOtv//9vb
29vb2//b27b//2YAZrb/tmYAZtv/tpBmkNv/2//b2///////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////////wAA
AAAAAP///wAAAAAAAP//////////////////////////////////////////////////////////
/////////////////9v//2Y6kP//ttv//9u2trb//2YAZv//tv///9v//wA6kP+2Ztv//2Y6kLb/
tmYAZtv/tpBmkNv/29vb22Y6kNv/tpBmkNv/25BmkP//29v//9vb2//b29v//wA6kNuQOv///9v/
/wA6kP+2Zv///////////9v//wA6kNuQOv///7b//2YAZrb/tmYAZtv/tmY6kNv/tmY6kP//tv//
/9v//wA6kP+2Zrb//5A6Zv//29v//2Y6kLb/tmYAZtv/tmY6kNv/tv/b2////9v//wA6kNuQOtv/
/wA6kP+2Zv///////////////9v//wA6kNuQOtv////b2////9v//5BmkLb/22YAZtv/tmY6kNv/
tmY6kP//ttv//wA6kP+2Ztv//7bb25A6Ztv/25BmkP//29v//5BmkNv/2//b29v//wA6kNuQOv//
/9v//wA6kP+2Zv//////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////7b//7ZmZv//////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////7b//7ZmZv//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////wAAAAAA
AP///wAAAAAAAP//////////////////////////////////////////////////////////////
/////////////9v//zo6kP/bkNv//9u22///29v//7a2tpCQtrbbtraQtv/bttv////b29v//2Y6
kP//tv//////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wAAAAAAAP//
/wAAAAAAAP//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////wAAAAAAAP///wAA
AAAAAP//////////////////////////////////////////////////////////////////////
/////////////////9v//wA6kNuQOtv//2ZmkGY6Ztv/ttu2ttv//9vb22Y6kNv/tmY6kP//trb/
/2YAZrb/tmYAZv//ttv//7a2tgA6kNuQOv///7b//5A6Zv//27b//2YAZtv/ttvb2//b29v//9vb
22Y6kNv/tgA6kNuQOv///7b//2YAZtv/tra2tpBmkP//2////9v//5C2tpA6Zrb/22YAZtv/tmY6
kNv/tpBmkP//29v//7bb22YAZrb/tmYAZtv/ttu2ttv////b29v//2Y6kLb/tmYAZv//ttv//wA6
kNuQOtv//5BmkNv/22Y6kNv/tra2tpBmkP//29v////b29v//2Y6kNv/tmY6kP//ttv//9vb27bb
22YAZtv/tmY6kNv/ttvb22Y6kNv/tmY6kP//ttv//2Y6kP//ttv//2Y6kNv/tmY6kLb/tmYAZtv/
tv/b2////9v//zo6kLbbkGYAZv//ttv//7a2ttvb27bb22YAZtv/tmY6kLb/tmYAZv//ttv//2Y6
kNv/tgA6kNuQOv///9v//2Y6kP//ttv//5C2tmYAZtv/trbb22YAZrb/tpA6Zv//27b//2YAZtv/
tv/b22a2////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////wAAAAAAAP///wAAAAAA
AP//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////
/////////////////////////////////////////////////9v//2Y6kLb/tmYAZtv/tpBmkNv/
29vb27bb25A6Ztv/22Y6kP//ttv//9vb22Y6kNv/ttu2trb//2YAZrb/tmYAZv//ttv//7a2tgA6
kNuQOv///////7b//5A6Zrb/22YAZtv/ttvb2//b29v//9vb22Y6kNv/tgA6kNuQOv///7b//2YA
Ztv/tra2tpBmkP//2////9v//5C2tpA6Zrb/22YAZtv/tmY6kNv/tpBmkP//29v//7bb22YAZrb/
tmYAZtv/ttu2ttv////b29v//2Y6kLb/tmYAZv//ttv//2Y6kLb/tmYAZv//ttv//5BmkNv/29vb
29vb25BmkP//29v//2Y6kP//ttv//5C2tmYAZtv/trbb22YAZrb/tpA6Zv//27b//2YAZtv/tv/b
22a2////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//
////////////////////////////////////////////////////////////////////////////
/wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAP//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////
/////////////////////////////////////8DAwMDAwMDAwImJpaXApaWJpcDApaXAwIlspYmJ
TInAwIlsicCliaXAwMClpcDAwMDAwImJpaXApYlsiaXApYmJpcCliYnAwEwATMDAicDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwP//////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////
/////////////////////////////////////////////////////////////////////////8DA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDAwMDA
wMDAwMDAwMDAwMDAwMDAwP//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////
/////////////////////////////////7a22///29v//5CQtrbbtmYAZv//tv///9v//5C2traQ
tv/bttv//7a2tpC2traQtv/bttv//2ZmkP/bttv//9u2ttv//5CQtrbbtraQtv/btv///9v//2Y6
kNv/tpCQtrbbtraQtv/bttv//9u229v/25C2traQtv/btv///9v//zpmtv+2Ztv//7a2ttu2tv//
/7a22///2////9v//7a227bbtmYAZv//tv///9v//7bb22YAZv//ttv//7a227bbtraQtv/bttv/
///b29v//5C2tmYAZrb/traQtv/btv///9v//9u229v/22Y6kNv/ttu2ttv//5CQtrbbtraQtv/b
tv///9v//7a2tpCQtv/bttv//7a2tmY6kP//ttv//7a229vbtv/b27b//7aQttvbttu2trb//7aQ
trbbtv+2trb//7aQtv/bttv//9u2tv//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////
/////////////////////////////////////////////////////////9v//5BmkP//29v//2Y6
kLb/tpA6Ztv/25C2tmYAZrb/tpA6Zv//27b//2YAZrb/tpA6Zrb/25A6Ztv/25BmkLb/22YAZrb/
tmYAZv//ttv//2Y6kNv/tv/b29v//2Y6kNv/tpC2tmYAZv//ttv//2Y6kNv/tv/b29v//9u2trb/
/2YAZtv/ttvb25C2tmYAZtv/tmY6kP//trb//2YAZtv/tra2ttvb27bb22YAZtv/tmY6kP//trb/
/2YAZtv/tmY6kNv/tgA6kNuQOtv////b2////9v//2Y6kLb/tmYAZrb/tpA6Ztv/25BmkP//29v/
///b29v//2Y6kNv/tmY6kLb/tmYAZv//tv///9v//9vb22Y6kNv/ttvb27a2tmY6kP//trb//5A6
Ztv/27a2tmY6kNv/tmY6kNv/ttvb22Y6kNv/tv/b2////9v//5BmkNv/29vb27bb22YAZtv/tpBm
kNv/2//b2///////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////////wAA
AAAAAP///wAAAAAAAP//////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////
/////////////////////////////////////////////////////////////9v//2Y6kNv/tmY6
kNv/ttvb25BmkP//2////9v//2Y6kNv/tpC2tmYAZtv/tv/b27b//2YAZrb/tpA6Zrb/22YAZtv/
tv/b29v//2Y6kNv/tmY6kP//ttv//2Y6kNv/ttvb27bb22YAZtv/tpBmkP//29v//7bb22YAZv//
tv///9v//2Y6kLb/tmYAZrb/tmYAZv//trb//2YAZv//ttv//9vb27a2trbb25A6Zv//29v//2Y6
kP//ttv//2Y6kLb/tmYAZv//ttv//2Y6kLb/tmYAZv//ttv//2Y6kNv/ttvb2//b29v//2Y6kNv/
tmY6kP//ttv//9vb27bb22YAZtv/tmY6kNv/ttvb25BmkP//2////9v//wA6kP+2Zrb///+2ttv/
/2Y6kP//trb//2YAZrb/tmYAZv//ttv//7a2tgA6kNuQOv///7b//5A6Zv//27b//2YAZtv/ttvb
2//b29v//9vb22Y6kNv/tgA6kNuQOv///7b//2YAZtv/tra2tpBmkP//2////9v//7bb22YAZrb/
tpA6Ztv/22Y6kNv/trbb22YAZrb/tmYAZv//tv///9v//9vb22Y6kP//ttv////b29v//2Y6kLb/
tmYAZv//ttv//wA6kNuQOv///7b//2YAZrb/tmYAZtv/ttvb22Y6kNv/tpBmkNv/29vb29vb22Y6
kP//ttv//2Y6kNv/tgA6kNuQOtv////b2///////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////wAAAAAA
AP///wAAAAAAAP//////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wAAAAAAAP//
/wAAAAAAAP//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////wAAAAAAAP///wAA
AAAAAP//////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////
/////////////////////////////////////////////7a22///29v//5CQttvbttu2ttv//2Y6
kP//ttv//7a229vbtv/b27b//7aQttvbttu2trb//7aQtrbbtv+2trb//7aQtv/bttv//9u2ttv/
/7a2tmY6kP//tv///9v//zpmttu2Zra2ttu2tv///7a22///2////9v////b27b//2YAZtv/tra2
2//bttv//9u229v/27a2tv/b27b//2YAZv//trb//7aQtv/bttv//9u2trb//7aQttvbtv/b2///
/9v//2Y6kLb/tv+2trb///+2tv///9v//7bb22YAZv//trb//7aQttvbtra2ttu2ttv//2Y6kNv/
tra2ttu2trb//7aQttvbtpCQtv/btv///9v//7a229vbttu22///29v//9vb27a22//btrb//7aQ
ttvbtmY6kLb/tmYAZv//ttv//2Y6kP//tv//////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////wAAAAAAAP///wAAAAAA
AP//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////
/////////////////////////////////9v//9vb22Y6kP//trb//5A6Ztv/29vb22Y6kLb/tmYA
Zrb/tmYAZtv/tpBmkP//2////9v//9vb22Y6kLb/tmYAZv//ttv//zo6kP/bkNv//2Y6kNv/ttvb
27bb22YAZtv/ttu2trb//2YAZtv/tmY6kP//ttv//5BmkP//29v//wA6kNuQOv///9v//2Y6kLb/
tpA6Zrb/22YAZtv/trbb22YAZrb/tmYAZtv/tpBmkP//2////9v//wA6kNuQOtv//5C2tmYAZtv/
tmY6kP//ttv//2Y6kP//ttv//5BmkNv/29vb22Y6kP//trb//2YAZtv/ttvb22Y6kLb/tmYAZv//
ttv//5BmkNv/25BmkP//29v//5BmkNv/27bb22YAZtv/tgA6kNuQOv//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////9v////b
2///////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////
/////////////////////////////////////////////////////////////////////2Zmtv//
trb//2YAZv//ttv//9vb22Y6kNv/tpC2traQtv/bttv//5CQtv/btv///////9v//wA6kNuQOrb/
/2YAZtv/tra2tgA6kNuQOv///9v//zo6kP/bkLb//2YAZtv/ttvb2//b29v//2Y6kNv/tv/b25CQ
ttv/2//b29v//2Y6kNv/ttvb25BmkP//2///////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////9v//9u2tv///9v////b27b/
/7aQttvbtpC2traQtv/btrb///+2trb//7aQttvbttu2tv///9v//9u2tv///7b//7aQttvbtmY6
kNv/tra2ttu2ttv//5CQtrbbtraQtv/btv///9v//5C2tv+2ttv//2Y6kNv/tpC2tmYAZv//tv//
/////9v//zo6kP/bkNv//2Y6kLb/tmYAZv//ttv//2Y6kNv/tpBmkNv/2//b29v//5BmkP//29v/
/2Y6kP//tpCQttv/22Y6kP//tv//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////////wAA
AAAAAP///wAAAAAAAP//////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////wBmttuQOv//////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////
/////////////////////////////////////////////////////9v//7aQkP//////////////
/wBmtv+2Zv///9v//7aQkNv//7aQkNv//5C2ttuQkP///9v//5CQkLaQkP///9v//5CQkLaQkP//
/9v//5CQkLaQkP///9v//5C2ttuQkP///9v//5CQkLaQkP///9v//5C2ttuQkP///9v//7aQkP//
/////5CQtpC22//bkP///9v//9u2tv///////9v//7aQkNv//5CQkJC2ttuQkP//////////////
/////7a2tpCQ2///tv///9v//9u2tv///9v//7aQkNv//7aQkP///////5C2///bkP///9v//5CQ
kLaQkP///9v//5CQkJC2ttuQkP///////9v//5CQkLaQkP///9v//7aQkP///////9v//9u2tv//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////wAAAAAA
AP///wAAAAAAAP//////////////////////////////////////////////////////////////
/////////////9v//7aQkP///////////9v//2aQkNuQkP///7b//2YAZtv/tmZmtv/bkABmtv+2
Zv///////zqQ27ZmAP///////zqQ2/+2Zv///9v//zpmkNuQZv///////wBmtv+2Zv///////zqQ
27ZmAP///////wBmtv+2Zv///9v//7aQkP///9v//7aQkNvb////2////////2aQ2//bkP///9v/
/2ZmttvbkDpmtmZmZv+2Zv///////////////9v//7aQkLa22///2////////2aQ2//bkNv//7aQ
kNv//7aQkP///////5C2///bkP///9v//5CQkLaQkP///9v//zpmtmZmZv+2Zv///////////zqQ
2/+2Zv///9v//2Zmtv/bkP///wBmtv+2Zv///////5CQtv//2///////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wAAAAAAAP//
/wAAAAAAAP//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////9v//7aQkP//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////
/////////////////////////////////////////////9v//7aQkP///////////9v//7aQkNv/
/5CQkLaQkP///9v//7aQkP///9v//5CQkLaQkP///9v//5CQkLaQkNv//5CQkLaQkP///9v//7aQ
kP///////////7a2ttv//5CQkLaQkP///9v//7aQkP///////9v//7aQkP///9v//5CQkLaQkP//
/9v//9u2tv///////////9v//7aQkP///////////////wBmtv+2Ztv//5C2ttuQkP///9v//5CQ
kJC2ttuQkP///////9v//5CQkJCQkLaQkP///9v//5C2ttuQkP///9v//7aQkNv//7aQkNv//5CQ
kLaQkP///9v//5CQkLaQkP///////////9v//5CQkLaQkP///////7a2tv///////9v//7aQkJCQ
tv//29v//7aQkLa2tv///9v//9u2tv///////9v//5CQkLaQkP///9v//5CQkJCQkJC2ttuQkP//
/////9v//9u2tv///////9v//5CQkLaQkP///////9v//9u2tv///////////9v//7aQkP//////
/9v//7aQkNv//5CQkLaQkP///9v//5CQkJC2ttuQkP///////////////9v//7aQkP///////9v/
/5C2ttuQkP///9v//7aQkNv//7aQkNv//9u2tv///////9v//5CQkLaQkP///9v//7aQkP///9v/
/9u2tv///////////////zpmtmaQkNuQOv///////9v//7aQkNv//7aQkNv//5CQkLaQkP//////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////wAAAAAAAP///wAA
AAAAAP//////////////////////////////////////////////////////////////////////
/////9v//7aQkLa22///2////9v//2Zmtv/bkDqQ2/+2Zv///7b//2YAZv//tv///zqQ2/+2Zv//
/////zqQ2/+2Zv///zqQ2/+2Zv///9v//7aQkP///////7b//2YAZv//tjqQ2/+2Zv///9v//2Zm
tv/bkP///7b//2YAZv//ttv//zpmkNuQZv///////2aQ2//bkP///////9v//7aQkP//////////
/9v//2aQkNuQkP///wBmtv+2Zv///9v//zpmtmZmZv+2Zv///////9v//5CQkDpmkNuQZv//////
/wBmtv+2Zv///7b//2YAZtv/traQkP///zqQ2/+2Zv///9v//zpmkNuQZv///////////////zqQ
2/+2Zv///7b//2YAZv//tv///9v//7aQkP///////9v//zpmkP+2kP///////2aQ2//bkP//////
/zqQ2/+2Zv///9v//5CQkDpmtmZmZv+2Zv///////////2aQ2//bkP///9v//zpmkNuQZv//////
/wBmtv+2Zv///////////9v//7aQkP///////9v//2Zmtv/bkDqQ2/+2Zv///9v//zpmtmZmZv+2
Zv///////////////9v//7aQkLa22///2////wBmtv+2Zv///7b//2YAZtv/traQkP///2aQ2//b
kP///9v//zpmkNuQZv///7b//2YAZv//tgBmtv+2Zv///////////9v//2aQkLZmkLa2kP//////
/9v//7aQkLb//2YAZtv/tjpmkNuQZv//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////wAAAAAAAP///wAAAAAA
AP//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////
////////////////////////////////////////////////////////////////////////////
////////8v//yN/e82Rjxd7e8N7csPr57KipsuTk48G/39bV7f//3v/+4f//////////////////
/////9TU1PHx8f////Dw8MzMzPn5+fHx8cnJyf7+/tHR0fr6+vz8/NLS0v///////9HR0f///97e
3sTExMXFxdbW1v///83NzcXFxdbW1vj4+MrKysfHx8TExO3t7f///+Hh4cHBwcTExMfHx/39/dDQ
0P7+/t7e3s7OzsbGxv39/fHx8dXV1f////Dw8M/Pz8DAwObm5v//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////
//////////////////////////////////z8//z9/+/v9b+90eDg8l9frePj9vT0+P///9jVnPj4
3rm56Nra9svKs9HQueDg/87O+v///////////////3V1daurq6urq9bW1oyMjJOTk3l5eby8vP//
/3Jycvb29vr6+l5eXsnJyby8vGxsbNra2oCAgOvr6/Dw8I2NjcfHx39/f8zMzPHx8Y+Pj7e3t/Pz
89jY2IGBgdjY2G1tbeTk5MbGxpGRkfj4+GxsbPz8/Li4uKWlpZOTk/v7+9jY2ICAgP///9zc3KSk
pI2Njc7Ozv//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////
//////////////////////////////////////////////////////////////////////Lvtffz
r+Dg6Hx9uPf28dDNlfn58ry9xefn8Z+cz8/O7Pz85/7+99XUvOXkybW23pmZyP//////////////
/6GhobOzs5mZmdPT0////42Njb6+vv///9HR0YKCgsXFxfj4+J2dnfDw8Ofn56CgoPT09LS0tMHB
wcTExLKysuzs7KioqOvr6////9LS0rS0tMbGxru7u8TExPPz87Gxsb6+vsLCwt3d3f39/aenp/39
/aCgoKqqquLi4vn5+bGxsYmJidvb29HR0ZCQkMPDw/z8/P//////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////
/////////////////////////////+rmteDdp/Pz7MzLwv79+Pf0xPz77r66eOno2FhYubm54NDQ
8uPi/dnXu93dzNvZrMrHjP///v////////////////Pz8/T09P////////////7+/vT09P39/f//
//r6+vj4+P39/f////////v7+/r6+v////j4+Ozs7P////////////n5+ff39/////////b29vLy
8v////////////z8/PT09Pz8/P///9DQ0P////////f39/z8/P////////////b29v////////v7
+/////////////////v7+/b29vz8/P////////////////////////////////n5+fPz8/7+/v39
/f//////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////
/////////////////////////////////////////////////////////////////+7u4eLhy/b2
+NPSzPb2/qan7PTz88O+dPPy29fWt/b248fH9+Pj/87Ns8/Ov//9zvj0tv///v////////39/by8
vLe3t8XFxcnJyfPz87S0tL+/v8TExLCwsOvr666urq2trc/Pz////5eXl729vdjY2PX19YmJib6+
vtDQ0Pb29q+vr7q6uq+vr5SUlPj4+IyMjL29vc7Ozv///////9/f352dnaCgoMTExIeHh/39/f//
/////6ysrLy8vN3d3ZaWlu3t7be3t97e3pycnLy8vMfHx9jY2MHBwZubm76+vvHx8cfHx7i4uMfH
x7CwsP///6CgoPT09LW1tbm5ucPDw9XV1efn55aWlt3d3bm5ubKysunp6bS0tPj4+LCwsP//////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/wAAAAAAAP///wAAAAAAAP//////////////////////////////////////////////////////
//////////////////////////z73//91eHh4nx8fvDv6a2pq/Lx7bu8xfDw9dbV9vLy/93cx+vr
5PXz0/Tz1fv7//r6//////////////n5+W9vb9PT0/Ly8uTk5Nvb235+funp6fHx8ZSUlMTExI2N
jc7Ozv///////3BwcPHx8f///+3t7VdXV7y8vN3d3eXl5WxsbOXl5dLS0rOzs/T09FlZWby8vNnZ
2f///////+zs7Ly8vMDAwM7OzmdnZ9bW1v7+/v///+np6Xx8fG9vb7CwsP///4CAgG1tbd7e3s3N
zU1NTcnJyaGhoYGBgcHBwfr6+qmpqXV1daKion9/f/z8/HFxceDg4G5ubuDg4PHx8eXl5f///6+v
r29vb3t7e+3t7d3d3V5eXrCwsMDAwP//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////
//////////////////////////////////////////////////////////////////////Dw8L2+
wvv66P34lPz76N7e3vj487Cuwujn6aChucfH1u/v9e3t8v///////////////////////+7u7sPD
w8XFxdHR0f///+Li4sTExMXFxdXV1f///9bW1u7u7v///////9HR0fn5+f////v7+8DAwNHR0dnZ
2f///+Tk5MPDw8rKyubm5v39/cLCwtHR0djY2P///////////////////////8/Pz9HR0f7+/v//
/////+vr68LCwv///////8rKytra2v///////8PDw+np6eLi4sTExNHR0fHx8efn58DAwNHR0dXV
1f7+/tDQ0P///+jo6MLCwsTExNjY2P///////8HBwezs7P////Ly8rq6uvr6+v//////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////////wAA
AAAAAP///wAAAAAAAP//////////////////////////////////////////////////////////
//////////////////////////////////////////797/v7/15fY9jXzv/5TP//p4qJ/7i49v//
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////////wAAAAAA
AP///wAAAAAAAP//////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wAAAAAAAP//
/wAAAAAAAP//////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////wAAAAAAAP///wAAAAAAAP//////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////wAAAAAAAP///wAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAP//////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////////////////wMAAAAAAA==

------=_NextPart_01D5389E.1DBD9690
Content-Location: file:///C:/9AEA4A32/cp-germcell-16protocol-3102_files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme
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------=_NextPart_01D5389E.1DBD9690
Content-Location: file:///C:/9AEA4A32/cp-germcell-16protocol-3102_files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01D5389E.1DBD9690
Content-Location: file:///C:/9AEA4A32/cp-germcell-16protocol-3102_files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="us-ascii"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dus-ascii">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link id=3DMain-File rel=3DMain-File href=3D"../cp-germcell-16protocol-3102=
.htm">
<![if IE]>
<base href=3D"file:///C:\9AEA4A32\cp-germcell-16protocol-3102_files\header.=
htm"
id=3D"webarch_temp_base_tag">
<![endif]><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"2049"/>
</xml><![endif]-->
</head>

<body lang=3DEN-US>

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-continua=
tion-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-notice' id=3Dfcn>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal><span style=3D'mso-special-character:footnote-continua=
tion-separator'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-notice' id=3Decn>

<p class=3DMsoNormal><o:p>&nbsp;</o:p></p>

</div>

<div style=3D'mso-element:header' id=3Dh1>

<p class=3DMsoHeader style=3D'tab-stops:right 504.0pt'><b style=3D'mso-bidi=
-font-weight:
normal'>CAP Approved <span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s=
pan>Pediatric
&#8226; Extragonadal Germ Cell Tumor<o:p></o:p></b></p>

<p class=3DMsoHeader style=3D'tab-stops:right 504.0pt'><b style=3D'mso-bidi=
-font-weight:
normal'><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp; </span></b><span
style=3D'font-size:9.0pt'>GermCell 3.1.0.0</span><b style=3D'mso-bidi-font-=
weight:
normal'><span style=3D'font-size:9.0pt;mso-bidi-font-size:10.0pt'><o:p></o:=
p></span></b></p>

</div>

<div style=3D'mso-element:footer' id=3Def1>

<div style=3D'mso-element:frame;mso-element-wrap:around;mso-element-anchor-=
vertical:
paragraph;mso-element-anchor-horizontal:margin;mso-element-left:right;
mso-element-top:.05pt;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dright>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0cm;padding-right:0cm;
  padding-bottom:0cm;padding-left:0cm'>
  <p class=3DMsoFooter style=3D'mso-element:frame;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:margi=
n;
  mso-element-left:right;mso-element-top:.05pt;mso-height-rule:exactly'><!-=
-[if supportFields]><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-element:field-begin'></span>PAGE<span
  style=3D'mso-spacerun:yes'>&nbsp; </span></span></span><![endif]--><!--[i=
f supportFields]><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-element:field-end'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><o:p></o:p></span></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoFooter style=3D'margin-right:18.0pt'><o:p>&nbsp;</o:p></p>

</div>

<div style=3D'mso-element:footer' id=3Df1>

<div style=3D'mso-element:frame;mso-element-wrap:around;mso-element-anchor-=
vertical:
paragraph;mso-element-anchor-horizontal:margin;mso-element-left:right;
mso-element-top:.05pt;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dright>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0cm;padding-right:0cm;
  padding-bottom:0cm;padding-left:0cm'>
  <p class=3DMsoFooter style=3D'mso-element:frame;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:margi=
n;
  mso-element-left:right;mso-element-top:.05pt;mso-height-rule:exactly'><!-=
-[if supportFields]><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-element:field-begin'></span>PAGE<span
  style=3D'mso-spacerun:yes'>&nbsp; </span><span style=3D'mso-element:field=
-separator'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-no-proof:yes'>2</span></span></span><!--[if supportFields]><=
span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-element:field-end'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><o:p></o:p></span></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoFooter style=3D'margin-left:9.0pt;text-indent:-9.0pt;tab-stop=
s:right 432.0pt'><span
style=3D'font-size:8.0pt;mso-bidi-font-size:10.0pt'><o:p>&nbsp;</o:p></span=
></p>

</div>

<div style=3D'mso-element:header' id=3Dfh1>

<p class=3DMsoNormal style=3D'tab-stops:center 216.0pt right 432.0pt'><span
style=3D'font-family:"Century Gothic","sans-serif";mso-fareast-language:ZH-=
TW;
mso-no-proof:yes'><!--[if gte vml 1]><v:shapetype id=3D"_x0000_t75" coordsi=
ze=3D"21600,21600"
 o:spt=3D"75" o:preferrelative=3D"t" path=3D"m@4@5l@4@11@9@11@9@5xe" filled=
=3D"f"
 stroked=3D"f">
 <v:stroke joinstyle=3D"miter"/>
 <v:formulas>
  <v:f eqn=3D"if lineDrawn pixelLineWidth 0"/>
  <v:f eqn=3D"sum @0 1 0"/>
  <v:f eqn=3D"sum 0 0 @1"/>
  <v:f eqn=3D"prod @2 1 2"/>
  <v:f eqn=3D"prod @3 21600 pixelWidth"/>
  <v:f eqn=3D"prod @3 21600 pixelHeight"/>
  <v:f eqn=3D"sum @0 0 1"/>
  <v:f eqn=3D"prod @6 1 2"/>
  <v:f eqn=3D"prod @7 21600 pixelWidth"/>
  <v:f eqn=3D"sum @8 21600 0"/>
  <v:f eqn=3D"prod @7 21600 pixelHeight"/>
  <v:f eqn=3D"sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok=3D"f" gradientshapeok=3D"t" o:connecttype=3D"rect"/>
 <o:lock v:ext=3D"edit" aspectratio=3D"t"/>
</v:shapetype><v:shape id=3D"Picture_x0020_1" o:spid=3D"_x0000_i1025" type=
=3D"#_x0000_t75"
 alt=3D"Macintosh HD:Users:ctursky:Documents:CT_Publications:CAP_Logo_2015:=
CAP_logo_cmyk.jpg"
 style=3D'width:230.25pt;height:39.75pt;visibility:visible;mso-wrap-style:s=
quare'>
 <v:imagedata src=3D"image001.png" o:title=3D"CAP_logo_cmyk"/>
</v:shape><![endif]--></span><span style=3D'font-family:"Century Gothic","s=
ans-serif";
mso-no-proof:yes'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'tab-stops:center 216.0pt right 432.0pt'><span
style=3D'font-size:24.0pt;mso-bidi-font-family:Arial;mso-no-proof:yes'><o:p=
>&nbsp;</o:p></span></p>

</div>

<div style=3D'mso-element:footer' id=3Dff1>

<p class=3DMsoNormal style=3D'mso-pagination:none;mso-layout-grid-align:non=
e;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:8.0pt;mso-bidi-font-family:Arial'>&copy; 2016 College of
American Pathologists (CAP). All rights reserved.</span></b><span
style=3D'font-size:8.0pt;mso-bidi-font-family:Arial;color:#1F497D'> <o:p></=
o:p></span></p>

<p class=3DMsoNormal style=3D'mso-pagination:none;mso-layout-grid-align:non=
e;
text-autospace:none'><span style=3D'font-size:8.0pt;mso-bidi-font-family:Ar=
ial;
color:black'>For Terms of Use please visit </span><a
href=3D"http://www.cap.org/cancerprotocols"><span style=3D'font-size:8.0pt;
mso-bidi-font-family:Arial;color:black'>www.cap.org/cancerprotocols</span><=
/a><span
style=3D'font-size:8.0pt;mso-bidi-font-family:Arial;color:black'>.</span></=
p>

<p class=3DMsoFooter><o:p>&nbsp;</o:p></p>

</div>

<div style=3D'mso-element:header' id=3Dh2>

<p class=3DMsoHeader style=3D'tab-stops:right 504.0pt'><b style=3D'mso-bidi=
-font-weight:
normal'>CAP Approved <span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s=
pan>Pediatric
&#8226; Extragonadal Germ Cell Tumor<o:p></o:p></b></p>

<p class=3DMsoHeader style=3D'tab-stops:right 504.0pt'><b style=3D'mso-bidi=
-font-weight:
normal'><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp; </span></b><span
style=3D'font-size:9.0pt'>GermCell 3.1.0.2<b style=3D'mso-bidi-font-weight:=
normal'><o:p></o:p></b></span></p>

</div>

<div style=3D'mso-element:footer' id=3Df2>

<div style=3D'mso-element:frame;mso-element-wrap:around;mso-element-anchor-=
vertical:
paragraph;mso-element-anchor-horizontal:margin;mso-element-left:right;
mso-element-top:.05pt;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dright>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0cm;padding-right:0cm;
  padding-bottom:0cm;padding-left:0cm'>
  <p class=3DMsoFooter style=3D'mso-element:frame;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:margi=
n;
  mso-element-left:right;mso-element-top:.05pt;mso-height-rule:exactly'><!-=
-[if supportFields]><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-element:field-begin'></span>PAGE<span
  style=3D'mso-spacerun:yes'>&nbsp; </span><span style=3D'mso-element:field=
-separator'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-no-proof:yes'>2</span></span></span><!--[if supportFields]><=
span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-element:field-end'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><o:p></o:p></span></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:18.0pt;margin-bot=
tom:
0cm;margin-left:9.0pt;margin-bottom:.0001pt;text-indent:-9.0pt;tab-stops:ri=
ght 432.0pt'><span
style=3D'mso-bidi-font-family:Arial'>+</span><span style=3D'font-size:8.0pt;
mso-bidi-font-family:Arial'><span style=3D'mso-tab-count:1'> </span>Data el=
ements
preceded by this symbol may be clinically important but are not yet validat=
ed
or regularly used in patient management.</span><span style=3D'font-size:8.0=
pt'><o:p></o:p></span></p>

<p class=3DMsoFooter style=3D'margin-left:9.0pt;text-indent:-9.0pt;tab-stop=
s:right 432.0pt'><span
style=3D'font-size:8.0pt'><o:p>&nbsp;</o:p></span></p>

</div>

<div style=3D'mso-element:header' id=3Dfh2>

<p class=3DMsoHeader style=3D'tab-stops:right 504.0pt'><b style=3D'mso-bidi=
-font-weight:
normal'>CAP Approved <span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbs=
p;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&=
nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </s=
pan>Pediatric
&#8226; Extragonadal Germ Cell Tumor<o:p></o:p></b></p>

<p class=3DMsoHeader style=3D'tab-stops:right 504.0pt'><b style=3D'mso-bidi=
-font-weight:
normal'><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp; </span></b><span
style=3D'font-size:9.0pt'>GermCell 3.1.0.0<b style=3D'mso-bidi-font-weight:=
normal'><o:p></o:p></b></span></p>

<p class=3DMsoHeader><o:p>&nbsp;</o:p></p>

</div>

<div style=3D'mso-element:header' id=3Dh3>

<p class=3DMsoHeader style=3D'tab-stops:right 504.0pt'><b style=3D'mso-bidi=
-font-weight:
normal'>Background Documentation<span style=3D'mso-tab-count:1'>&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Pediatric
&#8226; Extragonadal Germ Cell Tumor<o:p></o:p></b></p>

<p class=3DMsoHeader style=3D'tab-stops:right 504.0pt'><b style=3D'mso-bidi=
-font-weight:
normal'><span style=3D'mso-tab-count:1'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp=
;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&n=
bsp; </span></b><span
style=3D'font-size:9.0pt'>GermCell 3.1.0.2<b style=3D'mso-bidi-font-weight:=
normal'><o:p></o:p></b></span></p>

</div>

<div style=3D'mso-element:footer' id=3Df3>

<div style=3D'mso-element:frame;mso-element-wrap:around;mso-element-anchor-=
vertical:
paragraph;mso-element-anchor-horizontal:margin;mso-element-left:right;
mso-element-top:.05pt;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dright>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0cm;padding-right:0cm;
  padding-bottom:0cm;padding-left:0cm'>
  <p class=3DMsoFooter style=3D'mso-element:frame;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:margi=
n;
  mso-element-left:right;mso-element-top:.05pt;mso-height-rule:exactly'><!-=
-[if supportFields]><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-element:field-begin'></span>PAGE<span
  style=3D'mso-spacerun:yes'>&nbsp; </span><span style=3D'mso-element:field=
-separator'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-no-proof:yes'>18</span></span></span><!--[if supportFields]>=
<span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><span
  style=3D'mso-element:field-end'></span></span></span><![endif]--><span
  class=3DMsoPageNumber><span style=3D'mso-bidi-font-family:"Times New Roma=
n"'><o:p></o:p></span></span></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoFooter style=3D'margin-left:9.0pt;text-indent:-9.0pt;tab-stop=
s:right 432.0pt'><o:p>&nbsp;</o:p></p>

</div>

</body>

</html>

------=_NextPart_01D5389E.1DBD9690
Content-Location: file:///C:/9AEA4A32/cp-germcell-16protocol-3102_files/image001.png
Content-Transfer-Encoding: base64
Content-Type: image/png
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------=_NextPart_01D5389E.1DBD9690
Content-Location: file:///C:/9AEA4A32/cp-germcell-16protocol-3102_files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../cp-germcell-16protocol-3102.htm"/>
 <o:File HRef=3D"preview.wmf"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"image001.png"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01D5389E.1DBD9690--
